Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
33900.0 | 2016-05-03 00:00:00 UTC | After Hours Most Active for May 3, 2016 : IRM, QQQ, MU, EMC, BRCD, ABT, CETV, NVAX, FCAU, FDC, ESV | ABT | https://www.nasdaq.com/articles/after-hours-most-active-may-3-2016-irm-qqq-mu-emc-brcd-abt-cetv-nvax-fcau-fdc-esv-2016-05 | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.63 to 4,339.76. The total After hours volume is currently 31,755,489 shares traded.
The following are the most active stocks for the after hours session :
Iron Mountain Incorporated ( IRM ) is unchanged at $36.50, with 7,107,688 shares traded. IRM's current last sale is 90.12% of the target price of $40.5.
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.08 at $105.81, with 4,173,886 shares traded. This represents a 24.86% increase from its 52 Week Low.
Micron Technology, Inc. ( MU ) is unchanged at $10.36, with 1,552,976 shares traded. MU's current last sale is 76.74% of the target price of $13.5.
EMC Corporation ( EMC ) is unchanged at $26.16, with 1,267,881 shares traded. EMC's current last sale is 88.68% of the target price of $29.5.
Brocade Communications Systems, Inc. ( BRCD ) is unchanged at $8.25, with 950,800 shares traded. BRCD's current last sale is 82.5% of the target price of $10.
Abbott Laboratories ( ABT ) is -0.1389 at $38.41, with 924,280 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2016. The consensus EPS forecast is $0.59. As reported by Zacks, the current mean recommendation for ABT is in the "buy range".
Central European Media Enterprises Ltd. ( CETV ) is unchanged at $2.76, with 740,642 shares traded. As reported in the last short interest update the days to cover for CETV is 82.040994; this calculation is based on the average trading volume of the stock.
Novavax, Inc. ( NVAX ) is +0.06 at $5.09, with 734,819 shares traded.NVAX is scheduled to provide an earnings report on 5/4/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.27 per share, which represents a -10 percent increase over the EPS one Year Ago
Fiat Chrysler Automobiles N.V. ( FCAU ) is +0.19 at $8.15, with 699,036 shares traded. FCAU's current last sale is 81.5% of the target price of $10.
First Data Corporation ( FDC ) is +0.5986 at $11.61, with 682,949 shares traded. As reported by Zacks, the current mean recommendation for FDC is in the "buy range".
ENSCO plc ( ESV ) is -0.1316 at $10.66, with 676,802 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017. The consensus EPS forecast is $0.31. ESV's current last sale is 118.43% of the target price of $9.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is -0.1389 at $38.41, with 924,280 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The following are the most active stocks for the after hours session : Iron Mountain Incorporated ( IRM ) is unchanged at $36.50, with 7,107,688 shares traded. | Abbott Laboratories ( ABT ) is -0.1389 at $38.41, with 924,280 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The total After hours volume is currently 31,755,489 shares traded. | Abbott Laboratories ( ABT ) is -0.1389 at $38.41, with 924,280 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The following are the most active stocks for the after hours session : Iron Mountain Incorporated ( IRM ) is unchanged at $36.50, with 7,107,688 shares traded. | Abbott Laboratories ( ABT ) is -0.1389 at $38.41, with 924,280 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2016. |
33901.0 | 2016-05-02 00:00:00 UTC | Zoetis (ZTS): Stock Likely to Beat on Earnings in Q1 Again? | ABT | https://www.nasdaq.com/articles/zoetis-zts%3A-stock-likely-to-beat-on-earnings-in-q1-again-2016-05-02 | nan | nan | Zoetis Inc.ZTS is scheduled to report first-quarter 2016 results on May 4, before the opening bell. Last quarter, the company easily beat expectations with a positive earnings surprise of 10.26%. Let's see how things are shaping up for this announcement.
Factors to Consider
At the time of reporting fourth-quarter 2015 earnings results, Zoetis updated its 2016 guidance to reflect the impact of the European Commission's tax rulings in Belgium, foreign exchange rates as of late January, and changes related to the company's accounting for its operations in Venezuela. For 2016, the company expects earnings in the range of $1.71 to $1.81 per share on revenues of $4.65 billion and $4.775 billion.
Meanwhile, Zoetis' robust and diversified product portfolio including products for livestock and companion animals should continue to drive top-line growth at the company. The top line should also benefit from the addition of products acquired from Abbott Laboratories' ABT Animal Health business (acquired in Feb 2015), the Nov 2015 Pharmaq acquisition as well as from the performance of Apoquel and other key brands.
However, the company expects to see a greater impact from Apoquel in the second quarter of 2016 as it increases the availability of the product in the existing markets and launches it in new markets. Moreover, Zoetis doesn't expect to see the impact from new product launches in the first quarter and anticipates these products to ramp up during the year.
Considering that Zoetis' comprehensive operational efficiency initiatives (announced in May 2015) are anticipated to be largely complete in the second half of the year, the company expects to witness the positive impact from these initiatives in the second half of the year than in the first half.
On the first-quarter call, investor focus will be on the company's performance as well as on the company's update on 2016 guidance.
Surprise History
Zoetis' track record has been impressive with the company beating earnings estimates consistently. In fact, Zoetis has posted a positive earnings surprise in each of the trailing four quarters, with an average beat of 14.81%.
Why a Likely Positive Surprise?
For the first quarter of 2016, our proven model also shows that Zoetis is likely to beat earnings estimates because it has the right combination of two key ingredients.
Positive Zacks ESP:Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +2.44%. This is a meaningful and leading indicator of a likely positive earnings surprise for the shares.
Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks #1 (Strong Buy), #2 (Buy) and #3 have a significantly higher chance of beating earnings. However, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
The combination of Zoetis' Zacks Rank #3 and +2.44% ESP makes us reasonably confident of an earnings beat this season.
Other Stocks that Warrant a Look
Here are a couple of other health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Genocea Biosciences, Inc. GNCA has an Earnings ESP of +2.50% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 5.
Jazz Pharmaceuticals plc JAZZ has an Earnings ESP of +4.58% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 10.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
GENOCEA BIOSCI (GNCA): Free Stock Analysis Report
ZOETIS INC (ZTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top line should also benefit from the addition of products acquired from Abbott Laboratories' ABT Animal Health business (acquired in Feb 2015), the Nov 2015 Pharmaq acquisition as well as from the performance of Apoquel and other key brands. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report GENOCEA BIOSCI (GNCA): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Consider At the time of reporting fourth-quarter 2015 earnings results, Zoetis updated its 2016 guidance to reflect the impact of the European Commission's tax rulings in Belgium, foreign exchange rates as of late January, and changes related to the company's accounting for its operations in Venezuela. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report GENOCEA BIOSCI (GNCA): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The top line should also benefit from the addition of products acquired from Abbott Laboratories' ABT Animal Health business (acquired in Feb 2015), the Nov 2015 Pharmaq acquisition as well as from the performance of Apoquel and other key brands. Factors to Consider At the time of reporting fourth-quarter 2015 earnings results, Zoetis updated its 2016 guidance to reflect the impact of the European Commission's tax rulings in Belgium, foreign exchange rates as of late January, and changes related to the company's accounting for its operations in Venezuela. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report GENOCEA BIOSCI (GNCA): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The top line should also benefit from the addition of products acquired from Abbott Laboratories' ABT Animal Health business (acquired in Feb 2015), the Nov 2015 Pharmaq acquisition as well as from the performance of Apoquel and other key brands. Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks #1 (Strong Buy), #2 (Buy) and #3 have a significantly higher chance of beating earnings. | The top line should also benefit from the addition of products acquired from Abbott Laboratories' ABT Animal Health business (acquired in Feb 2015), the Nov 2015 Pharmaq acquisition as well as from the performance of Apoquel and other key brands. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report GENOCEA BIOSCI (GNCA): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, the company easily beat expectations with a positive earnings surprise of 10.26%. |
33902.0 | 2016-04-29 00:00:00 UTC | Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA | ABT | https://www.nasdaq.com/articles/drug-stocks-q1-earnings-preview%3A-aegr-aeri-mack-prta-2016-04-29 | nan | nan | The going has been quite satisfactory as we stand in the thick of the first earnings season of the year. As per our Earnings Trends report , approximately 209 S&P 500 companies (52.4% of the index's total market capitalization) have reported results so far. Of these, 47.8% have reported positive surprises for both earnings and revenues, which is possibly due to already lowered expectations. On the other hand, estimates for the second quarter continue to move south, although not as severely as in the fourth quarter. Earnings for this quarter are, however, still expected to decline 8% on a year-over-year basis, marking the fourth consecutive quarter of a bottom-line decline for the index.
What Should You Expect from These Drug Stocks?
For the medical sector, which is one of the few sectors slated to record earnings growth this season, things are definitely looking up. The sector expects an increase of 2.3% in earnings and 9.1% in revenues for the first quarter of 2016.
Johnson & Johnson JNJ kick-started the season on a positive note, wherein its earnings surpassed expectations and the company raised its outlook for the year. Abbott Laboratories ABT followed suit, while biotech major, Biogen Inc. BIIB reported better-than-expected quarterly earnings.
For the next week, quite a few companies are scheduled to release results. Let's find out what's in store for these companies.
Aegerion Pharmaceuticals, Inc . AEGR is expected to report first-quarter 2016 results on May 2. Although Aegerion sports a Zacks Rank #1 (Strong Buy), the company's Earnings ESP of 0.00% makes surprise prediction difficult. The company has an impressive track record, having beaten estimates in each of the last four trailing quarters with a positive average surprise of 62%. However, the launch of PCSK9 inhibitors - Repatha and Praluent - in the U.S. has dampened Juxtapid sales and will continue to do so in the upcoming quarters, thereby hurting Aegerion's revenues. (Read more: Aegerion: Can the Stock Surprise in Q1 Earnings? )
Aerie Pharmaceuticals, Inc.AERI is also scheduled to report first-quarter 2016 results on May 2, after the market closes. The company currently carries a Zacks Rank #3 (Hold), which when combined with its 0.00% ESP, makes surprise prediction difficult. Aerie's performance over the last four quarters (on an average) has been disappointing. The company does not have any approved product in its portfolio yet. Investors are, thus, expected to focus on pipeline updates on its lead candidates - Rhopressa and Roclatan. (Read more: Aerie: Can the Stock Pull a Surprise in Q1 Earnings? )
Merrimack Pharmaceuticals, Inc . MACK is another company slated to report first-quarter 2016 results on May 2. The company has beaten estimates in two of the last four trailing quarters with an average positive earnings surprise of 6.41%. However, the combination of Merrimack's Zacks Rank #3 (Hold) and 0.00% ESP makes surprise prediction difficult. We expect investors to focus on the performance of Onivyde. (Read more: Merrimack Q1 Earnings: What's Ahead for the Stock? )
Prothena Corporation plcPRTA is expected to report first-quarter 2016 results on May 3. Prothena's track record has been has mixed so far. The company currently has a Zacks Rank #4 (Sell) and 0.00% Earnings ESP, which makes it unlikely for the company to beat estimates this quarter. With no approved product in its portfolio yet, focus should remain on pipeline updates by the company. (Read more: Prothena: What's Ahead for the Stock in Q1 Earnings? )
So stay tuned and check later on our full write-up on earnings releases of these stocks!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BIOGEN INC (BIIB): Free Stock Analysis Report
AEGERION PHARMA (AEGR): Free Stock Analysis Report
AERIE PHARMACT (AERI): Free Stock Analysis Report
PROTHENA CP PLC (PRTA): Free Stock Analysis Report
MERRIMACK PHAR (MACK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT followed suit, while biotech major, Biogen Inc. BIIB reported better-than-expected quarterly earnings. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report AERIE PHARMACT (AERI): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Although Aegerion sports a Zacks Rank #1 (Strong Buy), the company's Earnings ESP of 0.00% makes surprise prediction difficult. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report AERIE PHARMACT (AERI): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT followed suit, while biotech major, Biogen Inc. BIIB reported better-than-expected quarterly earnings. Although Aegerion sports a Zacks Rank #1 (Strong Buy), the company's Earnings ESP of 0.00% makes surprise prediction difficult. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report AERIE PHARMACT (AERI): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT followed suit, while biotech major, Biogen Inc. BIIB reported better-than-expected quarterly earnings. As per our Earnings Trends report , approximately 209 S&P 500 companies (52.4% of the index's total market capitalization) have reported results so far. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report AERIE PHARMACT (AERI): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT followed suit, while biotech major, Biogen Inc. BIIB reported better-than-expected quarterly earnings. (Read more: Aegerion: Can the Stock Surprise in Q1 Earnings? ) |
33903.0 | 2016-04-29 00:00:00 UTC | ETF Flows Show Investors Are Riding the Stock Market Rebound | ABT | https://www.nasdaq.com/articles/etf-flows-show-investors-are-riding-stock-market-rebound-2016-04-29 | nan | nan | After a tumultuous start to the year, exchange traded fund investors have been easing back into the riskier segments of the market, focusing on income generation and some more defensive strategies that may keep the edge off their stock plays.
The SPDR S&P 500 ETF (NYSEArca: SPY ) was on track to become the most popular play of April, attracting $1.8 billion in net inflows for the month through Thursday, according to ETF.com data. SPY, the largest ETF and first U.S.-listed ETF to hit the market, has the most liquid options market of any ETF and tight bid-ask spreads, attractive attributes that has helped the fund attract a large institutional following.
The Vanguard 500 Index (NYSEArca: VOO ) also brought in $870.9 million this month. While not as active as SPY, VOO has been attracting more long-term investors as the Vanguard option comes with a cheap 0.05% expense ratio, compared to SPY's 0.09% expense ratio.
Additionally, ETF investors funneled about $1.2 billion into the iShares MSCI USA Minimum Volatility ETF (NYSEArca: USMV ) , which selects U.S. stocks based on variances and correlations along with other risk factors, and $547.2 million into the iShares MSCI EAFE Minimum Volatility ETF (NYSEArca: EFAV ) , which provide a low-volatile option for developed overseas markets.
These low-vol theme have grown in popularity as conservative investors turned to this smart-beta strategy in response to the recent market oscillations. The low or minimum volatility strategy targets stocks that have lower expected risk or less idiosyncratic risks. Specifically, the strategy focuses on equities that exhibit lower beta, a measure of volatility or systematic risk of a security to that of the overall market. Consequently, minimum volatility portfolios are constructed with securities that exhibit lower market risk or beta, which help limit drawdowns during market pullbacks.
Stock ETF investors are also warming up to the health care sector, one of the worst performing areas of the market, as a potential value play. The Health Care Select Sector SPDR (NYSEArca: XLV ) saw $643.6 million in net inflows. The health care sector may continue to attract investors as merger and acquisition activity picks up, with Abbott Laboratories ( ABT ) recently agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion.
Additionally, investors still demand income-generating assets. For example, the iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSEArca: LQD ) added $1.0 billion in net inflows this month, Vanguard REIT ETF (NYSEArca: VNQ ) attracted $767.5 million and iShares TIPS Bond ETF (NYSEArca: TIP ) brought in $733.3 million.
Trending on ETF Trends
ETFs That Value Investors Buffett, Munger Would Approve Of
How The Fed is Boosting Dividend ETFs
4 Oil ETFs Ignited by Recent Surges
Water ETFs Are Making a Big Splash
Health Care ETFs Can Still Strengthen on Increased M&A Activity
Yield-generating assets got a new lease on life after the Federal Reserve said it would only hike interest rates two times this year instead of the previously stated four hikes. The return to risk also pushed investors out of more conservative plays and into riskier income-generating assets like corporate debt and real estate investment trusts.
Moreover, Treasury Inflation Protected Securities has done surprisingly well this year as investors tried to hedge their positions ahead of the eventual rise in inflationary pressures, especially with a dovish Fed fanning the flames of rising inflation expectations.
On the other hand, Japan and currency-hedged ETFs continued to bleed assets. The iShares MSCI Japan ETF (NYSEArca: EWJ ) was the most unpopular ETF of April, experiencing almost $1.3 billion in net outflows. Additionally, the WisdomTree Japan Hedged Equity Fund (NYSEArca: DXJ ) lost $679.4 million and WisdomTree Europe Hedged Equity Fund (NYSEArca: HEDJ ) saw $636.3 million in outflows.
The exodus from Japan seems prescient as the Bank of Japan recently stated it won't be changing its monetary policy, catching the markets off guard and triggering a sell-off in Japanese markets.
Meanwhile, with the Fed pushing off interest rate normalization, the U.S. dollar has weakened and foreign currencies have strengthened, diminishing the appeal of currency-hedged international stock ETFs.
Treasury bonds were also among the most shunned assets in the ongoing equity market recovery. For instance, the iShares 1-3 Year Treasury Bond ETF (NYSEArca: SHY ) saw $1.1 billion in outflows, the iShares 20+ Year Treasury Bond ETF (NYSEArca: TLT ) shrunk by $1 billion, iShares 3-7 Year Treasury Bond ETF (NYSEArca: IEI ) experienced $604.3 million in outflows and SPDR Barclays 1-3 Month T-Bill (NYSEArca: BIL ) lost $520.9 million. Investors have been moving out of government debt as yields on benchmark 10-year Treasury bonds rose to 1.84% from about 1.77% at the start of the month.
Lastly, while gold continued to shine, investors yanked $658.7 million out of SPDR Gold Shares (NYSEArca: GLD ) . Traders may be trying to trim profits after an impressive run, or some may argue that the trade has grown long in the tooth after the depreciation in the U.S. dollar and diminished need for a safe-haven bet.
Want more Equities ETF news and analysis? Visit www.etftrends.com/equities
Full disclosure: Tom Lydon's clients own shares of SPY, LQD and GLD .
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This article was provided by our partner Tom Lydon of etftrends.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The health care sector may continue to attract investors as merger and acquisition activity picks up, with Abbott Laboratories ( ABT ) recently agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion. After a tumultuous start to the year, exchange traded fund investors have been easing back into the riskier segments of the market, focusing on income generation and some more defensive strategies that may keep the edge off their stock plays. The SPDR S&P 500 ETF (NYSEArca: SPY ) was on track to become the most popular play of April, attracting $1.8 billion in net inflows for the month through Thursday, according to ETF.com data. | The health care sector may continue to attract investors as merger and acquisition activity picks up, with Abbott Laboratories ( ABT ) recently agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion. For example, the iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSEArca: LQD ) added $1.0 billion in net inflows this month, Vanguard REIT ETF (NYSEArca: VNQ ) attracted $767.5 million and iShares TIPS Bond ETF (NYSEArca: TIP ) brought in $733.3 million. Additionally, the WisdomTree Japan Hedged Equity Fund (NYSEArca: DXJ ) lost $679.4 million and WisdomTree Europe Hedged Equity Fund (NYSEArca: HEDJ ) saw $636.3 million in outflows. | The health care sector may continue to attract investors as merger and acquisition activity picks up, with Abbott Laboratories ( ABT ) recently agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion. Additionally, ETF investors funneled about $1.2 billion into the iShares MSCI USA Minimum Volatility ETF (NYSEArca: USMV ) , which selects U.S. stocks based on variances and correlations along with other risk factors, and $547.2 million into the iShares MSCI EAFE Minimum Volatility ETF (NYSEArca: EFAV ) , which provide a low-volatile option for developed overseas markets. For example, the iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSEArca: LQD ) added $1.0 billion in net inflows this month, Vanguard REIT ETF (NYSEArca: VNQ ) attracted $767.5 million and iShares TIPS Bond ETF (NYSEArca: TIP ) brought in $733.3 million. | The health care sector may continue to attract investors as merger and acquisition activity picks up, with Abbott Laboratories ( ABT ) recently agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion. The Health Care Select Sector SPDR (NYSEArca: XLV ) saw $643.6 million in net inflows. For instance, the iShares 1-3 Year Treasury Bond ETF (NYSEArca: SHY ) saw $1.1 billion in outflows, the iShares 20+ Year Treasury Bond ETF (NYSEArca: TLT ) shrunk by $1 billion, iShares 3-7 Year Treasury Bond ETF (NYSEArca: IEI ) experienced $604.3 million in outflows and SPDR Barclays 1-3 Month T-Bill (NYSEArca: BIL ) lost $520.9 million. |
33904.0 | 2016-04-28 00:00:00 UTC | Why St. Jude Medical, Inc. Acquired a Higher Price Today | ABT | https://www.nasdaq.com/articles/why-st-jude-medical-inc-acquired-higher-price-today-2016-04-28 | nan | nan | What: St. Jude Medical is up about 28% at 11:30 a.m. EDT on news that the medical-device maker agreed to be acquired by Abbott .
So what: The deal calls for Abbott to pay St. Jude Medical's shareholders $46.75 in cash and 0.8708 shares of Abbott for each share of St. Jude Medical. That values St. Jude Medical's shares at a hair under $85 based on yesterday's closing price, and under $83 per share based on the current price of Abbott, which has fallen 2.3% as of 11:30 a.m. EDT.
From a sales standpoint, joining forces makes a lot of sense. According to Abbott, the combined company "will hold the number 1 or 2 positions across large and high-growth cardiovascular device markets and will compete in nearly every area of the market."
And of course, there's the ability to save money by reducing repetitive expenses by $500 million per year by 2020. Abbott estimates that adding St. Jude Medical will increase earnings by $0.21 per share in 2017 and $0.29 per share in 2018.
Now what:
In a deal that involves getting shares from the acquiring company, the decision is a little more complicated because the daily changing stock price of the acquiring company will affect the acquired company until the acquisition goes through.
Investors who have confidence in Abbott can continue to hold, perhaps even taking shares of the combined company in the exchange. Those who don't have confidence shouldn't look a gift horse in the mouth and should feel free to sell their shares now.
This iSecret stock could make this pop look tiny
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
The article Why St. Jude Medical, Inc. Acquired a Higher Price Today originally appeared on Fool.com.
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What: St. Jude Medical is up about 28% at 11:30 a.m. EDT on news that the medical-device maker agreed to be acquired by Abbott . Investors who have confidence in Abbott can continue to hold, perhaps even taking shares of the combined company in the exchange. This iSecret stock could make this pop look tiny The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Now what: In a deal that involves getting shares from the acquiring company, the decision is a little more complicated because the daily changing stock price of the acquiring company will affect the acquired company until the acquisition goes through. | So what: The deal calls for Abbott to pay St. Jude Medical's shareholders $46.75 in cash and 0.8708 shares of Abbott for each share of St. Jude Medical. That values St. Jude Medical's shares at a hair under $85 based on yesterday's closing price, and under $83 per share based on the current price of Abbott, which has fallen 2.3% as of 11:30 a.m. EDT. Now what: In a deal that involves getting shares from the acquiring company, the decision is a little more complicated because the daily changing stock price of the acquiring company will affect the acquired company until the acquisition goes through. | What: St. Jude Medical is up about 28% at 11:30 a.m. EDT on news that the medical-device maker agreed to be acquired by Abbott . Now what: In a deal that involves getting shares from the acquiring company, the decision is a little more complicated because the daily changing stock price of the acquiring company will affect the acquired company until the acquisition goes through. Investors who have confidence in Abbott can continue to hold, perhaps even taking shares of the combined company in the exchange. |
33905.0 | 2016-04-28 00:00:00 UTC | Reaction to the Abbott Deal Makes the Stock a Buy | ABT | https://www.nasdaq.com/articles/reaction-abbott-deal-makes-stock-buy-2016-04-28 | nan | nan | In the eyes of traders, it seems, not all growth is created equal. It is an old cliché in business that if you are not moving forward, you are going backwards; growth is seen as essential to survival. For all businesses, though, there is a limit to organic growth. Once sales have reached a certain point the only way to grow in a significant manner is by acquisition, but all too often, stock in the acquiring company is punished when a takeover is announced.
In some cases, such as with Abbott Laboratories (ABT) announced takeover of St. Jude Medical (STJ) this morning, the reason for the acquirer's stock falling initially is fairly clear. Abbott has announced that they will be issuing more stock to pay part of the cost of the acquisition, thereby diluting the value of current holdings.
Even with that in mind though, this looks like a deal with significant synergies that should, according to Abbott CEO Miles White, be immediately accretive and the big drop in ABT looks like a buying opportunity.
St. Jude is a manufacturer of cardio-vascular devices and products, a business that will mesh well with Abbott’s existing presence in the field, so from an industry perspective, the deal makes sense, but it is the broader picture that suggests that the timing and nature of the acquisition will be beneficial to Abbott for some time to come.
There are signs that Bernie Sanders’ campaign is finally accepting defeat in the Democratic primary here in the U.S., which makes it less likely that the new administration will be aggressive towards the healthcare business in general, and the fear of that possibility has kept stocks in the industry down over the last year or so. That has left ABT, for example trading at around 14x trailing earnings, a discount to the broader market.
In addition, if there was ever a time for a corporation to initiate medium and long term debt, which will cover the bulk of the acquisition costs in this deal, it is now. Interest rates at near record lows enable a corporation to borrow so cheaply that, even without the combined cost reductions that look likely here, buying a profitable company will increase profits more than enough to offset interest costs in most cases.
The Fed left rates unchanged yesterday and the pace of any rate increases looks like being extremely slow, but at some point they will come. In that context, borrowing now looks like a smart move.
Perhaps the biggest reason to like ABT after the roughly 10 percent fall in the price since the announcement, however, is that White has suggested that this will be the last major acquisition that Abbott will make for a while. That indicates that the recent buying spree of the company was not entirely about making use of cheap money, but that it was part of a well thought out, strategic long term plan.
With levered free cash flow of around $3.5 billion before the St. Jude deal it is reasonable to expect a rapid consolidation of Abbott’s balance sheet once the dust settles.
As I said, the issuance of stock, along with other measures such as a reduction in the share buyback scheme currently in place and a moderated rate of dividend growth, explain part of the reaction to the announcement of this deal, but I suspect there is another factor at play.
With the example of Valeant Pharmaceuticals (VRX) still fresh in their minds traders and investors are wary of growth by acquisition in the healthcare field. This case, however, is completely different. It is an example of a business doing what businesses should do, taking advantage of cheap money and relatively low stock prices in their industry to make planned strategic acquisitions.
Punishing the stock for that makes little sense, but does make for an opportunity for long term investors.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In some cases, such as with Abbott Laboratories (ABT) announced takeover of St. Jude Medical (STJ) this morning, the reason for the acquirer's stock falling initially is fairly clear. Even with that in mind though, this looks like a deal with significant synergies that should, according to Abbott CEO Miles White, be immediately accretive and the big drop in ABT looks like a buying opportunity. That has left ABT, for example trading at around 14x trailing earnings, a discount to the broader market. | In some cases, such as with Abbott Laboratories (ABT) announced takeover of St. Jude Medical (STJ) this morning, the reason for the acquirer's stock falling initially is fairly clear. Even with that in mind though, this looks like a deal with significant synergies that should, according to Abbott CEO Miles White, be immediately accretive and the big drop in ABT looks like a buying opportunity. That has left ABT, for example trading at around 14x trailing earnings, a discount to the broader market. | In some cases, such as with Abbott Laboratories (ABT) announced takeover of St. Jude Medical (STJ) this morning, the reason for the acquirer's stock falling initially is fairly clear. Even with that in mind though, this looks like a deal with significant synergies that should, according to Abbott CEO Miles White, be immediately accretive and the big drop in ABT looks like a buying opportunity. That has left ABT, for example trading at around 14x trailing earnings, a discount to the broader market. | In some cases, such as with Abbott Laboratories (ABT) announced takeover of St. Jude Medical (STJ) this morning, the reason for the acquirer's stock falling initially is fairly clear. Even with that in mind though, this looks like a deal with significant synergies that should, according to Abbott CEO Miles White, be immediately accretive and the big drop in ABT looks like a buying opportunity. That has left ABT, for example trading at around 14x trailing earnings, a discount to the broader market. |
33906.0 | 2016-04-28 00:00:00 UTC | Mid-Morning Market Update: Markets Mostly Lower; Ford Tops Q1 Expectations | ABT | https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-lower-ford-tops-q1-expectations-2016-04-28 | nan | nan | Following the market opening Thursday, the Dow traded down 0.44 percent to 17,962.18 while the NASDAQ gained 0.08 percent to 4,866.85. The S&P also fell, dropping 0.23 percent to 2,090.33.
Leading and Lagging Sectors
On Thursday, the non-cyclical consumer goods & services sector proved to be a source of strength for the market.
In trading on Thursday, financial shares fell by 0.81 percent. Meanwhile, top losers in the sector included Ocwen Financial Corp (NYSE: OCN ), down 21 percent, and American Equity Investment Life Holding (NYSE: AEL ), down 12 percent.
Top Headline
Ford Motor Company (NYSE: F ) reported better-than-expected results for its first quarter on Thursday.
Ford said it earned $0.68 per share in the first quarter on revenue of $37.7 billion. Wall Street analysts were expecting the company to earn $0.48 per share on revenue of $35.7 billion.
North America recorded a best quarter ever pre-tax profit of $3.1 billion, up $1.5 billion from a year ago with a record operating margin of 12.9 percent.
Equities Trading UP
National Holdings Corporation (NASDAQ: NHLD ) shares shot up 45 percent to $3.19 as Fortress Biotech Inc (NASDAQ: FBIO ) announced plans to acquire National Holdings for $3.25 per share in cash.
Shares of Textura Corp (NYSE: TXTR ) got a boost, shooting up 31 percent to $26.07 as the company agreed to be acquired by Oracle Corporation (NYSE: ORCL ) for $26 per share. Textura reported Q1 earnings of $0.09 per share on revenue of $24.7 million.
St. Jude Medical, Inc. (NYSE: STJ ) shares were also up, gaining 25 percent to $77.62 after Abbott Laboratories (NYSE: ABT ) announced it has entered into an agreement to acquire St. Jude for a total consideration of $25 billion.
Equities Trading DOWN
GNC Holdings Inc (NYSE: GNC ) shares dropped 25 percent to $26.69 as the company reported weaker-than-expected Q1 earnings.
Shares of Ocwen Financial Corp (NYSE: OCN ) were down 21 percent to $2.23. Ocwen Financial reported a quarterly loss of $0.90 per share on revenue of $330.8 million
Silicon Graphics International Corp (NASDAQ: SGI ) was down, falling around 31 percent to $4.86. Silicon Graphics reported FQ3 adjusted earnings of $0.03 per share on revenue of $132.1 million. The company also lowered its FY16 forecast.
Commodities
In commodity news, oil traded up 0.02 percent to $45.34 while gold traded up 0.85 percent to $1,261.00.
Silver traded up 0.46 percent Thursday to $17.42, while copper fell 0.13 percent to $2.22.
Eurozone
European shares were lower today. The eurozone's STOXX 600 dropped 1.02 percent, the Spanish Ibex Index fell 2.05 percent, while Italy's FTSE MIB Index slipped 0.46 percent. Meanwhile, the German DAX declined 1.09 percent, and the French CAC 40 dropped 1.30 percent, while U.K. shares fell 0.96 percent.
Economics
The U.S. economy expanded 0.5 percent in the first quarter.
U.S. jobless claims increased by 9,000 to 257,000 in the latest week.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | St. Jude Medical, Inc. (NYSE: STJ ) shares were also up, gaining 25 percent to $77.62 after Abbott Laboratories (NYSE: ABT ) announced it has entered into an agreement to acquire St. Jude for a total consideration of $25 billion. Top Headline Ford Motor Company (NYSE: F ) reported better-than-expected results for its first quarter on Thursday. Equities Trading UP National Holdings Corporation (NASDAQ: NHLD ) shares shot up 45 percent to $3.19 as Fortress Biotech Inc (NASDAQ: FBIO ) announced plans to acquire National Holdings for $3.25 per share in cash. | St. Jude Medical, Inc. (NYSE: STJ ) shares were also up, gaining 25 percent to $77.62 after Abbott Laboratories (NYSE: ABT ) announced it has entered into an agreement to acquire St. Jude for a total consideration of $25 billion. Meanwhile, top losers in the sector included Ocwen Financial Corp (NYSE: OCN ), down 21 percent, and American Equity Investment Life Holding (NYSE: AEL ), down 12 percent. Equities Trading DOWN GNC Holdings Inc (NYSE: GNC ) shares dropped 25 percent to $26.69 as the company reported weaker-than-expected Q1 earnings. | St. Jude Medical, Inc. (NYSE: STJ ) shares were also up, gaining 25 percent to $77.62 after Abbott Laboratories (NYSE: ABT ) announced it has entered into an agreement to acquire St. Jude for a total consideration of $25 billion. Meanwhile, top losers in the sector included Ocwen Financial Corp (NYSE: OCN ), down 21 percent, and American Equity Investment Life Holding (NYSE: AEL ), down 12 percent. Equities Trading UP National Holdings Corporation (NASDAQ: NHLD ) shares shot up 45 percent to $3.19 as Fortress Biotech Inc (NASDAQ: FBIO ) announced plans to acquire National Holdings for $3.25 per share in cash. | St. Jude Medical, Inc. (NYSE: STJ ) shares were also up, gaining 25 percent to $77.62 after Abbott Laboratories (NYSE: ABT ) announced it has entered into an agreement to acquire St. Jude for a total consideration of $25 billion. In trading on Thursday, financial shares fell by 0.81 percent. Meanwhile, top losers in the sector included Ocwen Financial Corp (NYSE: OCN ), down 21 percent, and American Equity Investment Life Holding (NYSE: AEL ), down 12 percent. |
33907.0 | 2016-04-28 00:00:00 UTC | US Stocks Eye Lower Open Amid Lackluster Q1 GDP Growth; Japan Holds Off on More Stimulus | ABT | https://www.nasdaq.com/articles/us-stocks-eye-lower-open-amid-lackluster-q1-gdp-growth-japan-holds-more-stimulus-2016-04 | nan | nan | U.S. stocks were set to open lower on Thursday as the first estimate for economic growth in the U.S. in Q1 fell short of already modest expectations, and as the Bank of Japan decided to leave its interest rates unchanged with no additional stimulus.
The first estimate for Q1 GDP showed a lackluster 0.5% growth from Q4, missing even the 0.7% increase that had been expected. The consensus range was between 0.1% and 1.1%, according to data compiled by Econoday. In Q4, GDP grew 1.4% and in Q3 it grew 2.0%.
Jobless claims in the week ended April 23 rose to 257,000, short of the 260,000 expected, while the previous week's claims were revised up to 248,000 from 247,000.
St. Jude Medical ( STJ ) shares were the most active in pre-market trade, surging over 24% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. ABT fell over 9%. Ford ( F ) meanwhile was another bright spot, up 2% after its Q1 results exceeded estimates.
U.S. PRE-MARKET INDICATORS
-Dow Jones Industrial down 0.76%
-S&P 500 futures down 0.67%
-Nasdaq 100 futures down 0.37%
GLOBAL SENTIMENT
Nikkei down 3.61%
Hang Seng up 0.12%
Shanghai Composite down 0.27%
FTSE-100 down 1.04%
DAX-30 down 1.19%
PRE-MARKET SECTOR WATCH
(+/-) Large cap tech: mixed
(+/-) Chip stocks: mixed
(-) Software stocks: unchanged to lower
(-) Hardware stocks: unchanged to lower
(+/-) Internet stocks: mixed
(-) Oil stocks: unchanged to lower
(-) Biotech: unchanged to lower
(+/-) Drug stocks: mixed
(-) Financial stocks: unchanged to lower
(+/-) Retail stocks: unchanged
(-) Industrial stocks: unchanged to lower
(+/-) Airlines: mixed
(+/-) Autos: mixed
UPSIDE MOVERS
(+) MDVN (+7.4%) SNY (-1.7%) discloses bid to buy co for $9.3 billion
(+) FB (+11.2%) Q1 results top expectations
(+) TXTR (+30.7%) ORCL to buy co for $26 per share
(+) CLF (+10.7%) Swings to Q1 profit
DOWNSIDE MOVERS
(-) CELG (-1.5%) Q1 revenue misses Street view, narrows FY guidance
(-) DPZ (-9.7%) Q1 results miss estimates
(-) POT (-6.3%) Q1 misses views
(-) TS (-3.4%) Reports Q1 results
(-) INFN (-15.7%) Reports Q1 EPS beat, misses on revenue
(-) VRTX (-3.0%) Q1 EPS comes in well below consensus
(-) EVEP (-5.6%) Halts distributions
(-) WLL (-3.2%) Q1 results misses expectations
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | St. Jude Medical ( STJ ) shares were the most active in pre-market trade, surging over 24% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. ABT fell over 9%. U.S. stocks were set to open lower on Thursday as the first estimate for economic growth in the U.S. in Q1 fell short of already modest expectations, and as the Bank of Japan decided to leave its interest rates unchanged with no additional stimulus. | St. Jude Medical ( STJ ) shares were the most active in pre-market trade, surging over 24% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. ABT fell over 9%. (+/-) Large cap tech: mixed (+/-) Chip stocks: mixed (-) Software stocks: unchanged to lower (-) Hardware stocks: unchanged to lower (+/-) Internet stocks: mixed (-) Oil stocks: unchanged to lower (-) Biotech: unchanged to lower (+/-) Drug stocks: mixed (-) Financial stocks: unchanged to lower (+/-) Retail stocks: unchanged (-) Industrial stocks: unchanged to lower (+/-) Airlines: mixed (+/-) Autos: mixed | St. Jude Medical ( STJ ) shares were the most active in pre-market trade, surging over 24% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. ABT fell over 9%. Nikkei down 3.61% Hang Seng up 0.12% Shanghai Composite down 0.27% FTSE-100 down 1.04% DAX-30 down 1.19% | ABT fell over 9%. St. Jude Medical ( STJ ) shares were the most active in pre-market trade, surging over 24% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. U.S. stocks were set to open lower on Thursday as the first estimate for economic growth in the U.S. in Q1 fell short of already modest expectations, and as the Bank of Japan decided to leave its interest rates unchanged with no additional stimulus. |
33908.0 | 2016-04-28 00:00:00 UTC | Pre-Market Most Active for Apr 28, 2016 : F, STJ, FB, ABT, TVIX, MDVN, TXTR, SIRI, SRPT, PHI, FE, XIV | ABT | https://www.nasdaq.com/articles/pre-market-most-active-apr-28-2016-f-stj-fb-abt-tvix-mdvn-txtr-siri-srpt-phi-fe-xiv-2016 | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 15.23 to 4,431.86. The total Pre-Market volume is currently 16,446,488 shares traded.
The following are the most active stocks for the pre-market session :
Ford Motor Company ( F ) is +0.3 at $13.96, with 3,630,154 shares traded. RTT News Reports: Ford Q1 Profit Rises; Stock Up
St. Jude Medical, Inc. ( STJ ) is +15.45 at $77.40, with 3,140,737 shares traded. Over the last four weeks they have had 12 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2016. The consensus EPS forecast is $1.06. As reported by Zacks, the current mean recommendation for STJ is in the "buy range".
Facebook, Inc. ( FB ) is +12.11 at $121.00, with 2,627,810 shares traded. As reported by Zacks, the current mean recommendation for FB is in the "buy range".
Abbott Laboratories ( ABT ) is -3.68 at $40.15, with 2,393,807 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2016. The consensus EPS forecast is $0.59. As reported by Zacks, the current mean recommendation for ABT is in the "buy range".
region ( TVIX ) is +0.18 at $3.41, with 1,529,824 shares traded., following a 52-week high recorded in prior regular session.
Medivation, Inc. ( MDVN ) is +3.9 at $55.95, with 1,219,656 shares traded.MDVN is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is 0.2 per share, which represents a 3 percent increase over the EPS one Year Ago
Textura Corporation ( TXTR ) is +6.11 at $26.00, with 638,107 shares traded. RTT News Reports: Oracle To Buy Textura For $663 Million - Quick Facts
Sirius XM Holdings Inc. ( SIRI ) is +0.01 at $3.99, with 589,887 shares traded. RTT News Reports: Sirius XM Holdings Inc. Earnings Advance 62% In Q1
Sarepta Therapeutics, Inc. ( SRPT ) is +2.05 at $13.60, with 499,305 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2016. The consensus EPS forecast is $-1.31. SRPT is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -1.31 per share, which represents a -149 percent increase over the EPS one Year Ago
Philippine Long Distance Telephone Company ( PHI ) is -0.4861 at $37.34, with 475,800 shares traded.PHI is scheduled to provide an earnings report on 5/3/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is 999 per share, which represents a 96 percent increase over the EPS one Year Ago
FirstEnergy Corporation ( FE ) is -3.05 at $33.00, with 424,474 shares traded. FE's current last sale is 84.62% of the target price of $39.
region ( XIV ) is -0.81 at $28.00, with 298,224 shares traded. This represents a 82.29% increase from its 52 Week Low.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is -3.68 at $40.15, with 2,393,807 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". RTT News Reports: Ford Q1 Profit Rises; Stock Up St. Jude Medical, Inc. ( STJ ) is +15.45 at $77.40, with 3,140,737 shares traded. | Abbott Laboratories ( ABT ) is -3.68 at $40.15, with 2,393,807 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The consensus earnings per share forecast is 0.2 per share, which represents a 3 percent increase over the EPS one Year Ago Textura Corporation ( TXTR ) is +6.11 at $26.00, with 638,107 shares traded. | Abbott Laboratories ( ABT ) is -3.68 at $40.15, with 2,393,807 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The consensus earnings per share forecast is 0.2 per share, which represents a 3 percent increase over the EPS one Year Ago Textura Corporation ( TXTR ) is +6.11 at $26.00, with 638,107 shares traded. | As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Abbott Laboratories ( ABT ) is -3.68 at $40.15, with 2,393,807 shares traded. The NASDAQ 100 Pre-Market Indicator is up 15.23 to 4,431.86. |
33909.0 | 2016-04-28 00:00:00 UTC | US Equities Futures Follow Europe, Asia Lower as Japan Leave Interest Rate Unchanged | ABT | https://www.nasdaq.com/articles/us-equities-futures-follow-europe-asia-lower-japan-leave-interest-rate-unchanged-2016-04 | nan | nan | U.S. stock futures were in the red Thursday, weighed down by the Bank of Japan's decision to leave interest rates unchanged with no additional stimulus. Some upbeat corporate earnings and merger activity failed to stem the negative sentiment.
In economic data out Thursday, at 8:30 a.m. E.T., the first estimate for Q1 GDP is expected to show 0.7% growth from Q4 when GDP grew 1.4%. The consensus range is between 0.1% and 1.1%, according to data compiled by Econoday.
Jobless claims in the week ended April 23 are meanwhile expected to have gained to 260,000 from 247,000 in the prior week. The consensus range is between 240,000 and 264,000.
St. Jude Medical ( STJ ) shares was the most active in pre-market trade, surging 25% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. Ford ( F ) was another bright spot, up 2% after its Q1 results exceeded estimates.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | St. Jude Medical ( STJ ) shares was the most active in pre-market trade, surging 25% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. U.S. stock futures were in the red Thursday, weighed down by the Bank of Japan's decision to leave interest rates unchanged with no additional stimulus. Some upbeat corporate earnings and merger activity failed to stem the negative sentiment. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. St. Jude Medical ( STJ ) shares was the most active in pre-market trade, surging 25% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. The consensus range is between 0.1% and 1.1%, according to data compiled by Econoday. | St. Jude Medical ( STJ ) shares was the most active in pre-market trade, surging 25% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. U.S. stock futures were in the red Thursday, weighed down by the Bank of Japan's decision to leave interest rates unchanged with no additional stimulus. E.T., the first estimate for Q1 GDP is expected to show 0.7% growth from Q4 when GDP grew 1.4%. | St. Jude Medical ( STJ ) shares was the most active in pre-market trade, surging 25% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. Some upbeat corporate earnings and merger activity failed to stem the negative sentiment. In economic data out Thursday, at 8:30 a.m. |
33910.0 | 2016-04-28 00:00:00 UTC | 3 Stocks to Watch on Thursday: Marriott International Inc (MAR), St. Jude Medical, Inc. (STJ) and Texas Instruments Incorporated (TXN) | ABT | https://www.nasdaq.com/articles/3-stocks-to-watch-on-thursday%3A-marriott-international-inc-mar-st.-jude-medical-inc.-stj | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Technology stocks have had a rough week, but the stock market still managed to post meager gains overall on hump day. The S&P 500 's Wednesday move was the same as the previous day, up 0.2%, while the Dow Jones Industrial Average managed to improve by 0.3% yesterday.
Another string of companies reported fiscal results for their most recent periods, including the likes of Marriott International Inc (NASDAQ: MAR ) and Texas Instruments Incorporated (NASDAQ: TXN ). St. Jude Medical, Inc. (NYSE: STJ ) will be moving, but for a much different reason.
Here's why all three will be heavily watched this morning:
St. Jude Medical, Inc. (STJ)
Medical device maker St. Jude Medical is going to pop this morning, and it has Abbott Laboratories ( ABT ) to thank.
Abbott has just announced that it plans to buy STJ for $25 billion in a cash-and-stock deal, giving Abbott access to technology such as cardiac navigation/visualization product MediGuide and Assura defibrillators.
The 10 Best Growth Stocks to Buy for Retirement
"St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share," according to an ABT press release.
That represents a roughly 37% premium to Wednesday's closing price of $61.97 for STJ stock, though shares were up "just" 27% in Thursday's premarket trade.
Marriott International Inc (MAR)
Hotel operator Marriott managed to get past Wall Street estimates for its most recent quarter. Q1 earnings came to 86 cents per share , topping expectations by a pair of pennies and growing substantially from last year's 73 cents. Revenue was rosy as well, coming in at $3.77 billion versus the $3.68 billion expected by analysts, and good for 7.4% growth.
Driving Marriott's success was a strong period in Asia, where the company is expanding. Its Asia-region hotels enjoyed a 4.3% improvement in occupancy.
Outlook was weak; Q2 earnings projections of 96 cents to $1 were just shy of the analysts' consensus mark.
But that didn't appear to be hindering shares - MAR stock looked set to rise a couple of percentage points at Thursday's open.
Texas Instruments Incorporated (TXN)
Texas Instruments' fiscal first-quarter results also came in ahead of expectations, though that might not help TXN shares today.
The company experienced success in its automotive and industrial segments, helping earnings reach 65 cents per share, topping the 62 cents per share Wall Street analysts expected. Revenues of $3.01 billion also barely beat consensus estimates of $2.98 billion.
Guidance for Q2 came to 67 to 77 cents in earnings per share, which covers estimates for 71 cents per share.
Facebook Crushes Earnings Expectations - Is FB Unstoppable?
The personal electronics market was a weak spot for Texas Instruments last quarter, according to CEO Rich Templeton.
TXN stock was set to open about 1% lower on Thursday.
As of this writing, Karl Utermohlen did not hold a position in any of the aforementioned securities.
More From InvestorPlace
3 Bank Stocks Getting Whipsawed by the Fed
7 Dividend Stocks With "Hidden" Yields You NEED to Own
The post 3 Stocks to Watch on Thursday: Marriott International Inc (MAR), St. Jude Medical, Inc. (STJ) and Texas Instruments Incorporated (TXN) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here's why all three will be heavily watched this morning: St. Jude Medical, Inc. (STJ) Medical device maker St. Jude Medical is going to pop this morning, and it has Abbott Laboratories ( ABT ) to thank. The 10 Best Growth Stocks to Buy for Retirement "St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share," according to an ABT press release. The S&P 500 's Wednesday move was the same as the previous day, up 0.2%, while the Dow Jones Industrial Average managed to improve by 0.3% yesterday. | Here's why all three will be heavily watched this morning: St. Jude Medical, Inc. (STJ) Medical device maker St. Jude Medical is going to pop this morning, and it has Abbott Laboratories ( ABT ) to thank. The 10 Best Growth Stocks to Buy for Retirement "St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share," according to an ABT press release. Another string of companies reported fiscal results for their most recent periods, including the likes of Marriott International Inc (NASDAQ: MAR ) and Texas Instruments Incorporated (NASDAQ: TXN ). | Here's why all three will be heavily watched this morning: St. Jude Medical, Inc. (STJ) Medical device maker St. Jude Medical is going to pop this morning, and it has Abbott Laboratories ( ABT ) to thank. The 10 Best Growth Stocks to Buy for Retirement "St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share," according to an ABT press release. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Technology stocks have had a rough week, but the stock market still managed to post meager gains overall on hump day. | The 10 Best Growth Stocks to Buy for Retirement "St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share," according to an ABT press release. Here's why all three will be heavily watched this morning: St. Jude Medical, Inc. (STJ) Medical device maker St. Jude Medical is going to pop this morning, and it has Abbott Laboratories ( ABT ) to thank. Q1 earnings came to 86 cents per share , topping expectations by a pair of pennies and growing substantially from last year's 73 cents. |
33911.0 | 2016-04-28 00:00:00 UTC | Why Abbott Laboratories (ABT), GNC Holdings Inc (GNC) and Symantec Corporation (SYMC) Are 3 of Today’s Worst Stocks | ABT | https://www.nasdaq.com/articles/why-abbott-laboratories-abt-gnc-holdings-inc-gnc-and-symantec-corporation-symc-are-3-of | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The bulls held on as long as they could after this morning's lackluster gross domestic product report for the first quarter of the year. But the longer the news had to fester, the longer traders had to decide there's simply more risk than reward in owning stocks today. The S&P 500 ended the session at 2075.81, down 0.92%.
Leading the charge lower were Abbott Laboratories (NYSE: ABT ), GNC Holdings Inc (NYSE: GNC ) and Symantec Corporation (NASDAQ: SYMC ).
Here's a closer look at each one's demise.
Abbott Laboratories (ABT)
At another time and in a different situation, an acquisition may have been a big hit with investors. With a great deal of uncertainty on the horizon, however, Abbott Laboratories shareholders were more concerned than thrilled with the company's decision to acquire cardiovascular medical technology name Saint Jude Medical .
The premise and logic of the deal mustered a few supporters. Mostly though, professionals and amateurs alike don't see a ton of upside given the $19.3 billion price tag on the union.
5 Stocks to Sell for May
BMO Capital Markets analyst Joanne Wuensch asked the following: "St. Jude is in more mature cardiac rhythm management markets, so does this really become additive to the overall Abbott revenue growth rate?" Meanwhile, Morningstar's Debbie Wang worried, "Once they make those purchases, it does not seem like management is very good at producing meaningful innovation."
The near-8% loss ABT shares logged today says the majority of shareholders have the same concerns.
GNC Holdings Inc (GNC)
GNC Holdings shares lost a whopping 29% today following the company's Q1 earnings report and news that it was aiming to close more than 80 company-owned stores.
In its first fiscal quarter of 2016, nutritional supplement company GNC Holdings reported a profit of 69 cents per share on revenue of $668.9 million. The pros, however, were calling for a bottom line of 75 cents per share and a top line of $671.5 million.
The real red flag that did most of the damage on Thursday, however, was the announcement that GNC intended to sell 84 of its company-owned units as a prelude to the sale of around 1,000 GNC stores . That much interest in discarding company-owned stores is an indirect hint that the organization lacks confidence in its plausible future.
Symantec Corporation (SYMC)
Last but not least, cybersecurity outfit Symantec dished out a double-sized dose of bad news to SYMC shareholders on Thursday, reporting a disappointing fourth-quarter forecast, and underscoring that bad news by announcing its CEO was stepping down.
3 Shiny Dividend Stocks With Horrid Fundamentals
Per this morning's news release, Symantec Corporation now believes it's going to earn 22 cents per share on $873 million in revenue for the quarter ending in March . The top-line outlook fell short of previous guidance of $885 million to $915 million, while the bottom-line ended up short of the previously forecasted per-share earnings of 24 to 27 cents per share.
On average, analysts had been calling for a profit of 25 cents per share on sales of $901.2 million.
To what extent the tepid numbers were the reason isn't clear, but along with the revised forecast, Chief Executive Officer Michael Brown announced he would be stepping down from his post as soon as a replacement is found.
SYMC ended the day down 7%.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities.
More From InvestorPlace
The 10 Best Stocks of the Past 10 Years
Whole Foods Market, Inc.: 365 Is a Really, REALLY Dumb Idea
The post Why Abbott Laboratories (ABT), GNC Holdings Inc (GNC) and Symantec Corporation (SYMC) Are 3 of Today's Worst Stocks appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leading the charge lower were Abbott Laboratories (NYSE: ABT ), GNC Holdings Inc (NYSE: GNC ) and Symantec Corporation (NASDAQ: SYMC ). Abbott Laboratories (ABT) At another time and in a different situation, an acquisition may have been a big hit with investors. The near-8% loss ABT shares logged today says the majority of shareholders have the same concerns. | Leading the charge lower were Abbott Laboratories (NYSE: ABT ), GNC Holdings Inc (NYSE: GNC ) and Symantec Corporation (NASDAQ: SYMC ). More From InvestorPlace The 10 Best Stocks of the Past 10 Years Whole Foods Market, Inc.: 365 Is a Really, REALLY Dumb Idea The post Why Abbott Laboratories (ABT), GNC Holdings Inc (GNC) and Symantec Corporation (SYMC) Are 3 of Today's Worst Stocks appeared first on InvestorPlace . Abbott Laboratories (ABT) At another time and in a different situation, an acquisition may have been a big hit with investors. | Leading the charge lower were Abbott Laboratories (NYSE: ABT ), GNC Holdings Inc (NYSE: GNC ) and Symantec Corporation (NASDAQ: SYMC ). More From InvestorPlace The 10 Best Stocks of the Past 10 Years Whole Foods Market, Inc.: 365 Is a Really, REALLY Dumb Idea The post Why Abbott Laboratories (ABT), GNC Holdings Inc (GNC) and Symantec Corporation (SYMC) Are 3 of Today's Worst Stocks appeared first on InvestorPlace . Abbott Laboratories (ABT) At another time and in a different situation, an acquisition may have been a big hit with investors. | Leading the charge lower were Abbott Laboratories (NYSE: ABT ), GNC Holdings Inc (NYSE: GNC ) and Symantec Corporation (NASDAQ: SYMC ). More From InvestorPlace The 10 Best Stocks of the Past 10 Years Whole Foods Market, Inc.: 365 Is a Really, REALLY Dumb Idea The post Why Abbott Laboratories (ABT), GNC Holdings Inc (GNC) and Symantec Corporation (SYMC) Are 3 of Today's Worst Stocks appeared first on InvestorPlace . Abbott Laboratories (ABT) At another time and in a different situation, an acquisition may have been a big hit with investors. |
33912.0 | 2016-04-28 00:00:00 UTC | Why Dreamworks Animation Skg Inc (DWA), St. Jude Medical, Inc. (STJ) and Textura Corp (TXTR) Are 3 of Today’s Best Stocks | ABT | https://www.nasdaq.com/articles/why-dreamworks-animation-skg-inc-dwa-st.-jude-medical-inc.-stj-and-textura-corp-txtr-are-3 | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Stocks slumped again as global investors were spooked by a perceived lack of initiative from the Bank of Japan, which during Thursday's Asian session, did exactly what it did not want to do: Send the yen soaring.
With the yen being one of this year's preferred safe-haven destinations, stocks could not endure the storm even though oil climbed to its highest levels since early November. The S&P 500 lost nearly 1% while the Dow Jones Industrial Average and the Nasdaq Composite each lost more than 1%.
Obviously, it is Thursday, not Monday, but it felt like a "Merger Monday" today, and that explains why Dreamworks Animation Skg Inc (NASDAQ: DWA ), St. Jude Medical, Inc. (NYSE: STJ ) and Textura Corp (NYSE: TXTR ) are three of today's best stocks.
D reamworks Animation Skg Inc
A day after soaring on rumors Comcast Corporation (NASDAQ: CMCSA ) could be interested in acquiring the company, shares of Dreamworks surged 24% as cable giant Comcast made a formal offer for the maker of animated movies.
The 10 Best Growth Stocks to Buy for Retirement
CMCSA said it will buy DWA for $3.55 billion. The deal values DWA at $41 a share, a 27% premium to where DWA closed yesterday.
The transaction is expected to close by year end. DWA CEO Jeffrey Katzenberg will leave the company, but serve as a consultant to CMCSA's NBC Universal unit.
St. Jude Medical, Inc.
Shares of medical device maker St. Jude Medical climbed 25.6% on about 14 times the average daily volume after Abbott Laboratories (NYSE: ABT ) said it will acquire STJ for $19.3 billion in cash and stock. STJ investors will receive $46.75 a share in cash and part of an ABT share for each STJ share they own.
ABT's offer values STJ at $85 per share, a 37% premium to where the stock closed yesterday. The total deal value is $25 billion when factoring in STJ debt to be assumed by ABT . Boards of both ABT and STJ have approved the deal, which is expected to close in the fourth quarter.
Textura Corp
Textura Corp, the cloud-computing firm, jumped 30.7% on volume that was more than 100 times the daily average after Oracle Corporation (NYSE: ORCL ) said it will buy the company for $633 million. ORCL's offer of $26 per share in cash represents a 30% premium for TXTR.
The 10 Best Stocks of the Past 10 Years
TXTR specializes in construction billing and invoices, serving "85,000 general and subcontractors processing $3.4 billion in payments a month," according to Barron's .
TXTR will become part of ORCL's Primavera business.
At the time of this writing, Todd Shriber did not own any of the aforementioned securities.
More From InvestorPlace
7 Index Funds That Are Built to Beat the Market
7 Dividend Stocks With "Hidden" Yields You NEED to Own
The post Why Dreamworks Animation Skg Inc (DWA), St. Jude Medical, Inc. (STJ) and Textura Corp (TXTR) Are 3 of Today's Best Stocks appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | St. Jude Medical, Inc. Shares of medical device maker St. Jude Medical climbed 25.6% on about 14 times the average daily volume after Abbott Laboratories (NYSE: ABT ) said it will acquire STJ for $19.3 billion in cash and stock. STJ investors will receive $46.75 a share in cash and part of an ABT share for each STJ share they own. ABT's offer values STJ at $85 per share, a 37% premium to where the stock closed yesterday. | St. Jude Medical, Inc. Shares of medical device maker St. Jude Medical climbed 25.6% on about 14 times the average daily volume after Abbott Laboratories (NYSE: ABT ) said it will acquire STJ for $19.3 billion in cash and stock. STJ investors will receive $46.75 a share in cash and part of an ABT share for each STJ share they own. ABT's offer values STJ at $85 per share, a 37% premium to where the stock closed yesterday. | St. Jude Medical, Inc. Shares of medical device maker St. Jude Medical climbed 25.6% on about 14 times the average daily volume after Abbott Laboratories (NYSE: ABT ) said it will acquire STJ for $19.3 billion in cash and stock. STJ investors will receive $46.75 a share in cash and part of an ABT share for each STJ share they own. ABT's offer values STJ at $85 per share, a 37% premium to where the stock closed yesterday. | STJ investors will receive $46.75 a share in cash and part of an ABT share for each STJ share they own. ABT's offer values STJ at $85 per share, a 37% premium to where the stock closed yesterday. St. Jude Medical, Inc. Shares of medical device maker St. Jude Medical climbed 25.6% on about 14 times the average daily volume after Abbott Laboratories (NYSE: ABT ) said it will acquire STJ for $19.3 billion in cash and stock. |
33913.0 | 2016-04-28 00:00:00 UTC | Health Care ETFs Can Still Strengthen on Increased M&A Activity | ABT | https://www.nasdaq.com/articles/health-care-etfs-can-still-strengthen-increased-ma-activity-2016-04-28 | nan | nan | While the health industry has underperformed so far this year, health care stocks and sector-related exchange traded funds can gain momentum on increased merger and acquisition activity.
About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories ( ABT ) agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion, Bloomberg reports.
Premiums on health care deals are also holding, with almost 30% of deals this year commanding premiums of 40% to 50%, mirroring premiums paid this time last year.
The rash of new deals is already up 27% on a dollar basis from a year ago when the industry was on its way to over a 12-year record in deal making. Businesses are expanding their product lines through acquisitions as they face increased competition and look to new merchandise to raise sales.
"We are likely see more M&A in health care this year as companies streamline their portfolios and seek to build up those areas of higher future growth," Nigel Jones, co-head of health care at Linklaters law firm, told Bloomberg.
Trending on ETF Trends
How The Fed is Boosting Dividend ETFs
4 Oil ETFs Ignited by Recent Surges
ETF Flows Show Investors Are Riding the Stock Market Rebound
Water ETFs Are Making a Big Splash
Why It's Time to Consider High Dividend ETFs
More companies may continue to capitalize on the ongoing low interest rate environment and engage in greater merger and acquisitions, or at least try to squeeze out some deals before the Federal Reserve decides to hike rates again.
"Large M&A is likely to continue in the coming months, not only in health care but also in other sectors, as financing remains cheap and companies have loads of cash to put to use and expand their portfolios," Tomasz Michalski, an economics professor at the HEC business school, told Bloomberg.
ETF investors can also capitalize on the spate of acquisitions through health care-related ETFs that tilt toward mid- and small-cap stocks, or smaller companies that are more likely to be buyout targets. For instance, the Guggenheim S&P Equal Weight Healthcare ETF (NYSEArca: RYH ) , which equally weights its component holdings, includes a 30.4% tilt toward mid-caps, alon gwith 48.3% large-caps and 21.4% mega-caps. The PowerShares S&P SmallCap Health Care Portfolio (NasdaqGS: PSCH ) focuses more on smaller companies, with a 59.9% tilt toward small-caps and 40.1% in micro-caps.
Additionally, looking at biotechnology-related ETFs, the BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC ) tracks potential up-and-coming biotechnology companies that are in the clinical trials stage. The Loncar Cancer Immunotheraphy ETF (NasdaqGM: CNCR) tracks companies that are developing new classes of therapies. The ALPS Medical Breakthroughs ETF (NYSEArca: SBIO ) focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III U.S. FDA clinical trials. The broader SPDR S&P Biotech ETF (NYSEArca: XBI ) follows an equal-weight index of biotechnology companies, with 26.8% in micro-caps, 35.0% small-caps and 20.9% mid-caps.
Want more Healthcare ETF news and analysis? Visit www.etftrends.com/healthcare
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This article was provided by our partner Tom Lydon of etftrends.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories ( ABT ) agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion, Bloomberg reports. "Large M&A is likely to continue in the coming months, not only in health care but also in other sectors, as financing remains cheap and companies have loads of cash to put to use and expand their portfolios," Tomasz Michalski, an economics professor at the HEC business school, told Bloomberg. The PowerShares S&P SmallCap Health Care Portfolio (NasdaqGS: PSCH ) focuses more on smaller companies, with a 59.9% tilt toward small-caps and 40.1% in micro-caps. | About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories ( ABT ) agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion, Bloomberg reports. Premiums on health care deals are also holding, with almost 30% of deals this year commanding premiums of 40% to 50%, mirroring premiums paid this time last year. For instance, the Guggenheim S&P Equal Weight Healthcare ETF (NYSEArca: RYH ) , which equally weights its component holdings, includes a 30.4% tilt toward mid-caps, alon gwith 48.3% large-caps and 21.4% mega-caps. | About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories ( ABT ) agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion, Bloomberg reports. "We are likely see more M&A in health care this year as companies streamline their portfolios and seek to build up those areas of higher future growth," Nigel Jones, co-head of health care at Linklaters law firm, told Bloomberg. Trending on ETF Trends How The Fed is Boosting Dividend ETFs 4 Oil ETFs Ignited by Recent Surges ETF Flows Show Investors Are Riding the Stock Market Rebound Water ETFs Are Making a Big Splash Why It's Time to Consider High Dividend ETFs More companies may continue to capitalize on the ongoing low interest rate environment and engage in greater merger and acquisitions, or at least try to squeeze out some deals before the Federal Reserve decides to hike rates again. | About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories ( ABT ) agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion, Bloomberg reports. ETF investors can also capitalize on the spate of acquisitions through health care-related ETFs that tilt toward mid- and small-cap stocks, or smaller companies that are more likely to be buyout targets. The PowerShares S&P SmallCap Health Care Portfolio (NasdaqGS: PSCH ) focuses more on smaller companies, with a 59.9% tilt toward small-caps and 40.1% in micro-caps. |
33914.0 | 2016-04-21 00:00:00 UTC | Abbott Earnings Review: Foreign Currency Effects Subdue An Otherwise Strong Operational Growth | ABT | https://www.nasdaq.com/articles/abbott-earnings-review-foreign-currency-effects-subdue-otherwise-strong-operational-growth | nan | nan | Leading healthcare major, Abbott Laboratories ( ABT ) reported its Q1 2016 earnings on April 20, 2016. Despite a strong operating growth, led by the established pharmaceutical division in key emerging markets, Abbott's key metrics declined year over year due to currency headwinds. The company's net income and EPS figures were significantly affected by the write down of its assets in Venezuela. Below we analyse Abbott's performance in Q1 2016:
Notes:
1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Abbott
See More at Trefis |View Interactive Institutional Research(Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leading healthcare major, Abbott Laboratories ( ABT ) reported its Q1 2016 earnings on April 20, 2016. The company's net income and EPS figures were significantly affected by the write down of its assets in Venezuela. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com 2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. | Leading healthcare major, Abbott Laboratories ( ABT ) reported its Q1 2016 earnings on April 20, 2016. Despite a strong operating growth, led by the established pharmaceutical division in key emerging markets, Abbott's key metrics declined year over year due to currency headwinds. For precise figures, please refer to our complete analysis for Abbott See More at Trefis |View Interactive Institutional Research(Powered by Trefis) Get Trefis Technology The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leading healthcare major, Abbott Laboratories ( ABT ) reported its Q1 2016 earnings on April 20, 2016. Despite a strong operating growth, led by the established pharmaceutical division in key emerging markets, Abbott's key metrics declined year over year due to currency headwinds. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com 2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. | Leading healthcare major, Abbott Laboratories ( ABT ) reported its Q1 2016 earnings on April 20, 2016. Despite a strong operating growth, led by the established pharmaceutical division in key emerging markets, Abbott's key metrics declined year over year due to currency headwinds. The company's net income and EPS figures were significantly affected by the write down of its assets in Venezuela. |
33915.0 | 2016-04-20 00:00:00 UTC | See Which Of The Latest 13F Filers Holds Abbott Laboratories | ABT | https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-abbott-laboratories-2016-04-20 | nan | nan | At Holdings Channel , we have reviewed the latest batch of the 28 most recent 13F filings for the 03/31/2016 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 21 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen .
Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers:
In terms of shares owned, we count 8 of the above funds having increased existing ABT positions from 12/31/2015 to 03/31/2016, with 8 having decreased their positions and 1 new position.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 03/31/2016 reporting period (out of the 438 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 12/31/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. We found that between these two periods, funds increased their holdings by 303,217 shares in the aggregate, from 24,856,308 up to 25,159,525 for a share count increase of approximately 1.22%. The overall top three funds holding ABT on 03/31/2016 were:
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT).
10 S&P 500 Components Hedge Funds Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At Holdings Channel , we have reviewed the latest batch of the 28 most recent 13F filings for the 03/31/2016 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 21 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT). Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count 8 of the above funds having increased existing ABT positions from 12/31/2015 to 03/31/2016, with 8 having decreased their positions and 1 new position. | At Holdings Channel , we have reviewed the latest batch of the 28 most recent 13F filings for the 03/31/2016 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 21 of these funds. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count 8 of the above funds having increased existing ABT positions from 12/31/2015 to 03/31/2016, with 8 having decreased their positions and 1 new position. Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 03/31/2016 reporting period (out of the 438 we looked at in total). | Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count 8 of the above funds having increased existing ABT positions from 12/31/2015 to 03/31/2016, with 8 having decreased their positions and 1 new position. We then compared that number to the sum total of ABT shares those same funds held back at the 12/31/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 03/31/2016 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. | Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count 8 of the above funds having increased existing ABT positions from 12/31/2015 to 03/31/2016, with 8 having decreased their positions and 1 new position. We then compared that number to the sum total of ABT shares those same funds held back at the 12/31/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 03/31/2016 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. |
33916.0 | 2016-04-20 00:00:00 UTC | Midday Update: Stocks Regain Momentum As Oil Rebounds; Mostly Positive Earnings Also Lift Markets | ABT | https://www.nasdaq.com/articles/midday-update-stocks-regain-momentum-oil-rebounds-mostly-positive-earnings-also-lift | nan | nan | Stocks were cautiously building on Tuesday's gains, with a rebound in oil prices and mostly upbeat earnings drive the Dow Jones Industrial Average through 18,100, its third consecutive rise.
Existing home sales rose 5.1% during March to a seasonally-adjusted annual rate of 5.33 million, beating Wall Street estimates for gain of 3.7% advance. But one small piece of downbeat news saw February home sales revised lower from initial reports.
In earnings news, Yahoo ( YHOO ) was higher today after beating analyst expectations and said that it continues to focus on "strategic alternatives" while chipmaker Intel ( INTC ) rose after topping Wall Street estimates but also forecast Q2 revenue below consensus and lowered its FY16 guidance and disclosed plans to eliminate 12,000 jobs.
Dow component stock Coca-Cola ( KO ) reported better-than-expected profits but investors still were selling off the stock as a result of declining revenue and flat overseas sales. As a result, KO was the Dow's leading laggard on Wednesday, trading more than 4% lower.
European indices all closed higher, shrugging off weakness in China as oil recovered and U.S. equities turned positive. EU-zone equities also were buoyed by tomorrow's European Central Bank policy meeting. Although the ECB is not expected to adjust interest rates, Mario Draghi will likely maintain his very dovish bias towards future monetary policy.
Crude oil was up 28 cents to $41.36 per barrel. Natural gas was up 3 cents to $2.21 per 1 million BTU. Gold was up $1.70 to $1,256 per ounce, while silver was up 15 cents to $17.13 per ounce. Copper was up a penny to $2.24 per pound.
Among energy ETFs, the United States Oil Fund was up 1.49% to $10.59 with the United States Natural Gas Fund was up 1.20% to $7.16. Among precious-metal funds, the Market Vectors Gold Miners ETF was up 1.50% to 23.61 while SPDR Gold Shares was up 0.23% to $199.85. The iShares Silver Trust was up 1.20% to $16.31.
Here's where the U.S. markets stood at mid-day:
NYSE Composite Index up 13.74 (+0.13%) to 10,531.04
Dow Jones Industrial Average up 50.51 (+0.28%) to 18,104.11
S&P 500 up 4.11 (+0.20%) to 2,104.91
Nasdaq Composite Index up 14.13 (+0.29%) to 4,954.46
GLOBAL SENTIMENT
Nikkei 225 Index up 0.19%
Hang Seng Index down 0.93%
Shanghai China Composite Index down 2.31%
FTSE 100 Index up 0.08%
CAC 40 up 0.56%
DAX up 0.69%
NYSE SECTOR INDICES
NYSE Energy Sector Index up 0.83%
NYSE Financial Sector Index up 0.32%
NYSE Healthcare Sector Index up 0.10%
UPSIDE MOVERS
(+) HNSN (+30.56%) To be acquired by Auris Surgical
(+) VMW (+12.98%) Reported better-than-expected Q1 earnings and authorized a $1.2 billion share buyback
(-) ONCS (12.82%) Reported positive melanoma clinical trial data
(+) LXK (+10.07%) To be acquired for $40.50 per share by a group of investors led by Apex Technology and PAG Asia Capital
DOWNSIDE MOVERS
(-) ALR (-16.62%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere
(-) CAMP (-10.15%) Reported in-line Q4 earnings but issued weak FY16 guidance
(-) CHKP (-2.88%) Beats Q1 earnings estimates but revenue in-line
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) ALR (-16.62%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.15%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-2.88%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Stocks were cautiously building on Tuesday's gains, with a rebound in oil prices and mostly upbeat earnings drive the Dow Jones Industrial Average through 18,100, its third consecutive rise. Existing home sales rose 5.1% during March to a seasonally-adjusted annual rate of 5.33 million, beating Wall Street estimates for gain of 3.7% advance. | (-) ALR (-16.62%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.15%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-2.88%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Existing home sales rose 5.1% during March to a seasonally-adjusted annual rate of 5.33 million, beating Wall Street estimates for gain of 3.7% advance. NYSE Energy Sector Index up 0.83% NYSE Financial Sector Index up 0.32% NYSE Healthcare Sector Index up 0.10% | (-) ALR (-16.62%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.15%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-2.88%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. NYSE Energy Sector Index up 0.83% NYSE Financial Sector Index up 0.32% NYSE Healthcare Sector Index up 0.10% (+) HNSN (+30.56%) To be acquired by Auris Surgical (+) VMW (+12.98%) Reported better-than-expected Q1 earnings and authorized a $1.2 billion share buyback (-) ONCS (12.82%) Reported positive melanoma clinical trial data (+) LXK (+10.07%) To be acquired for $40.50 per share by a group of investors led by Apex Technology and PAG Asia Capital | (-) ALR (-16.62%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.15%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-2.88%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Dow component stock Coca-Cola ( KO ) reported better-than-expected profits but investors still were selling off the stock as a result of declining revenue and flat overseas sales. Natural gas was up 3 cents to $2.21 per 1 million BTU. |
33917.0 | 2016-04-20 00:00:00 UTC | Key Morning Earnings for April 20: ABT, DISH, KO, USB | ABT | https://www.nasdaq.com/articles/key-morning-earnings-april-20-abt-dish-ko-usb-2016-04-20 | nan | nan | As Q1 earnings season continues, more and more big names are starting to post their earnings results. Yesterday, tech giants Intel Corp. INTC and Yahoo! Inc. YHOO reported interesting results. Intel beat earnings estimates but missed on revenue , and announced a restructuring plan that includes slashing 12,000 jobs. Yahoo saw first-quarter earnings and revenue results that edged past estimates, with management taking plans for a company sale more serious than ever.
Wednesday morning saw a good amount of companies report their results before the bell. Let's take a look.
Abbott Labs ABT
Global healthcare company Abbot Labs reported an earnings beat of $0.41 per share (from continuing operations excluding one-time items), topping the Zacks Consensus Estimate of $0.39 per share. Revenues of $4.9 billion also surpassed our consensus estimate of $4.8 billion, with sales growth bring driven by new product launches in the first quarter.
Dish Network CP DISH
The satellite television provider posted strong first quarter financial results . Earnings came in at $0.84 per share, beating the Zacks Consensus Estimate of $0.65 per share. Total revenue stood at $3.787 billion, reflecting a 1.7% year-over-year increase; revenues were on par with the Zacks Consensus Estimate.
The Coca-Cola Company KO
Coca-Cola, the world's largest beverage company, reported Q1 adjusted earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.44. Revenues came in at $10.28 billion, declining 4% year-over-year and topping our consensus estimate of $10.26 billion by 0.2%. Despite these beats, soda volumes declined in the first quarter.
U.S. Bancorp USB
The financial services company reported earnings of $0.76 per share for the first quarter, beating the Zacks Consensus Estimate by a penny. Net revenues came in at $5.04 billion, missing our consensus estimate of $5.07 billion but increasing 2.7% on a year-over-year basis. Organic growth was driven by higher revenues along with elevated average loans and deposits.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
US BANCORP (USB): Free Stock Analysis Report
YAHOO! INC (YHOO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
COCA COLA CO (KO): Free Stock Analysis Report
DISH NETWORK CP (DISH): Free Stock Analysis Report
INTEL CORP (INTC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ABT Global healthcare company Abbot Labs reported an earnings beat of $0.41 per share (from continuing operations excluding one-time items), topping the Zacks Consensus Estimate of $0.39 per share. INC (YHOO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report DISH NETWORK CP (DISH): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. Intel beat earnings estimates but missed on revenue , and announced a restructuring plan that includes slashing 12,000 jobs. | INC (YHOO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report DISH NETWORK CP (DISH): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT Global healthcare company Abbot Labs reported an earnings beat of $0.41 per share (from continuing operations excluding one-time items), topping the Zacks Consensus Estimate of $0.39 per share. U.S. Bancorp USB The financial services company reported earnings of $0.76 per share for the first quarter, beating the Zacks Consensus Estimate by a penny. | Abbott Labs ABT Global healthcare company Abbot Labs reported an earnings beat of $0.41 per share (from continuing operations excluding one-time items), topping the Zacks Consensus Estimate of $0.39 per share. INC (YHOO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report DISH NETWORK CP (DISH): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. U.S. Bancorp USB The financial services company reported earnings of $0.76 per share for the first quarter, beating the Zacks Consensus Estimate by a penny. | INC (YHOO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report DISH NETWORK CP (DISH): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT Global healthcare company Abbot Labs reported an earnings beat of $0.41 per share (from continuing operations excluding one-time items), topping the Zacks Consensus Estimate of $0.39 per share. Revenues of $4.9 billion also surpassed our consensus estimate of $4.8 billion, with sales growth bring driven by new product launches in the first quarter. |
33918.0 | 2016-04-20 00:00:00 UTC | Parade of Mixed Earnings | ABT | https://www.nasdaq.com/articles/parade-mixed-earnings-2016-04-20 | nan | nan | Wednesday, April 20, 2016
The major indexes are on track for a flat open despite a parade of mixed Q1 earnings releases and weakness in oil prices . Stocks have made solid gains in recent sessions, pushing the S&P 500 index above the 2100 level.
Today's oil weakness comes after the commodity's steady gains in recent days, with this week's Doha-inspired bearishness offset by supply disruptions at Kuwait, Iraq, Nigeria and a number of other places. The consensus narrative about Doha notwithstanding, the odds of supply cut coming out of that meeting were low to begin with given the animus between Saudi Arabia and Iran. The key factor supporting oil prices at present is the steady decline in U.S. production, which the U.S. government's Energy Information Administration estimates will fall by roughly -8% this year and another -7% next year. I have long been of the view that oil prices can't be kept in the $20's and low $30's for an extended period on purely supply-demand grounds. The commodity's day-to-day prices will continue reflecting headlines about the still-elevated global inventory levels and noise coming out of OPEC. But I strongly feel that in the absence of a major economic shock like a bigger than expected fall in the Chinese economy, the worst is behind us in the oil patch.
With respect to the Q1 earnings season, we now have results from 71 S&P 500 members that combined account for 19.9% of the index's total market capitalization. This includes all of this morning's reports from the likes of Coke ( KO ), U.S. Bancorp ( USB ), Abbot Labs ( ABT ) and others. Total earnings for these 71 index members are down -9% on +0.6% higher revenues, with 80.3% beating EPS estimates and 54.9% coming ahead of top-line estimates. This is weak growth relative to what we have seen from the same group of 71 index members in other recent periods, though the ratio of companies beating estimates compares favorably to other the recent past, likely indicating that estimates may have fallen more than they needed to ahead of the start of this reporting cycle.
For Q1 as a whole, combining the actual results from the 71 index members that have reported with estimates for the still to come 429 companies, total earnings are expected to be down -9.7% from the same period last year on -0.8% lower revenues. This would be the 4 th quarter in a row of earnings declines for the index. Growth is expected to be in the negative for the current period (2016 Q2) as well, with the total earnings expected to be down -4.5% from the same period last year. Q2 estimates have started coming down as companies report Q1 results and guide lower, but the magnitude of negative revisions is not as bad as we had seen in the comparable period during the Q1 reporting cycle.
Sheraz Mian
Director of Research
Note: In addition to this daily pre-open article about the market, economy, and the corporate earnings picture, Sheraz Mian also provides detailed earnings analysis in his weeklyEarnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz Mian publishes a new article, please click here .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
US BANCORP (USB): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
COCA COLA CO (KO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This includes all of this morning's reports from the likes of Coke ( KO ), U.S. Bancorp ( USB ), Abbot Labs ( ABT ) and others. Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report To read this article on Zacks.com click here. Today's oil weakness comes after the commodity's steady gains in recent days, with this week's Doha-inspired bearishness offset by supply disruptions at Kuwait, Iraq, Nigeria and a number of other places. | Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report To read this article on Zacks.com click here. This includes all of this morning's reports from the likes of Coke ( KO ), U.S. Bancorp ( USB ), Abbot Labs ( ABT ) and others. Today's oil weakness comes after the commodity's steady gains in recent days, with this week's Doha-inspired bearishness offset by supply disruptions at Kuwait, Iraq, Nigeria and a number of other places. | Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report To read this article on Zacks.com click here. This includes all of this morning's reports from the likes of Coke ( KO ), U.S. Bancorp ( USB ), Abbot Labs ( ABT ) and others. This is weak growth relative to what we have seen from the same group of 71 index members in other recent periods, though the ratio of companies beating estimates compares favorably to other the recent past, likely indicating that estimates may have fallen more than they needed to ahead of the start of this reporting cycle. | Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report To read this article on Zacks.com click here. This includes all of this morning's reports from the likes of Coke ( KO ), U.S. Bancorp ( USB ), Abbot Labs ( ABT ) and others. For Q1 as a whole, combining the actual results from the 71 index members that have reported with estimates for the still to come 429 companies, total earnings are expected to be down -9.7% from the same period last year on -0.8% lower revenues. |
33919.0 | 2016-04-20 00:00:00 UTC | Health Care Sector Update for 04/20/2016: CARA, AMGN, MRK, ABT, PFE, JNJ, STJ | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04202016-cara-amgn-mrk-abt-pfe-jnj-stj-2016-04-20 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +0.3%
ABT: +1.5%
MRK: flat
AMGN: -1.7%
Health care shares were mixed in pre-market trade Wednesday.
In health care stocks news, St. Jude Medical ( STJ ) reported Q1 adjusted net income was $259 million, or $0.90 per diluted share, down from last year's $266 million, or $0.93 per diluted share, but still came in ahead of the Capital IQ consensus of $0.88. Net sales were $1.45 billion, up from $1.35 billion in 2015, exceeding the mean estimate of $1.43 billion. For its outlook, the company expects revenue to grow 1% to 3% in Q2 and 2% and 4% in 2016. Adjusted EPS is estimated to be in the range of $1.05 to $1.07 in Q2 and $4.01 to $4.11 in 2016. The Street is at $1.02 per share in earnings for Q2 and $4.00 per share for 2016.
STJ shares were up 1.5% at 59.49 in pre-market trading , with a 52-week range of $48.83 - $80.84.
Cara Therapeutics ( CARA ) said it received a notice from the U.S. Food and Drug Administration (FDA) for the removal of a clinical hold on its Phase 3 trial for postoperative pain. The clinical hold on I.V. CR845 was triggered by a stopping criterion, based on elevated serum sodium levels, that was met during the first phase, according to a company statement early Wednesday. A subsequent review of safety data from the first 90 patients dosed was completed by Cara, the study's Independent Data Monitoring Committee, and the FDA. The results of this safety data review confirmed that increases in serum sodium levels in CR845-treated patients beyond the normal range were dose-dependent. Based on this safety review and an analysis of efficacy trends, the study will continue as a three-arm trial testing two doses of CR845 versus placebo.
CARA shares were up 12.2% at $9.22, with a 52-week range of $4.26 - $23.61.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | CR845 was triggered by a stopping criterion, based on elevated serum sodium levels, that was met during the first phase, according to a company statement early Wednesday. The results of this safety data review confirmed that increases in serum sodium levels in CR845-treated patients beyond the normal range were dose-dependent. Based on this safety review and an analysis of efficacy trends, the study will continue as a three-arm trial testing two doses of CR845 versus placebo. | Health care shares were mixed in pre-market trade Wednesday. In health care stocks news, St. Jude Medical ( STJ ) reported Q1 adjusted net income was $259 million, or $0.90 per diluted share, down from last year's $266 million, or $0.93 per diluted share, but still came in ahead of the Capital IQ consensus of $0.88. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, St. Jude Medical ( STJ ) reported Q1 adjusted net income was $259 million, or $0.90 per diluted share, down from last year's $266 million, or $0.93 per diluted share, but still came in ahead of the Capital IQ consensus of $0.88. Cara Therapeutics ( CARA ) said it received a notice from the U.S. Food and Drug Administration (FDA) for the removal of a clinical hold on its Phase 3 trial for postoperative pain. A subsequent review of safety data from the first 90 patients dosed was completed by Cara, the study's Independent Data Monitoring Committee, and the FDA. | STJ shares were up 1.5% at 59.49 in pre-market trading , with a 52-week range of $48.83 - $80.84. A subsequent review of safety data from the first 90 patients dosed was completed by Cara, the study's Independent Data Monitoring Committee, and the FDA. CARA shares were up 12.2% at $9.22, with a 52-week range of $4.26 - $23.61. |
33920.0 | 2016-04-20 00:00:00 UTC | Close Update: Dow Makes New 2016 High As Oil Shrugs off Supply Pressures | ABT | https://www.nasdaq.com/articles/close-update-dow-makes-new-2016-high-oil-shrugs-supply-pressures-2016-04-20 | nan | nan | The Dow Jones Industrial Average returned some of its triple-digit gain into the close, but was positive for a third straight day as an unexpected rally in oil coupled with upbeat corporate earnings drove the blue-chip index to its highest level in 10 months.
The S&P 500 struggled to stay positive, but was left holding onto a slim gain with the aid of strength in energy, financial and healthcare stocks. The defensive sector underperformed, as did consumer stocks as the strengthening dollar threatened profits for multi-national corporations like Coca-Cola ( KO ).
Oil was lower at the open when striking oil workers in Kuwait went back to work, rekindling supply pressures on the energy sector. By midday, oil had erased its early losses, underpinning equities, and enabling the Dow to pierce 18,100. The index touched a high of 18,167 before turning south into the close.
Quarterly results from Yahoo ( YHOO ), Coca-Cola and Abbot Labs ( ABT ) offset lower-than-expected revenue from Intel ( INTC ) and a miss from EMC ( EMC ) and Angie's List (ANGI).
Wednesday's economic data was a non-event with Wall Street distracted by corporate earnings. Existing home sales increased by 3.7% in March to a seasonally-adjusted annual rate of 5.33 million, beating the estimated SAAR of 5.268 million.
Here's where the markets stood at the close:
US MARKETS
Dow Jones Industrial Index was up 42.67 points (+0.24%)
S&P 500 was up 1.60 points (+0.08%)
Nasdaq Composite Index was up 7.80 points (0.16%)
GLOBAL SENTIMENT
FTSE 100 was up 0.08%
Nikkei 225 was up 0.19%
Hang Seng Index was down 0.93%
Shanghai China Composite Index was down 2.31%
UPSIDE MOVERS
(+) HNSN (+39.86%) To be acquired by Auris Surgical
(+) BBSI (+16.48%) Forensic accounting investigation finds no effect on net profit
(+) VMW (+13.76%) Reported better-than-expected Q1 earnings and authorized a $1.2 billion share buyback
(-) ONCS (10.37%) Reported positive melanoma clinical trial data
DOWNSIDE MOVERS
(-) ARGS (-24.70%) CEO Fred Miesowicz announced resignation after Tuesday's close, plans to reduce workforce by 13%
(-) ALR (-12.35%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere
(-) CAMP (-10.73%) Reported in-line Q4 earnings but issued weak FY16 guidance
(-) CHKP (-3.17%) Beats Q1 earnings estimates but revenue in-line
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) ARGS (-24.70%) CEO Fred Miesowicz announced resignation after Tuesday's close, plans to reduce workforce by 13% (-) ALR (-12.35%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.73%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-3.17%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Quarterly results from Yahoo ( YHOO ), Coca-Cola and Abbot Labs ( ABT ) offset lower-than-expected revenue from Intel ( INTC ) and a miss from EMC ( EMC ) and Angie's List (ANGI). The Dow Jones Industrial Average returned some of its triple-digit gain into the close, but was positive for a third straight day as an unexpected rally in oil coupled with upbeat corporate earnings drove the blue-chip index to its highest level in 10 months. | (-) ARGS (-24.70%) CEO Fred Miesowicz announced resignation after Tuesday's close, plans to reduce workforce by 13% (-) ALR (-12.35%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.73%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-3.17%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Quarterly results from Yahoo ( YHOO ), Coca-Cola and Abbot Labs ( ABT ) offset lower-than-expected revenue from Intel ( INTC ) and a miss from EMC ( EMC ) and Angie's List (ANGI). Dow Jones Industrial Index was up 42.67 points (+0.24%) S&P 500 was up 1.60 points (+0.08%) Nasdaq Composite Index was up 7.80 points (0.16%) | (-) ARGS (-24.70%) CEO Fred Miesowicz announced resignation after Tuesday's close, plans to reduce workforce by 13% (-) ALR (-12.35%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.73%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-3.17%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Quarterly results from Yahoo ( YHOO ), Coca-Cola and Abbot Labs ( ABT ) offset lower-than-expected revenue from Intel ( INTC ) and a miss from EMC ( EMC ) and Angie's List (ANGI). The Dow Jones Industrial Average returned some of its triple-digit gain into the close, but was positive for a third straight day as an unexpected rally in oil coupled with upbeat corporate earnings drove the blue-chip index to its highest level in 10 months. | Quarterly results from Yahoo ( YHOO ), Coca-Cola and Abbot Labs ( ABT ) offset lower-than-expected revenue from Intel ( INTC ) and a miss from EMC ( EMC ) and Angie's List (ANGI). (-) ARGS (-24.70%) CEO Fred Miesowicz announced resignation after Tuesday's close, plans to reduce workforce by 13% (-) ALR (-12.35%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.73%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-3.17%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The S&P 500 struggled to stay positive, but was left holding onto a slim gain with the aid of strength in energy, financial and healthcare stocks. |
33921.0 | 2016-04-20 00:00:00 UTC | What's Behind Alere Inc.'s Sinking Shares Today | ABT | https://www.nasdaq.com/articles/whats-behind-alere-incs-sinking-shares-today-2016-04-20 | nan | nan | IMAGE SOURCE: ABBOTT LABS.
What: After would-be acquirer Abbott Labs skirted questions regarding its planned purchase of Alere , Alere's shares tumbled by 14.1% at 2:30 p.m. ET today.
So what: Abbott Labs inked a deal to acquire Alere for $5.8 billion in February, but since then, Alere has failed to file its annual 10-K financial report with the Securities and Exchange Commission and that's raising doubt that this deal will close as planned.
Abbott Labs agreed to buy Alere to boost its exposure to the point-of-care diagnostics market, a market that is valued at $5.5 billion thanks to the adoption of in-office testing by healthcare clinics, urgent care centers, and doctors' offices.
Alere generates $2.5 billion in sales annually from serving the point-of-care market and Abbott anticipates that combining Alere's business with its own $473 million per year in point-of-care sales will lead to significant cost savings. Specifically, Abbott Labs estimates that it can shave $500 million per year by 2019. If Abbott Labs executes on its cost-cutting plans, it estimates acquiring Alere will be accretive to its EPS by $0.12 to $0.13 next year and by $0.20 per share in 2018.
Of course, that accretion will only happen if this deal closes, and during Abbott Lab's conference call earlier today, management's response when asked to reaffirm their commitment to the deal was less than convincing.
"I am going to be careful how I answer any questions about Alere...because as you know they've had delays filing their 10-K. We don't know when they'll file their proxy. We don't know when they're going to have a shareholder vote. So right now I'd say it's not appropriate for me to comment on Alere," said Miles D. White, CEO of Abbott Labs.
Now what: It would have been nice for White to have said that Abbott Labs is 100% committed to Alere, but his remarks don't necessarily indicate Abbott Labs is suffering buyer's remorse and planning to walk away.
The financial review that is being conducted by Alere is evaluating the timing of when it reported sales that were made in Africa and China since 2012. Absent discovering fraudulence, this type of review often ends with a simple restatement of revenue from one period to another period. If that's the case with Alere, it would hardly seem to me that such a restatement would be worthy of scuttling this merger.
Nevertheless, uncertainty regarding the timing of a potential SEC filing and a vote on the planned merger makes Alere less alluring than it might otherwise be. Therefore, while Alere's business is intriguing and Abbott Labs' global diagnostics business is well positioned to make the most of a combination, I'm not running out to buy shares on this drop.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article What's Behind Alere Inc.'s Sinking Shares Today originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If Abbott Labs executes on its cost-cutting plans, it estimates acquiring Alere will be accretive to its EPS by $0.12 to $0.13 next year and by $0.20 per share in 2018. The financial review that is being conducted by Alere is evaluating the timing of when it reported sales that were made in Africa and China since 2012. Nevertheless, uncertainty regarding the timing of a potential SEC filing and a vote on the planned merger makes Alere less alluring than it might otherwise be. | What: After would-be acquirer Abbott Labs skirted questions regarding its planned purchase of Alere , Alere's shares tumbled by 14.1% at 2:30 p.m. Alere generates $2.5 billion in sales annually from serving the point-of-care market and Abbott anticipates that combining Alere's business with its own $473 million per year in point-of-care sales will lead to significant cost savings. Therefore, while Alere's business is intriguing and Abbott Labs' global diagnostics business is well positioned to make the most of a combination, I'm not running out to buy shares on this drop. | So what: Abbott Labs inked a deal to acquire Alere for $5.8 billion in February, but since then, Alere has failed to file its annual 10-K financial report with the Securities and Exchange Commission and that's raising doubt that this deal will close as planned. Alere generates $2.5 billion in sales annually from serving the point-of-care market and Abbott anticipates that combining Alere's business with its own $473 million per year in point-of-care sales will lead to significant cost savings. Now what: It would have been nice for White to have said that Abbott Labs is 100% committed to Alere, but his remarks don't necessarily indicate Abbott Labs is suffering buyer's remorse and planning to walk away. | What: After would-be acquirer Abbott Labs skirted questions regarding its planned purchase of Alere , Alere's shares tumbled by 14.1% at 2:30 p.m. Nevertheless, uncertainty regarding the timing of a potential SEC filing and a vote on the planned merger makes Alere less alluring than it might otherwise be. The Motley Fool has no position in any of the stocks mentioned. |
33922.0 | 2016-04-19 00:00:00 UTC | Commit To Buy Abbott Laboratories At $33, Earn 5.3% Using Options | ABT | https://www.nasdaq.com/articles/commit-buy-abbott-laboratories-33-earn-53-using-options-2016-04-19 | nan | nan | Investors eyeing a purchase of Abbott Laboratories (Symbol: ABT) stock, but tentative about paying the going market price of $43.53/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $33 strike, which has a bid at the time of this writing of $1.74. Collecting that bid as the premium represents a 5.3% return against the $33 commitment, or a 3% annualized rate of return (at Stock Options Channel we call this the YieldBoost ).
Selling a put does not give an investor access to ABT's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $33 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless Abbott Laboratories sees its shares decline 24.2% and the contract is exercised (resulting in a cost basis of $31.26 per share before broker commissions, subtracting the $1.74 from $33), the only upside to the put seller is from collecting that premium for the 3% annualized rate of return.
Worth considering, is that the annualized 3% figure actually exceeds the 2.4% annualized dividend paid by Abbott Laboratories, based on the current share price of $43.53. And yet, if an investor was to buy the stock at the going market price in order to collect the dividend, there is greater downside because the stock would have to fall 24.23% to reach the $33 strike price.
Always important when discussing dividends is the fact that, in general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.4% annualized dividend yield.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $33 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2018 put at the $33 strike for the 3% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Abbott Laboratories (considering the last 253 trading day closing values as well as today's price of $43.53) to be 25%. For other put options contract ideas at the various different available expirations, visit the ABT Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Tuesday, the put volume among S&P 500 components was 1.00M contracts, with call volume at 1.00M, for a put:call ratio of 0.75 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today .
Top YieldBoost Puts of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors eyeing a purchase of Abbott Laboratories (Symbol: ABT) stock, but tentative about paying the going market price of $43.53/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABT's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.4% annualized dividend yield. | Investors eyeing a purchase of Abbott Laboratories (Symbol: ABT) stock, but tentative about paying the going market price of $43.53/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABT's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.4% annualized dividend yield. | Investors eyeing a purchase of Abbott Laboratories (Symbol: ABT) stock, but tentative about paying the going market price of $43.53/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABT's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.4% annualized dividend yield. | In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.4% annualized dividend yield. Investors eyeing a purchase of Abbott Laboratories (Symbol: ABT) stock, but tentative about paying the going market price of $43.53/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABT's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. |
33923.0 | 2016-04-19 00:00:00 UTC | How Will Drug Stocks BIIB, ABT, NVS Perform in Q1 Earnings? | ABT | https://www.nasdaq.com/articles/how-will-drug-stocks-biib-abt-nvs-perform-in-q1-earnings-2016-04-19 | nan | nan | With the Q1 earnings season gaining momentum, focus will be on the medical sector which is facing challenges in the form of growing political pressure on drug prices, currency headwinds, biosimilar and generic competition as well as European pricing pressure. Stressed balance sheets and other broad-based factors could continue to hurt the performance of the sector.
However, all is not lost. As per our Earnings Trends report, the Medical sector is expected to witness earnings growth of 0.9% and revenue growth of 9.1% in the first quarter of 2016. It is one of the six sectors that are anticipated to record earnings growth this season.
As of Apr 15, 35 S&P 500 members have released their first quarter results. On the whole, the picture is not encouraging with total earnings expected to decline 10.1% on a year-over-year basis.
What to Expect from these Drug Stocks?
With industry bellwether Johnson & Johnson's JNJ first-quarter earnings surpassing expectations and the company raising its outlook for the year, will other major drug companies follow suit?
Earnings releases and guidance of the likes of Abbott LaboratoriesABT , Biogen Inc.BIIB , and Novartis AGNVS have always held investors' attention. Let's have a look at how these companies are expected to perform when they come up with their releases this week.
First on our list is the manufacturer of a diversified line of health care products, Abbott Labs. The company is expected to face challenging conditions in Venezuela (which has been a historically good market for the company) due to factors like high inflation, increasing price and margin controls, regulations on imports, and slowing demand.
Its reporting segments include Established Pharmaceuticals Division, Medical Devices, Diagnostics and Nutrition. The company expects first-quarter sales to decline in the low single digits, reflecting a 6% negative currency impact. Earnings per share for the first quarter are projected around 38-40 cents.
Abbott Labs is scheduled to report first-quarter results before the opening bell on Apr 20. Though the company has beaten estimates in each of the trailing four quarters, its Earnings ESP of 0.00% and a Zacks Rank #2 (Buy) make surprise prediction difficult this quarter. The Zacks Consensus Estimate is 39 cents per share (read more: Will Currency Woes Hurt Abbott Labs' Q1 Earnings? ).
A well-known name in the multiple sclerosis market (MS), Biogen is set to report first-quarter results on Apr 21, before the market opens. The company's positive Earnings ESP and Zacks Rank #3 (Hold) make us confident of an earnings beat this quarter. The Zacks Consensus Estimate is $4.48 per share.
Focus will remain on the performance of MS drug, Tecfidera, and recently launched hemophilia drugs, Eloctate and Alprolix (read more: Will MS Franchise Sales Boost Biogen's 1Q Earnings? ).
Novartis, which is a well known name in the oncology market, expects 2016 to be transformational year.
In a bid to revamp its struggling Alcon business, Novartis announced that its ophthalmic pharmaceuticals business will be moved to the pharmaceuticals division. Consequently, the Alcon division will focus solely on the surgical and vision care businesses. Meanwhile, Novartis' generic arm, Sandoz, with a strong biosimilar portfolio and pipeline, should offset the weakness in the Alcon segment.
However, the company is expected to face headwinds in the form of generic competition for some products as well as negative currency movement. Notably, unfavorable currency movement is estimated to impact sales by 5% in the first quarter. Focus should remain on the sales ramp up of newly launched drugs, Entresto, Glatopa and Cosentyx.
This Zacks Rank #3 stock is scheduled to report first-quarter results on Apr 21 (read more: Will Weak Alcon Sales Hurt Novartis' Q1 Earnings? ).
So, do check back on our full earnings release articles on these stocks to see how they've finally fared.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BIOGEN INC (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Earnings releases and guidance of the likes of Abbott LaboratoriesABT , Biogen Inc.BIIB , and Novartis AGNVS have always held investors' attention. Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate is 39 cents per share (read more: Will Currency Woes Hurt Abbott Labs' Q1 Earnings? | Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings releases and guidance of the likes of Abbott LaboratoriesABT , Biogen Inc.BIIB , and Novartis AGNVS have always held investors' attention. With the Q1 earnings season gaining momentum, focus will be on the medical sector which is facing challenges in the form of growing political pressure on drug prices, currency headwinds, biosimilar and generic competition as well as European pricing pressure. | Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings releases and guidance of the likes of Abbott LaboratoriesABT , Biogen Inc.BIIB , and Novartis AGNVS have always held investors' attention. As per our Earnings Trends report, the Medical sector is expected to witness earnings growth of 0.9% and revenue growth of 9.1% in the first quarter of 2016. | Earnings releases and guidance of the likes of Abbott LaboratoriesABT , Biogen Inc.BIIB , and Novartis AGNVS have always held investors' attention. Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. What to Expect from these Drug Stocks? |
33924.0 | 2016-04-19 00:00:00 UTC | Health Care Sector Update for 04/19/2016: SCMP, AMGN, MRK, ABT, PFE, JNJ | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04192016-scmp-amgn-mrk-abt-pfe-jnj-2016-04-19 | nan | nan | Top Health-care stocks:
JNJ: +0.7
PFE: flat
ABT: flat
MRK: flat
AMGN: +0.3%
Health care shares were mostly unchanged in pre-market trade Tuesday.
In health care stocks news, Sucampo Pharmaceuticals ( SCMP ) reported that its drug candidate cobiprostone did not meaningfully improve heartburn symptoms in a Phase 2a study. Cobiprostone was being investigated for patients with non-erosive reflux disease (NERD), a subtype of gastro-esophagael reflux disease (GERD). The company said that because the trial did not meet its primary endpoints, it will discontinue development of cobiprostone for PPI-refractory NERD/sGERD.
SCMP shares were down 1.9% at $11.11 in pre-market trading , with a 52-week range of $9.59 - $29.67.
Johnson & Johnson ( JNJ ) reported Q1 adjusted earnings rose to $1.68 per diluted share from $1.56 a | PFE: flat ABT: flat MRK: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Sucampo Pharmaceuticals ( SCMP ) reported that its drug candidate cobiprostone did not meaningfully improve heartburn symptoms in a Phase 2a study. | PFE: flat ABT: flat MRK: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Sucampo Pharmaceuticals ( SCMP ) reported that its drug candidate cobiprostone did not meaningfully improve heartburn symptoms in a Phase 2a study. | PFE: flat ABT: flat MRK: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Sucampo Pharmaceuticals ( SCMP ) reported that its drug candidate cobiprostone did not meaningfully improve heartburn symptoms in a Phase 2a study. | PFE: flat ABT: flat MRK: flat Top Health-care stocks: Health care shares were mostly unchanged in pre-market trade Tuesday. |
33925.0 | 2016-04-18 00:00:00 UTC | Health Care Select Sector SPDR Fund Experiences Big Outflow | ABT | https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-outflow-2016-04-18 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $136.6 million dollar outflow -- that's a 1.1% decrease week over week (from 177,765,324 to 175,815,324). Among the largest underlying components of XLV, in trading today Eli Lilly & Co. (Symbol: LLY) is up about 0.6%, Biogen Inc (Symbol: BIIB) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $70.41. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Eli Lilly & Co. (Symbol: LLY) is up about 0.6%, Biogen Inc (Symbol: BIIB) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $136.6 million dollar outflow -- that's a 1.1% decrease week over week (from 177,765,324 to 175,815,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Eli Lilly & Co. (Symbol: LLY) is up about 0.6%, Biogen Inc (Symbol: BIIB) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $70.41. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today Eli Lilly & Co. (Symbol: LLY) is up about 0.6%, Biogen Inc (Symbol: BIIB) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $136.6 million dollar outflow -- that's a 1.1% decrease week over week (from 177,765,324 to 175,815,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $70.41. | Among the largest underlying components of XLV, in trading today Eli Lilly & Co. (Symbol: LLY) is up about 0.6%, Biogen Inc (Symbol: BIIB) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $70.41. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33926.0 | 2016-04-18 00:00:00 UTC | Will Currency Woes Hurt Abbott Labs' (ABT) Q1 Earnings? | ABT | https://www.nasdaq.com/articles/will-currency-woes-hurt-abbott-labs-abt-q1-earnings-2016-04-18 | nan | nan | Abbott LaboratoriesABT is scheduled to report first-quarter 2016 results before the opening bell on Apr 20.
Abbott Labs has an impressive track record with the company having surpassed estimates in each of the trailing four quarters, with an average earnings surprise of 4.86%. Let's see how things are shaping up for this announcement.
Factors Driving the Quarter
Abbott Labs expects to face challenging conditions in Venezuela, which has been a historically good market for the company, due to high inflation, increasing price and margin controls, regulations on imports, and slowing demand. This, in turn, will hurt sales growth rate by 3% in the first quarter.
Strengthening of the dollar against almost every currency has significantly clouded the outlook for 2016. Unfavorable movement in foreign currency rates is, thus, expected to impact 2016 results adversely, particularly in those emerging markets where currencies have been devalued. In fact, this impact is estimated to be higher in 2016 than the 2015 level due to the combined blow of currency movement and certain timing effects. Consequently, sales in 2016 will suffer about 4% due to currency movements. In particular, first-quarter sales are expected to decline in the low single digits, reflecting a 6% negative currency impact. Earnings per share are projected around 38-40 cents.
On a segmental basis, nutrition sales are estimated to increase in the low-to-mid single digits driven by market expansion in China, Latin America and other priority markets. Sales from the diagnostic unit should grow in the mid single digits. On the other hand, growth rates have slowed down considerably in emerging markets in recent times, thereby impacting demand. Vascular sales are projected to witness a single-digit decline on an operational basis in first-quarter 2016 and the full year. Nevertheless, market uptake is expected to be strong for MitraClip. Abbott Labs expects to launch its fully dissolving stent, Absorb, in the U.S. market. Diabetes care sales are estimated to increase in mid single digits. The company recently expanded its capacities to meet the strong demand for FreeStyle Libre in Europe. It is also looking forward to launch this technology in a number of new markets in 2016, targeting the multibillion dollar global blood glucose monitoring market.
Meanwhile, the established pharmaceuticals division (EPD) is expected to increase in mid single digits, reflecting double-digit operational growth excluding the impact of Venezuela.
What Our Model Indicates
Our proven model does not conclusively show that Abbott Labs is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. However, that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 39 cents.
Zacks Rank: Abbott Labs currently carries a Zacks Rank #2 (Buy). Though this increases the predictive power of the ESP, the company's 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with Zacks Rank #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Johnson & Johnson JNJ has an Earnings ESP of +1.22% and a Zacks Rank #2. The company is scheduled to report first-quarter results on Apr 19.
The Earnings ESP for Sanofi SNY is +4.17% and it carries a Zacks Rank #2. The company is scheduled to release results on Apr 29.
Gilead Sciences Inc. GILD has an Earnings ESP of +1.65% and a Zacks Rank #1. The company will report results on Apr 28.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is scheduled to report first-quarter 2016 results before the opening bell on Apr 20. Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs has an impressive track record with the company having surpassed estimates in each of the trailing four quarters, with an average earnings surprise of 4.86%. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report first-quarter 2016 results before the opening bell on Apr 20. In particular, first-quarter sales are expected to decline in the low single digits, reflecting a 6% negative currency impact. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report first-quarter 2016 results before the opening bell on Apr 20. Zacks ESP: The Earnings ESP which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. | Abbott LaboratoriesABT is scheduled to report first-quarter 2016 results before the opening bell on Apr 20. Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Unfavorable movement in foreign currency rates is, thus, expected to impact 2016 results adversely, particularly in those emerging markets where currencies have been devalued. |
33927.0 | 2016-04-18 00:00:00 UTC | Health Care Sector Update for 04/18/2016: MDVN, BIIB, AMGN, MRK, ABT, PFE, JNJ | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04182016-mdvn-biib-amgn-mrk-abt-pfe-jnj-2016-04-18 | nan | nan | Top Health Care stocks:
JNJ: flat
PFE: -0.5%
ABT: -0.02%
MRK: -0.3%
AMGN: -0.8%
Health care shares were mostly lower in pre-market trade Monday.
In health care stocks news, Biogen ( BIIB ) unveiled new research that it claimed reinforces a "strong and sustained efficacy" in newly diagnosed multiple sclerosis patients and further supports its long-term safety profile. "Data from a post-hoc analysis show that more than half of newly diagnosed patients treated with TECFIDERA were free from relapses and disability progression for six years, reinforcing that early, effective treatment with TECFIDERA improves long-term clinical outcomes," the statement added.
BIIB shares were down 1.3% at $265 in pre-market trading , with a 52-week range of $242.07 - $431.84.
Medivation ( MDVN ) reported that Phase I data on its drug talazoparib indicated "objective response" in fighting tumors and that the "findings are encouraging and support further evaluation" of the tumor-fighting drug. The phase 1 data was presented at the American Association for Cancer Research annual meeting in New Orleans by the study's lead investigator Zev Wainberg, Associate Professor of Medicine at the University of California Los Angeles and Co-Director of the UCLA GI Oncology Program. The primary objective of the study was to determine the maximum tolerated dose of talazoparib in combination with either low-dose temozolomide or low-dose irinotecan in heavily pretreated patients with advanced malignancies. Medivation said the data from the 40 patient trial demonstrated that combination treatment with talazoparib and low-dose chemotherapy resulted in stable disease or an objective response in 23 of 40 heavily pretreated patients with a variety of advanced cancers (clinical benefit rate of 58%).
MDVN shares were up 3.4% at $52.90, with a 52-week range of $26.41 - $66.90.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Biogen ( BIIB ) unveiled new research that it claimed reinforces a "strong and sustained efficacy" in newly diagnosed multiple sclerosis patients and further supports its long-term safety profile. "Data from a post-hoc analysis show that more than half of newly diagnosed patients treated with TECFIDERA were free from relapses and disability progression for six years, reinforcing that early, effective treatment with TECFIDERA improves long-term clinical outcomes," the statement added. The phase 1 data was presented at the American Association for Cancer Research annual meeting in New Orleans by the study's lead investigator Zev Wainberg, Associate Professor of Medicine at the University of California Los Angeles and Co-Director of the UCLA GI Oncology Program. | Medivation ( MDVN ) reported that Phase I data on its drug talazoparib indicated "objective response" in fighting tumors and that the "findings are encouraging and support further evaluation" of the tumor-fighting drug. The primary objective of the study was to determine the maximum tolerated dose of talazoparib in combination with either low-dose temozolomide or low-dose irinotecan in heavily pretreated patients with advanced malignancies. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Biogen ( BIIB ) unveiled new research that it claimed reinforces a "strong and sustained efficacy" in newly diagnosed multiple sclerosis patients and further supports its long-term safety profile. "Data from a post-hoc analysis show that more than half of newly diagnosed patients treated with TECFIDERA were free from relapses and disability progression for six years, reinforcing that early, effective treatment with TECFIDERA improves long-term clinical outcomes," the statement added. Medivation said the data from the 40 patient trial demonstrated that combination treatment with talazoparib and low-dose chemotherapy resulted in stable disease or an objective response in 23 of 40 heavily pretreated patients with a variety of advanced cancers (clinical benefit rate of 58%). | Health care shares were mostly lower in pre-market trade Monday. Medivation said the data from the 40 patient trial demonstrated that combination treatment with talazoparib and low-dose chemotherapy resulted in stable disease or an objective response in 23 of 40 heavily pretreated patients with a variety of advanced cancers (clinical benefit rate of 58%). MDVN shares were up 3.4% at $52.90, with a 52-week range of $26.41 - $66.90. |
33928.0 | 2016-04-15 00:00:00 UTC | Health Care Sector Update for 04/15/2016: AMGN, MRK, ABT, PFE, JNJ, VRX, MRNS | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04152016-amgn-mrk-abt-pfe-jnj-vrx-mrns-2016-04-15 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: +0.3%
AMGN: flat
Health care shares were mostly unchanged in pre-market trade Friday.
In health care stocks news, Valeant Pharmaceuticals International ( VRX ) rose in pre-market trading after Reuters said late Thursday the company has brought in investment banks to review its options after getting interest from buyout firms and other companies for some of its businesses. It reportedly is working with Goldman Sachs and Centerview Partners Holdings LLC. One coveted asset is Xifaxin, the largest product in Valeant's gastrointestinal division, which it acquired last year as part of its $11 billion acquisition of Salix Pharmaceuticals, the sources reportedly said. Other assets that have attracted interest from potential bidders include its aesthetics products, Obagi and Solta, and its skin care product, CeraVe, some of the sources had added.
VRX shares were up 1.6% at $32.86, with a 52-week range of $25.27 - $263.81.
Marinus Pharmaceuticals ( MRNS ) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the intravenous formulation ganaxolone, CNS-selective GABAA modulator, for the treatment of status epilepticus. Status epilepticus is a dangerous condition in which epileptic seizures follow one another without recovery of consciousness between them. A Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of ganaxolone IV is expected to begin in the first half of 2016. Ganaxolone has previously been given orphan drug designation for two other indications - as treatment for Protocadherin 19 (PCDH19) female epilepsy and as treatment for infantile spasms.
MRNS shares were up 1.9% at $5.27, with a 52-week range of $4.00 - $20.72
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat In health care stocks news, Valeant Pharmaceuticals International ( VRX ) rose in pre-market trading after Reuters said late Thursday the company has brought in investment banks to review its options after getting interest from buyout firms and other companies for some of its businesses. One coveted asset is Xifaxin, the largest product in Valeant's gastrointestinal division, which it acquired last year as part of its $11 billion acquisition of Salix Pharmaceuticals, the sources reportedly said. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Friday. In health care stocks news, Valeant Pharmaceuticals International ( VRX ) rose in pre-market trading after Reuters said late Thursday the company has brought in investment banks to review its options after getting interest from buyout firms and other companies for some of its businesses. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat In health care stocks news, Valeant Pharmaceuticals International ( VRX ) rose in pre-market trading after Reuters said late Thursday the company has brought in investment banks to review its options after getting interest from buyout firms and other companies for some of its businesses. Marinus Pharmaceuticals ( MRNS ) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the intravenous formulation ganaxolone, CNS-selective GABAA modulator, for the treatment of status epilepticus. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Friday. VRX shares were up 1.6% at $32.86, with a 52-week range of $25.27 - $263.81. |
33929.0 | 2016-04-13 00:00:00 UTC | Health Care Sector Update for 04/13/2016: OCLS, PSTI, AMGN, MRK, ABT, PFE, JNJ | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04132016-ocls-psti-amgn-mrk-abt-pfe-jnj-2016-04-13 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: flat
AMGN: flat
Health care shares were unchanged in pre-market trade Wednesday.
In health care stocks news, Pluristem ( PSTI ) rose in pre-market trade after it said it has been awarded in Japan two new patents related to cell therapy. The patents cover the company's core technology of three-dimensional expansion methods for producing therapeutic cell products derived from placental or fat cells and the use of placenta-derived cells grown with this 3D technology to treat disorders of the hematopoietic system.
PSTI shares were up 7.2% at $1.64, with a 52-week range of $0.71 - $2.97.
Oculus Innovative Sciences ( OCLS ) also surged in pre-market trade after the company said it has received a new CE Mark in Europe for its Microcyn-based Sinudox solution, intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity.
OCLS shares were up 25.8% at $1.17, with a 52-week range of $0.65 - $1.97.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Wednesday. In health care stocks news, Pluristem ( PSTI ) rose in pre-market trade after it said it has been awarded in Japan two new patents related to cell therapy. The patents cover the company's core technology of three-dimensional expansion methods for producing therapeutic cell products derived from placental or fat cells and the use of placenta-derived cells grown with this 3D technology to treat disorders of the hematopoietic system. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Wednesday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Wednesday. The patents cover the company's core technology of three-dimensional expansion methods for producing therapeutic cell products derived from placental or fat cells and the use of placenta-derived cells grown with this 3D technology to treat disorders of the hematopoietic system. Oculus Innovative Sciences ( OCLS ) also surged in pre-market trade after the company said it has received a new CE Mark in Europe for its Microcyn-based Sinudox solution, intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Wednesday. In health care stocks news, Pluristem ( PSTI ) rose in pre-market trade after it said it has been awarded in Japan two new patents related to cell therapy. PSTI shares were up 7.2% at $1.64, with a 52-week range of $0.71 - $2.97. |
33930.0 | 2016-04-12 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 13, 2016 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-april-13-2016-2016-04-12 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 13, 2016. A cash dividend payment of $0.26 per share is scheduled to be paid on May 16, 2016. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 8.33% increase over the same period a year ago. At the current stock price of $42.48, the dividend yield is 2.45%.
The previous trading day's last sale of ABT was $42.48, representing a -17.9% decrease from the 52 week high of $51.74 and a 18% increase over the 52 week low of $36.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $3. Zacks Investment Research reports ABT's forecasted earnings growth in 2016 as .17%, compared to an industry average of 3.9%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Medical Devices ETF ( IHI )
SPDR S&P Health Care Equipment ( XHE ).
The top-performing ETF of this group is IHI with an increase of 4.14% over the last 100 days. It also has the highest percent weighting of ABT at 9.59%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2016 as .17%, compared to an industry average of 3.9%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | ABT's current earnings per share, an indicator of a company's profitability, is $3. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 13, 2016. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $42.48, representing a -17.9% decrease from the 52 week high of $51.74 and a 18% increase over the 52 week low of $36. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ). | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. ABT's current earnings per share, an indicator of a company's profitability, is $3. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ). |
33931.0 | 2016-04-12 00:00:00 UTC | Health Care Sector Update for 04/12/2016: AMGN, MRK, ABT, PFE, JNJ, CLVS, CBRP | ABT | https://www.nasdaq.com/articles/health-care-sector-update-04122016-amgn-mrk-abt-pfe-jnj-clvs-cbrp-2016-04-12 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: +0.3%
ABT: flat
MRK: flat
AMGN: flat
Health care shares were mostly unchanged in pre-market trade Tuesday.
In health care stocks news, Clovis Oncology ( CLVS ) said the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee meets Tuesday morning to discuss the company's New Drug Application for rociletinib. The drug is for the treatment of patients with mutant epidermal growth factor receptor non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation.
CLVS shares were halted in pre-market trading , and closed the previous session at $15.06, with a 52-week range of $14.38 - $116.75.
Corbus Pharmaceuticals ( CRBP ) said the U.S. Food and Drug Administration has approved a 12-month open-label extension study of its Phase 2 clinical trial of Resunab for the treatment of scleroderma. The goal of the open label extension study is to provide subjects with the option of receiving Resunab following the completion of the 84-day treatment period and to collect long term safety and efficacy data. All subjects in the 12-month extension study will receive Resunab, including those who previously received placebo. The same clinical endpoints from the placebo-controlled portion of the trial will be monitored throughout the 12-month extension.
CRBP shares closed at $2.37, with a 52-week range of $1.01 - $4.31.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. The drug is for the treatment of patients with mutant epidermal growth factor receptor non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation. Corbus Pharmaceuticals ( CRBP ) said the U.S. Food and Drug Administration has approved a 12-month open-label extension study of its Phase 2 clinical trial of Resunab for the treatment of scleroderma. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Clovis Oncology ( CLVS ) said the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee meets Tuesday morning to discuss the company's New Drug Application for rociletinib. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Clovis Oncology ( CLVS ) said the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee meets Tuesday morning to discuss the company's New Drug Application for rociletinib. Corbus Pharmaceuticals ( CRBP ) said the U.S. Food and Drug Administration has approved a 12-month open-label extension study of its Phase 2 clinical trial of Resunab for the treatment of scleroderma. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. The drug is for the treatment of patients with mutant epidermal growth factor receptor non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation. Corbus Pharmaceuticals ( CRBP ) said the U.S. Food and Drug Administration has approved a 12-month open-label extension study of its Phase 2 clinical trial of Resunab for the treatment of scleroderma. |
33932.0 | 2016-04-11 00:00:00 UTC | Unloved Health Care ETFs May Surprise This Earnings Season | ABT | https://www.nasdaq.com/articles/unloved-health-care-etfs-may-surprise-earnings-season-2016-04-11 | nan | nan | The health care sector remains one of the worst performing areas of the market, despite the recovery off the Feb. 11 lows. With the earnings season coming up, health care stocks could be one of the few bright spots in the markets and exchange traded funds that track the sector could lead ahead.
Based on a percentage of "Buy" ratings at the end of March, analysts are most optimistic on the health care sector, according to FactSet . About 61% of analysts had a Buy rating on health care at the end of the first quarter.
The improved outlook for the health care industry comes as many expect continued growth in the sector, despite an ongoing so-called earnings recession in the S&P 500. While FactSet anticipates the broad S&P 500 to show an earnings decline of -9.1% for Q1 2016, the health care sector is expected to report revenue growth of 8.9%.
S&P Global Market Intelligence also mirrors this sentiment, projecting S&P 500 Q1 EPS to decline 7.5% year-over-year but anticipating 2.9% earnings growth for the health care sector.
Investors seeking high-quality exposure to the health care industry have a number of options available, including the Health Care Select Sector SPDR (NYSEArca: XLV ) , iShares U.S. Healthcare ETF (NYSEArca: IYH ) and Vanguard Health Care ETF (NYSEArca: VHT ) .
XLV is the largest ETF option in the space, with $12.4 billion in assets under management. The Health Care Select Sector SPDR ETF tracks health care companies taken from the S&P 500. XLV has a 0.14% expense ratio.
VHT provides similar exposure to XLV, except the Vanguard option includes a broader 340 component holdings, compared to XLV's smaller 58 stock portfolio. Additionally, VHT has a cheaper 0.09% expense ratio, compared to XLV's 0.14% expense ratio. However, the Vanguard Health Care ETF is much less actively traded, showing an average daily volume of about 300,000 shares, according to Morningstar data.
IYH is another alternative that comes with about 122 stock components, but the iShares U.S. Healthcare ETF shows a costlier 0.48% expense ratio.
Trending on ETF Trends
Flatter Yield Curve Ways on Bank ETFs
Technical Talk on a big Tech ETF
International ETF Strategy to Balance Risk & Opportunity
Inverse ETFs Step into the Limelight
Gaming ETF Faces Technical Challenges
Looking deeper into the health care industry, FactSet projects health care technology will lead the industry, with sales growth of 17% for the first quarter, followed by biotechnology's 12% sales growth.
The broad health care ETFs include significant tilts toward these sub-sectors. For instance, health care equipment & supplies make up 15.4% of XLV's holdings, 15.8% of IYH and 15.5% of VHT. Biotech accounts for 22.8% of XLV, 25.3% of IYH and 23.7% of VHT.
Alternatively, investors who want to specifically target these areas may also look to ETF options like the iShares U.S. Medical Devices ETF (NYSEArca: IHI ) or SPDR S&P Health Care Equipment ETF (NYSEArca: XHE ) . Both IHI and XHE are comprised of medical devices and health care equipment stocks. However, IHI follows a more traditional market cap-weighted index, which tilts toward Medtronic ( MDC ) 14.1%, Abbot Laboratories ( ABT ) 9.5% and Thermo Fisher Scientific ( TMO ) 8.6%. In contrast, XHE follows a more equal-weight methodology, which means it has a larger tilt toward smaller companies, including micro-caps 29.2%, small-cap 23.2%, mid-caps 30.6% and large-cap 15.2%.
Additionally, for biotechnology exposure, investors can turn to the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB ) , SPDR S&P Biotech ETF (NYSEArca: XBI ) and First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT ) .
IBB, the largest biotech-related ETF, follows the cap-weighted Nasdaq Biotechnology Index, which includes a 78.1% tilt toward biotechs, 14.5% pharmaceuticals and 7.3% life sciences tools & services. The fund comes with a 0.48% expense ratio.
XBI follows a more equally weight indexing methodology, so investors can expect greater exposure to small- and mid-cap names. The fund has a 0.35% expense ratio.
Lastly, FBT also follows the equally weighted NYSE Arca Biotechnology Index which includes over two-thirds of its components in small- and mid-sized biotech names. The ETF has a 0.58% expense ratio.
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This article was provided by our partner Tom Lydon of etftrends.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, IHI follows a more traditional market cap-weighted index, which tilts toward Medtronic ( MDC ) 14.1%, Abbot Laboratories ( ABT ) 9.5% and Thermo Fisher Scientific ( TMO ) 8.6%. With the earnings season coming up, health care stocks could be one of the few bright spots in the markets and exchange traded funds that track the sector could lead ahead. S&P Global Market Intelligence also mirrors this sentiment, projecting S&P 500 Q1 EPS to decline 7.5% year-over-year but anticipating 2.9% earnings growth for the health care sector. | However, IHI follows a more traditional market cap-weighted index, which tilts toward Medtronic ( MDC ) 14.1%, Abbot Laboratories ( ABT ) 9.5% and Thermo Fisher Scientific ( TMO ) 8.6%. Investors seeking high-quality exposure to the health care industry have a number of options available, including the Health Care Select Sector SPDR (NYSEArca: XLV ) , iShares U.S. Healthcare ETF (NYSEArca: IYH ) and Vanguard Health Care ETF (NYSEArca: VHT ) . Alternatively, investors who want to specifically target these areas may also look to ETF options like the iShares U.S. Medical Devices ETF (NYSEArca: IHI ) or SPDR S&P Health Care Equipment ETF (NYSEArca: XHE ) . | However, IHI follows a more traditional market cap-weighted index, which tilts toward Medtronic ( MDC ) 14.1%, Abbot Laboratories ( ABT ) 9.5% and Thermo Fisher Scientific ( TMO ) 8.6%. Investors seeking high-quality exposure to the health care industry have a number of options available, including the Health Care Select Sector SPDR (NYSEArca: XLV ) , iShares U.S. Healthcare ETF (NYSEArca: IYH ) and Vanguard Health Care ETF (NYSEArca: VHT ) . Trending on ETF Trends Flatter Yield Curve Ways on Bank ETFs Technical Talk on a big Tech ETF International ETF Strategy to Balance Risk & Opportunity Inverse ETFs Step into the Limelight Gaming ETF Faces Technical Challenges Looking deeper into the health care industry, FactSet projects health care technology will lead the industry, with sales growth of 17% for the first quarter, followed by biotechnology's 12% sales growth. | However, IHI follows a more traditional market cap-weighted index, which tilts toward Medtronic ( MDC ) 14.1%, Abbot Laboratories ( ABT ) 9.5% and Thermo Fisher Scientific ( TMO ) 8.6%. Investors seeking high-quality exposure to the health care industry have a number of options available, including the Health Care Select Sector SPDR (NYSEArca: XLV ) , iShares U.S. Healthcare ETF (NYSEArca: IYH ) and Vanguard Health Care ETF (NYSEArca: VHT ) . The Health Care Select Sector SPDR ETF tracks health care companies taken from the S&P 500. |
33933.0 | 2016-04-06 00:00:00 UTC | 3 Best Dividend Stocks to Buy in April | ABT | https://www.nasdaq.com/articles/3-best-dividend-stocks-to-buy-in-april-2016-04-06 | nan | nan | InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
The best dividend stocks provide dependable, rising income each and every year.
Source: ©iStock.com/vaeenma
These blue-chip dividend stocks typically maintain reasonable payout ratios, keep low amounts of debt, generate consistent free cash flow and dominate their markets.
The best dividend stocks offer strong potential for current income and long-term income growth, and we own each of the following three stocks. Two of them are even in our Top 20 Dividend Stocks portfolio .
After the market's surge since mid-February, it has been hard to find high-quality dividend stocks trading at reasonable prices.
10 Dividend Stocks to Buy for the Second Quarter
However, we believe each of the following businesses is a potentially appealing investment opportunity for long-term dividend investors to consider.
Best Dividend Stocks: Wells Fargo & Co (WFC)
Stubbornly low interest rates have caused bank stocks to remain largely out of favor during the past year. Low interest rates reduce the amount of profits banks can make from their lending operations.
The best time to buy stocks that benefit from higher interest rates is when the market is pessimistic about rates rising, which makes Wells Fargo & Co ( WFC ) an interesting dividend candidate today.
The bank was founded in 1852 and was the third-largest bank in the country as measured by assets at the end of 2015. The company's business is split nearly down the middle between traditional loan-making operations and noninterest income in the form of brokerage advisory services, credit card fees, mortgage originations, commissions and other services.
We believe Wells Fargo is one of the best dividend stocks for several reasons, beginning with its massive base of low-cost deposits used to fund many of its loans.
Wells Fargo's annual reports show that the company's total deposits have grown from $3.7 billion in 1966 to $1.2 trillion in 2015, representing consistent growth of approximately 12.6% per year.
Importantly, the company was paying just 8 basis points on its deposits as of the last quarter of 2015, virtually guaranteeing the company's ability to generate a positive return on its loan portfolio despite today's low interest rates.
As one of the biggest banks in the country, Wells Fargo also enjoys economies of scale that allow it generate a higher return on equity compared to its peers.
Another notable fact is that Wells Fargo is Warren Buffett's largest position, and the Oracle boosted his stake in the business during the fourth quarter of 2015 at prices above where Wells Fargo's stock currently trades.
Wells Fargo increased its dividend by 7% in 2015 and will likely announce another increase within the next month. With a payout ratio below 40% and capital ratios that exceed regulators' requirements, we think the bank is poised for continued dividend growth.
WFC stock offers a dividend yield of 3.1% and trades for 10.6 times forward earnings estimates. For income investors looking for a hedge against rising interest rates, Wells Fargo could be a high-quality idea to consider.
Best Dividend Stocks: Cummins Inc. (CMI)
Cummins Inc. ( CMI ) is a manufacturer of diesel and natural gas engines that are primarily used in the truck market and in off-highway vehicles.
Despite its cyclicality, we think Cummins is one of the best dividend stocks and possesses several competitive advantages.
The company owns an arsenal of patents surrounding its engine technology, has built a strong brand and owns one of the biggest distribution networks in the industry. Engines are very expensive purchases, and customers need a supplier that can quickly and efficiently provide aftermarket services to keep its equipment up and running.
While Cummins is dealing with several near-term macro challenges that are weighing on its business, the company's dividend continues to look very safe.
Cummins has more cash on hand than debt and maintains a dividend payout ratio below 50%. Even if earnings were unexpectedly cut in half, the company appears to have plenty of financial strength to keep paying its dividend, which management has increased for six straight years.
8 High-Quality, High-Dividend Stocks to Buy for Q2
CMI's stock trades at a forward price-to-earnings multiple of 13.3 and has a dividend yield of 3.6%.
Best Dividend Stocks: Abbott Laboratories (ABT)
Abbott Laboratories ( ABT ) is a member of the dividend aristocrats list and has been in business for more than 125 years. The healthcare company operates across four segments - nutritionals, generic drugs, medical devices and diagnostics - and owns a number of well-known brands.
Healthcare is one of the best stock sectors for dividend income because of the non-discretionary nature of many of its products. Abbott should also benefit over the long term because it derives 50% of its sales from faster-growing emerging markets, which should see per capita healthcare spending rise over time.
Many of Abbott's markets are also highly fragmented, require substantial investments in research and development, are protected by patents and require global distribution networks for success.
With an earnings payout ratio below 50% and a healthy balance sheet, Abbott is primed for continued dividend growth. Management last boosted the dividend by 8%, and we expect at least mid-single-digit dividend growth going forward.
ABT's stock has a dividend yield of 2.5% and trades for 18 times forward earnings estimates.
At the time of this writing, the author was long WFC, CMI and ABT.
The post 3 Best Dividend Stocks to Buy in April appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Best Dividend Stocks: Abbott Laboratories (ABT) Abbott Laboratories ( ABT ) is a member of the dividend aristocrats list and has been in business for more than 125 years. ABT's stock has a dividend yield of 2.5% and trades for 18 times forward earnings estimates. At the time of this writing, the author was long WFC, CMI and ABT. | Best Dividend Stocks: Abbott Laboratories (ABT) Abbott Laboratories ( ABT ) is a member of the dividend aristocrats list and has been in business for more than 125 years. ABT's stock has a dividend yield of 2.5% and trades for 18 times forward earnings estimates. At the time of this writing, the author was long WFC, CMI and ABT. | Best Dividend Stocks: Abbott Laboratories (ABT) Abbott Laboratories ( ABT ) is a member of the dividend aristocrats list and has been in business for more than 125 years. ABT's stock has a dividend yield of 2.5% and trades for 18 times forward earnings estimates. At the time of this writing, the author was long WFC, CMI and ABT. | Best Dividend Stocks: Abbott Laboratories (ABT) Abbott Laboratories ( ABT ) is a member of the dividend aristocrats list and has been in business for more than 125 years. ABT's stock has a dividend yield of 2.5% and trades for 18 times forward earnings estimates. At the time of this writing, the author was long WFC, CMI and ABT. |
33934.0 | 2016-04-04 00:00:00 UTC | iShares U.S. Healthcare ETF Experiences Big Outflow | ABT | https://www.nasdaq.com/articles/ishares-us-healthcare-etf-experiences-big-outflow-2016-04-04 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $21.1 million dollar outflow -- that's a 1.2% decrease week over week (from 12,600,000 to 12,450,000). Among the largest underlying components of IYH, in trading today Eli Lilly & Co. (Symbol: LLY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.4%, and Biogen Inc (Symbol: BIIB) is higher by about 0.9%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $143.63. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Eli Lilly & Co. (Symbol: LLY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.4%, and Biogen Inc (Symbol: BIIB) is higher by about 0.9%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $143.63. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IYH, in trading today Eli Lilly & Co. (Symbol: LLY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.4%, and Biogen Inc (Symbol: BIIB) is higher by about 0.9%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $143.63. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IYH, in trading today Eli Lilly & Co. (Symbol: LLY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.4%, and Biogen Inc (Symbol: BIIB) is higher by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $21.1 million dollar outflow -- that's a 1.2% decrease week over week (from 12,600,000 to 12,450,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $143.63. | Among the largest underlying components of IYH, in trading today Eli Lilly & Co. (Symbol: LLY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.4%, and Biogen Inc (Symbol: BIIB) is higher by about 0.9%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $143.63. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33935.0 | 2016-03-29 00:00:00 UTC | Prepare for Earnings Season with These 49 Trades | ABT | https://www.nasdaq.com/articles/prepare-earnings-season-these-49-trades-2016-03-29 | nan | nan | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
During these busy times it pays to stay on top of the latest profit opportunities. Today's blog post is a great place to start.
After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 49 big blue chips.
7 A-Rated Stocks to Buy and Hold for Q2 and Beyond!
Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.
This Week's Ratings Changes
To stay on top of my latest stock ratings, plug your holdings into Portfolio Grader , my proprietary stock screening tool. You may get started here .
More From InvestorPlace
10 Stocks That Could Derail Your Retirement
7 Low-Risk Healthcare Stocks to Buy Now
7 Best Funds for a New Rollover IRA Portfolio
The post Prepare for Earnings Season with These 49 Trades appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips During these busy times it pays to stay on top of the latest profit opportunities. After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 49 big blue chips. More From InvestorPlace 10 Stocks That Could Derail Your Retirement 7 Low-Risk Healthcare Stocks to Buy Now 7 Best Funds for a New Rollover IRA Portfolio The post Prepare for Earnings Season with These 49 Trades appeared first on InvestorPlace . | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This Week's Ratings Changes To stay on top of my latest stock ratings, plug your holdings into Portfolio Grader , my proprietary stock screening tool. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips During these busy times it pays to stay on top of the latest profit opportunities. This Week's Ratings Changes To stay on top of my latest stock ratings, plug your holdings into Portfolio Grader , my proprietary stock screening tool. More From InvestorPlace 10 Stocks That Could Derail Your Retirement 7 Low-Risk Healthcare Stocks to Buy Now 7 Best Funds for a New Rollover IRA Portfolio The post Prepare for Earnings Season with These 49 Trades appeared first on InvestorPlace . | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips During these busy times it pays to stay on top of the latest profit opportunities. Today's blog post is a great place to start. This Week's Ratings Changes To stay on top of my latest stock ratings, plug your holdings into Portfolio Grader , my proprietary stock screening tool. |
33936.0 | 2016-03-24 00:00:00 UTC | Health Care Sector Update for 03/24/2016: NVIV, JNJ, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-03242016-nviv-jnj-pfe-abt-mrk-amgn-2016-03-24 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: flat
ABT: flat
MRK: flat
AMGN: flat
Health-care shares were mostly flat in pre-market trade Thursday.
In health-care stocks news, InVivo Therapeutics ( NVIV ) was up 4.8% at $7 after the biotechnology firm said a seventh patient was enrolled in the INSPIRE study, a study that is designed to evaluate the benefit of the Neuro-Spinal Scaffold in subjects with complete thoracic AIS A spinal cord injury. The seventh patient was implanted with the Neuro-Spinal Scaffold approximately 21 hours after the injury occurred, InVivo noted. Dr. Domagoj Coric, a member of the INSPIRE Study Steering Committee said, "The implantation procedure was a success, and the patient is doing well." InVivo chairman and CEO Mark Perrin said the company expects to approach full enrollment in the INSPIRE study by the end of 2016.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were mostly flat in pre-market trade Thursday. The seventh patient was implanted with the Neuro-Spinal Scaffold approximately 21 hours after the injury occurred, InVivo noted. Dr. Domagoj Coric, a member of the INSPIRE Study Steering Committee said, "The implantation procedure was a success, and the patient is doing well." | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were mostly flat in pre-market trade Thursday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were mostly flat in pre-market trade Thursday. In health-care stocks news, InVivo Therapeutics ( NVIV ) was up 4.8% at $7 after the biotechnology firm said a seventh patient was enrolled in the INSPIRE study, a study that is designed to evaluate the benefit of the Neuro-Spinal Scaffold in subjects with complete thoracic AIS A spinal cord injury. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were mostly flat in pre-market trade Thursday. In health-care stocks news, InVivo Therapeutics ( NVIV ) was up 4.8% at $7 after the biotechnology firm said a seventh patient was enrolled in the INSPIRE study, a study that is designed to evaluate the benefit of the Neuro-Spinal Scaffold in subjects with complete thoracic AIS A spinal cord injury. The seventh patient was implanted with the Neuro-Spinal Scaffold approximately 21 hours after the injury occurred, InVivo noted. |
33937.0 | 2016-03-23 00:00:00 UTC | Zacks Industry Outlook Highlights: Bayer, Abbott Laboratories, Roche Holding, Medtronic and DENTSPLY International | ABT | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-bayer-abbott-laboratories-roche-holding-medtronic-and | nan | nan | For Immediate Release
Chicago, IL - March 23, 2016 - Today, Zacks Equity Research discusses the MedTech, part 2, including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) , Roche Holding AG ( RHHBY ), Medtronic ( MDT ) and DENTSPLY International Inc. ( XRAY ).
Industry: MedTech, part 2
Link: http://www.zacks.com/commentary/75772/lots-happening-in-medtech-should-you-buy-these-stocks
In recent years, 2015 can be taken as a case study considering the medley of factors, both domestic and international, that were at play. However, this is not the end of uncertainties as a possible change in the government will likely bring in sectora | For Immediate Release Chicago, IL - March 23, 2016 - Today, Zacks Equity Research discusses the MedTech, part 2, including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) , Roche Holding AG ( RHHBY ), Medtronic ( MDT ) and DENTSPLY International Inc. ( XRAY ). Industry: MedTech, part 2 Link: http://www.zacks.com/commentary/75772/lots-happening-in-medtech-should-you-buy-these-stocks In recent years, 2015 can be taken as a case study considering the medley of factors, both domestic and international, that were at play. However, this is not the end of uncertainties as a possible change in the government will likely bring in sectora | For Immediate Release Chicago, IL - March 23, 2016 - Today, Zacks Equity Research discusses the MedTech, part 2, including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) , Roche Holding AG ( RHHBY ), Medtronic ( MDT ) and DENTSPLY International Inc. ( XRAY ). Industry: MedTech, part 2 Link: http://www.zacks.com/commentary/75772/lots-happening-in-medtech-should-you-buy-these-stocks In recent years, 2015 can be taken as a case study considering the medley of factors, both domestic and international, that were at play. However, this is not the end of uncertainties as a possible change in the government will likely bring in sectora | For Immediate Release Chicago, IL - March 23, 2016 - Today, Zacks Equity Research discusses the MedTech, part 2, including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) , Roche Holding AG ( RHHBY ), Medtronic ( MDT ) and DENTSPLY International Inc. ( XRAY ). Industry: MedTech, part 2 Link: http://www.zacks.com/commentary/75772/lots-happening-in-medtech-should-you-buy-these-stocks In recent years, 2015 can be taken as a case study considering the medley of factors, both domestic and international, that were at play. However, this is not the end of uncertainties as a possible change in the government will likely bring in sectora | For Immediate Release Chicago, IL - March 23, 2016 - Today, Zacks Equity Research discusses the MedTech, part 2, including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) , Roche Holding AG ( RHHBY ), Medtronic ( MDT ) and DENTSPLY International Inc. ( XRAY ). Industry: MedTech, part 2 Link: http://www.zacks.com/commentary/75772/lots-happening-in-medtech-should-you-buy-these-stocks In recent years, 2015 can be taken as a case study considering the medley of factors, both domestic and international, that were at play. However, this is not the end of uncertainties as a possible change in the government will likely bring in sectora |
33938.0 | 2016-03-21 00:00:00 UTC | XLV, GILD, AGN, ABT: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/xlv-gild-agn-abt-large-outflows-detected-etf-2016-03-21 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $341.5 million dollar outflow -- that's a 2.9% decrease week over week (from 177,215,324 to 172,115,324). Among the largest underlying components of XLV, in trading today Gilead Sciences, Inc. (Symbol: GILD) is up about 1.8%, Allergan PLC (Symbol: AGN) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $67.03. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Gilead Sciences, Inc. (Symbol: GILD) is up about 1.8%, Allergan PLC (Symbol: AGN) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $341.5 million dollar outflow -- that's a 2.9% decrease week over week (from 177,215,324 to 172,115,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Gilead Sciences, Inc. (Symbol: GILD) is up about 1.8%, Allergan PLC (Symbol: AGN) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $67.03. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today Gilead Sciences, Inc. (Symbol: GILD) is up about 1.8%, Allergan PLC (Symbol: AGN) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $341.5 million dollar outflow -- that's a 2.9% decrease week over week (from 177,215,324 to 172,115,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $67.03. | Among the largest underlying components of XLV, in trading today Gilead Sciences, Inc. (Symbol: GILD) is up about 1.8%, Allergan PLC (Symbol: AGN) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $341.5 million dollar outflow -- that's a 2.9% decrease week over week (from 177,215,324 to 172,115,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $67.03. |
33939.0 | 2016-03-09 00:00:00 UTC | New Strong Sell Stocks for March 9th | ABT | https://www.nasdaq.com/articles/new-strong-sell-stocks-for-march-9th-2016-03-09 | nan | nan | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today:
Abbott LaboratoriesABT
Active Power, IncACPW
Altisource Residential CorpRESI
American Campus Communities, Inc ACC
American Tower Corp.AMT
View the entire Zacks Rank #5 List .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
AMER TOWER CORP (AMT): Free Stock Analysis Report
ACTIVE POWER (ACPW): Free Stock Analysis Report
AMER CAMPUS CTY (ACC): Free Stock Analysis Report
ALTISOURCE RESI (RESI): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Active Power, IncACPW Altisource Residential CorpRESI American Campus Communities, Inc ACC American Tower Corp.AMT View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER TOWER CORP (AMT): Free Stock Analysis Report ACTIVE POWER (ACPW): Free Stock Analysis Report AMER CAMPUS CTY (ACC): Free Stock Analysis Report ALTISOURCE RESI (RESI): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Active Power, IncACPW Altisource Residential CorpRESI American Campus Communities, Inc ACC American Tower Corp.AMT View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER TOWER CORP (AMT): Free Stock Analysis Report ACTIVE POWER (ACPW): Free Stock Analysis Report AMER CAMPUS CTY (ACC): Free Stock Analysis Report ALTISOURCE RESI (RESI): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Active Power, IncACPW Altisource Residential CorpRESI American Campus Communities, Inc ACC American Tower Corp.AMT View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER TOWER CORP (AMT): Free Stock Analysis Report ACTIVE POWER (ACPW): Free Stock Analysis Report AMER CAMPUS CTY (ACC): Free Stock Analysis Report ALTISOURCE RESI (RESI): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Active Power, IncACPW Altisource Residential CorpRESI American Campus Communities, Inc ACC American Tower Corp.AMT View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER TOWER CORP (AMT): Free Stock Analysis Report ACTIVE POWER (ACPW): Free Stock Analysis Report AMER CAMPUS CTY (ACC): Free Stock Analysis Report ALTISOURCE RESI (RESI): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? |
33940.0 | 2016-03-04 00:00:00 UTC | S&P 500 Analyst Moves: ABT | ABT | https://www.nasdaq.com/articles/sp-500-analyst-moves-abt-2016-03-04 | nan | nan | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #129 analyst pick, moving up by 3 spots.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values.
Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is lower by about 13.0%.
VIDEO: S&P 500 Analyst Moves: ABT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #129 analyst pick, moving up by 3 spots. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is lower by about 13.0%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is lower by about 13.0%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #129 analyst pick, moving up by 3 spots. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #129 analyst pick, moving up by 3 spots. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is lower by about 13.0%. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #129 analyst pick, moving up by 3 spots. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is lower by about 13.0%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33941.0 | 2016-02-29 00:00:00 UTC | New Strong Sell Stocks for February 29th | ABT | https://www.nasdaq.com/articles/new-strong-sell-stocks-for-february-29th-2016-02-29 | nan | nan | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today:
Abbott LaboratoriesABT
Acceleron Pharma IncXLRN
Alliance Fiber Optic Products IncAFOP
American Capital Senior Floating Ltd. ACSF
American Science & Engineering, Inc.ASEI
View the entire Zacks Rank #5 List .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
AMER SCI & ENG (ASEI): Free Stock Analysis Report
ALLIANCE FIBER (AFOP): Free Stock Analysis Report
AMER CAP SNR FL (ACSF): ETF Research Reports
ACCELERON PHARM (XLRN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Acceleron Pharma IncXLRN Alliance Fiber Optic Products IncAFOP American Capital Senior Floating Ltd. ACSF American Science & Engineering, Inc.ASEI View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER SCI & ENG (ASEI): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Acceleron Pharma IncXLRN Alliance Fiber Optic Products IncAFOP American Capital Senior Floating Ltd. ACSF American Science & Engineering, Inc.ASEI View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER SCI & ENG (ASEI): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Acceleron Pharma IncXLRN Alliance Fiber Optic Products IncAFOP American Capital Senior Floating Ltd. ACSF American Science & Engineering, Inc.ASEI View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER SCI & ENG (ASEI): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Acceleron Pharma IncXLRN Alliance Fiber Optic Products IncAFOP American Capital Senior Floating Ltd. ACSF American Science & Engineering, Inc.ASEI View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER SCI & ENG (ASEI): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
33942.0 | 2016-02-24 00:00:00 UTC | New Strong Sell Stocks for February 24th | ABT | https://www.nasdaq.com/articles/new-strong-sell-stocks-for-february-24th-2016-02-24 | nan | nan | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Abbott Laboratories ( ABT )
Alliance Fiber Optic Products Inc ( AFOP )
American Capital Senior Floating Ltd ( ACSF )
Arctic Cat Inc ( ACAT )
Bank of Commerce Holdings ( BOCH )
View the entire Zacks Rank #5 List .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLIANCE FIBER (AFOP): Free Stock Analysis Report
AMER CAP SNR FL (ACSF): ETF Research Reports
ARCTIC CAT INC (ACAT): Free Stock Analysis Report
BANK OF COMMRC (BOCH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Alliance Fiber Optic Products Inc ( AFOP ) American Capital Senior Floating Ltd ( ACSF ) Arctic Cat Inc ( ACAT ) Bank of Commerce Holdings ( BOCH ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ARCTIC CAT INC (ACAT): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Alliance Fiber Optic Products Inc ( AFOP ) American Capital Senior Floating Ltd ( ACSF ) Arctic Cat Inc ( ACAT ) Bank of Commerce Holdings ( BOCH ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ARCTIC CAT INC (ACAT): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Alliance Fiber Optic Products Inc ( AFOP ) American Capital Senior Floating Ltd ( ACSF ) Arctic Cat Inc ( ACAT ) Bank of Commerce Holdings ( BOCH ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ARCTIC CAT INC (ACAT): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Alliance Fiber Optic Products Inc ( AFOP ) American Capital Senior Floating Ltd ( ACSF ) Arctic Cat Inc ( ACAT ) Bank of Commerce Holdings ( BOCH ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ARCTIC CAT INC (ACAT): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? |
33943.0 | 2016-02-22 00:00:00 UTC | UPRO, BIIB, ABT, DHR: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/upro-biib-abt-dhr-large-outflows-detected-etf-2016-02-22 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $69.1 million dollar outflow -- that's a 7.5% decrease week over week (from 18,100,000 to 16,750,000). Among the largest underlying components of UPRO, in trading today Biogen Inc (Symbol: BIIB) is up about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.4%, and Danaher Corp. (Symbol: DHR) is higher by about 1.1%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $42.98 per share, with $73.66 as the 52 week high point - that compares with a last trade of $53.15. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Biogen Inc (Symbol: BIIB) is up about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.4%, and Danaher Corp. (Symbol: DHR) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $69.1 million dollar outflow -- that's a 7.5% decrease week over week (from 18,100,000 to 16,750,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of UPRO, in trading today Biogen Inc (Symbol: BIIB) is up about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.4%, and Danaher Corp. (Symbol: DHR) is higher by about 1.1%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $42.98 per share, with $73.66 as the 52 week high point - that compares with a last trade of $53.15. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of UPRO, in trading today Biogen Inc (Symbol: BIIB) is up about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.4%, and Danaher Corp. (Symbol: DHR) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $69.1 million dollar outflow -- that's a 7.5% decrease week over week (from 18,100,000 to 16,750,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $42.98 per share, with $73.66 as the 52 week high point - that compares with a last trade of $53.15. | Among the largest underlying components of UPRO, in trading today Biogen Inc (Symbol: BIIB) is up about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.4%, and Danaher Corp. (Symbol: DHR) is higher by about 1.1%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $42.98 per share, with $73.66 as the 52 week high point - that compares with a last trade of $53.15. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33944.0 | 2016-02-19 00:00:00 UTC | Daily Dividend Report: ANTM, EQIX, MDT, ABT, FDX, CCI, K | ABT | https://www.nasdaq.com/articles/daily-dividend-report-antm-eqix-mdt-abt-fdx-cci-k-2016-02-19 | nan | nan | Anthem ( ANTM ) authorized an increase of 4 percent in the Company's shareholder dividend and declared a $0.65 per share dividend for the first quarter of 2016. The first quarter dividend is payable on March 25, 2016, to shareholders of record at the close of business on March 10, 2016.
Equinix ( EQIX ) has declared a quarterly cash dividend of $1.75 per share on common stock, a 3.6% increase over its prior cash dividend per share. The quarterly common stock dividend will be paid on March 23, 2016, to shareholders of record on March 9, 2016.
Medtronic ( MDT ) the fiscal year 2016 fourth quarter cash dividend of $0.38 per ordinary share, representing a 25 percent increase over the prior year. The dividend is payable on April 15, 2016, to shareholders of record at the close of business on March 24, 2016.
Abbott ( ABT ) declared a quarterly common dividend of 26 cents per share. The cash dividend is payable May 16, 2016, to shareholders of record at the close of business on April 15, 2016.
FedEx Corporation ( FDX ) declared a quarterly cash dividend of $0.25 per share on FedEx Corporation common stock. The dividend is payable April 1, 2016 to stockholders of record at the close of business on March 14, 2016.
Crown Castle International (CCI) has declared a quarterly cash dividend of $0.885 per common share. The quarterly dividend will be payable on March 31, 2016 to common stockholders of record at the close of business on March 18, 2016.
Kellogg Company (K) declared a dividend of $0.50 per share on the common stock of the Company. The dividend is payable on March 15, 2016, to shareowners of record at the close of business on March 1, 2016. The ex-dividend date is February 26, 2016.
VIDEO: Daily Dividend Report: ANTM, EQIX, MDT, ABT, FDX, CCI, K
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) declared a quarterly common dividend of 26 cents per share. VIDEO: Daily Dividend Report: ANTM, EQIX, MDT, ABT, FDX, CCI, K The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The cash dividend is payable May 16, 2016, to shareholders of record at the close of business on April 15, 2016. | VIDEO: Daily Dividend Report: ANTM, EQIX, MDT, ABT, FDX, CCI, K The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 26 cents per share. Equinix ( EQIX ) has declared a quarterly cash dividend of $1.75 per share on common stock, a 3.6% increase over its prior cash dividend per share. | Abbott ( ABT ) declared a quarterly common dividend of 26 cents per share. VIDEO: Daily Dividend Report: ANTM, EQIX, MDT, ABT, FDX, CCI, K The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The first quarter dividend is payable on March 25, 2016, to shareholders of record at the close of business on March 10, 2016. | Abbott ( ABT ) declared a quarterly common dividend of 26 cents per share. VIDEO: Daily Dividend Report: ANTM, EQIX, MDT, ABT, FDX, CCI, K The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Anthem ( ANTM ) authorized an increase of 4 percent in the Company's shareholder dividend and declared a $0.65 per share dividend for the first quarter of 2016. |
33945.0 | 2016-02-16 00:00:00 UTC | Zoetis Tops Q4 Earnings and Revenues, Updates Guidance | ABT | https://www.nasdaq.com/articles/zoetis-tops-q4-earnings-and-revenues-updates-guidance-2016-02-16 | nan | nan | Zoetis ' ZTS fourth-quarter 2015 adjusted earnings of 43 cents per share came ahead of the Zacks Consensus Estimate of 39 cents. Earnings were also above the year-ago figure by 3 cents.
On the other hand, revenues declined 3.5% year over year to $1.274 billion in the fourth quarter of 2015. Foreign currency movements impacted revenues negatively by approximately 9%. Reported revenues were, however, slightly ahead of the Zacks Consensus Estimate of $1.256 billion.
Full-year earnings were down 41% to 68 cents per share, while revenues were flat at $4.765 billion.
Quarterly Details
Zoetis boasts a robust and diversified product portfolio. The company markets its offerings primarily across the following species: cattle, swine, poultry and others (livestock), and dogs, cats and horses (companion animals). In the fourth quarter of 2015, sales of livestock products accounted for 63% of the total revenue. Approximately 35.9% of revenues in the quarter came from the sale of companion animal products, while the remaining came from contract manufacturing.
Geographically, the company has consolidated its four-region structure to a two-region structure comprising the U.S. and International.
Sales improved 8% in the U.S. to $636 million driven by strong sales of companion animal products. The addition of Abbott Laboratories' ABT Animal Health business and increased availability of Apoquel also boosted revenues. Sales at the International segment were, however, down 13% to $624 million (up 3% operationally).
In the fourth quarter, the company acquired PHARMAQ for $765 million on a debt-free basis. The addition of PHARMAQ has strengthened Zoetis' core livestock business.
Outlook
Zoetis updated its guidance to reflect impact of the European Commission's tax rulings in Belgium, foreign exchange rates as of late January, and changes related to the company's accounting for its operations in Venezuela. For 2016, earnings are expected to be in the range of $1.71 to $1.81 per share.
The Zacks Consensus Estimate of $1.82 is slightly above the guidance range. The company expects revenues to be between $4.65 billion and $4.775 billion. The Zacks Consensus Estimate is pegged higher at $4.833 billion.
The company also updated its outlook for 2017. In 2017, earnings are expected to be in the range of $2.18 to $2.32 per share on revenues of $4.95 billion to $5.15 billion.
Our Take
We are impressed with the company beating on earnings and revenues. However, the negative impact of foreign exchange rates continues to hurt revenues. Nevertheless, we are positive on the company's PHARMAQ acquisition. We expect to see more of such acquisitions/deals at the company in the near future, as it continues to focus on its strategy of acquiring complementary businesses and products.
Zoetis carries a Zack Rank #4 (Sell). Some better-ranked stocks in the health care sector include Gilead Sciences Inc. GILD and Celgene Corp. CELG , both sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ZOETIS INC (ZTS): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The addition of Abbott Laboratories' ABT Animal Health business and increased availability of Apoquel also boosted revenues. Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. The company markets its offerings primarily across the following species: cattle, swine, poultry and others (livestock), and dogs, cats and horses (companion animals). | Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. The addition of Abbott Laboratories' ABT Animal Health business and increased availability of Apoquel also boosted revenues. Zoetis ' ZTS fourth-quarter 2015 adjusted earnings of 43 cents per share came ahead of the Zacks Consensus Estimate of 39 cents. | Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. The addition of Abbott Laboratories' ABT Animal Health business and increased availability of Apoquel also boosted revenues. The company expects revenues to be between $4.65 billion and $4.775 billion. | The addition of Abbott Laboratories' ABT Animal Health business and increased availability of Apoquel also boosted revenues. Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. In the fourth quarter of 2015, sales of livestock products accounted for 63% of the total revenue. |
33946.0 | 2016-02-11 00:00:00 UTC | Mylan Q4 Earnings and Revenues Lag, Set To Acquire Meda | ABT | https://www.nasdaq.com/articles/mylan-q4-earnings-and-revenues-lag-set-to-acquire-meda-2016-02-11 | nan | nan | Mylan 's MYL fourth-quarter 2015 earnings (excluding special items) of $1.22 per share missed the Zacks Consensus Estimate of $1.25. However, reported earnings surged 16% from the year-ago quarter, driven by higher revenues.
Mylan Inc. (MYL) Street EPS & Surprise Percent - Last 5 Quarters | FindTheCompany
Revenues also grew 19.6% to $2.5 billion, but fell short of the Zacks Consensus Estimate of $2.7 billion. The top line recorded year-over-year growth on the back of solid revenue growth at the Generics segment.
Full-year earnings were up 21% to $4.30 per share, while revenues came in at $9.4 billion, up 22%.
Quarter in Details
Generics third-party net sales, derived from sales in North America, Europe and rest of the world, soared 22% to $2.22 billion. Segmental third-party net sales grew 3% to $1.03 billion in North America. New product launches and acquisitions aided revenues.
Third-party net sales from the European market increased 65% to $616.4 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations, lower volumes on existing products and lower pricing. Third-party net sales from rest of the world escalated 29% to $570.5 million. Segmental performance improved on the back of acquisitions, new product launches in Australia and Japan, and increased sales of antiretroviral products.
Third-party net sales at the Specialty segment were up 5% to $254.1 million. Specialty segment sales benefited from higher volumes for its flagship product, EpiPen Auto-Injector, for severe allergic reactions.
Adjusted gross margin during the fourth quarter of 2015 expanded to 56% from 54% in the year-ago quarter on the back of new product introductions and net sales from acquisitions.
2016 Outlook
Mylan provided its 2016 guidance. The company expects adjusted earnings per share in range of $4.85 to $5.15, the midpoint of which represents a 16% increase. Total revenue is expected in the range of $10.5 billion to $11.5 billion, with or without Meda, the midpoint of which again represents 16% growth. The Zacks Consensus Estimate for 2016 earnings is $4.98 on revenues of $10.8 billion.
The Proposed Meda Acquisition
Meanwhile, Mylan has proposed to buy a leading international specialty pharmaceutical company, Meda, via a recommended public offer. The total offer consideration consists of a combination of cash and Mylan shares, with a value at announcement of SEK 165 per Meda share. The transaction is valued at $9.9 billion. It is expected to be complete by the end of the third quarter of 2016.
The combination of Meda and Mylan will create a global pharmaceutical leader with combined revenues of $11.8 billion as per 2015 figures. The combined company will boast of a portfolio of more than 2,000 products and critical mass across all commercial channels, including an OTC business worth more than $1 billion. The Meda acquisition will also expand Mylan's global footprint and strengthen its presence across Europe and emerging markets including China, Southeast Asia, Russia, the Middle East and Mexico.
Moreover, Mylan expects to generate synergies of approximately $1.1 billion in EBITDA. The transaction is expected to be accretive immediately and will contribute in the range of 35-40 cents per share to 2017 earnings. Thus, the transaction could accelerate the achievement of Mylan's previously stated $6.00 adjusted earnings target to as early as 2017 instead of the previous projection of 2018.
Our Take
Mylan's fourth-quarter results were disappointing, with the company missing both earnings and revenue estimates. Consequently, shares of the company dropped 9.1% in the afterhours trading session. Although we were encouraged by strong sales at the Generics segment, the performance of the company's Specialty segment remain a cause of concern. Moreover, the company is facing competitive market conditions for EpiPen Auto-Injector and has lowered the average net selling price.
We note that Mylan's offer to acquire Meda comes closely on the heels of its failed attempts to acquire Perrigo Company PRGO . Further, during its fourth-quarter results conference call, the company hinted at its intention of pursuing more acquisitions in the near-term.
Mylan sports a Zacks Rank #1 (Strong Buy). Anika Therapeutics Inc. ANIK is a well-ranked stock in the health care sector, with the same Zacks Rank as Mylan.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
PERRIGO CO PLC (PRGO): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
MYLAN NV (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Third-party net sales from the European market increased 65% to $616.4 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations, lower volumes on existing products and lower pricing. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Specialty segment sales benefited from higher volumes for its flagship product, EpiPen Auto-Injector, for severe allergic reactions. | Third-party net sales from the European market increased 65% to $616.4 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations, lower volumes on existing products and lower pricing. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. The Proposed Meda Acquisition Meanwhile, Mylan has proposed to buy a leading international specialty pharmaceutical company, Meda, via a recommended public offer. | Third-party net sales from the European market increased 65% to $616.4 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations, lower volumes on existing products and lower pricing. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan Inc. (MYL) Street EPS & Surprise Percent - Last 5 Quarters | FindTheCompany Revenues also grew 19.6% to $2.5 billion, but fell short of the Zacks Consensus Estimate of $2.7 billion. | Third-party net sales from the European market increased 65% to $616.4 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations, lower volumes on existing products and lower pricing. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Full-year earnings were up 21% to $4.30 per share, while revenues came in at $9.4 billion, up 22%. |
33947.0 | 2016-02-11 00:00:00 UTC | Why Earnings Sent Mylan N.V. Shares Tumbling 18% Today | ABT | https://www.nasdaq.com/articles/why-earnings-sent-mylan-nv-shares-tumbling-18-today-2016-02-11 | nan | nan | Image source: Mylan N.V.
What: After reporting 2015 revenue and earnings and an acquisition yesterday, shares in Mylan N.V. fell 18.05% at 4:00 p.m. ET today.
So what: The generic drugmaker reported that its ex-currency sales grew 28% to $9.45 billion last year and that its full-year diluted earnings per share advanced 21% to $4.30. The company's EPS came in at the high end of previously issued guidance.
The biggest impact on the company's top line last year came from the generics drug segment. After adjusting for the effects of currency conversion, sales in that division grew 33% to $8.17 billion. Results benefited from both new generic drug launches and the positive impact of Mylan's recent acquisition of Abbott Laboratories ' non-U.S. developed markets generic business. That business added $145 million in North America, $947 million in Europe, and $375 million in rest of world sales during 2015.
Full-year sales in its specialty drug segment were essentially flat, rising 1% to $1.2 billion as demand for the company's EpiPen remained strong.
Those results were solid, but investors were disappointed by its fourth-quarter performance. In the quarter, sales of $2.5 billion and EPS of $1.22 both fell shy of industry watchers' targets.
Now what : Mylan issued guidance for 2016 that includes revenue of be | So what: The generic drugmaker reported that its ex-currency sales grew 28% to $9.45 billion last year and that its full-year diluted earnings per share advanced 21% to $4.30. Full-year sales in its specialty drug segment were essentially flat, rising 1% to $1.2 billion as demand for the company's EpiPen remained strong. In the quarter, sales of $2.5 billion and EPS of $1.22 both fell shy of industry watchers' targets. | Image source: Mylan N.V. What: After reporting 2015 revenue and earnings and an acquisition yesterday, shares in Mylan N.V. fell 18.05% at 4:00 p.m. So what: The generic drugmaker reported that its ex-currency sales grew 28% to $9.45 billion last year and that its full-year diluted earnings per share advanced 21% to $4.30. The biggest impact on the company's top line last year came from the generics drug segment. | So what: The generic drugmaker reported that its ex-currency sales grew 28% to $9.45 billion last year and that its full-year diluted earnings per share advanced 21% to $4.30. Results benefited from both new generic drug launches and the positive impact of Mylan's recent acquisition of Abbott Laboratories ' non-U.S. developed markets generic business. Full-year sales in its specialty drug segment were essentially flat, rising 1% to $1.2 billion as demand for the company's EpiPen remained strong. | Image source: Mylan N.V. What: After reporting 2015 revenue and earnings and an acquisition yesterday, shares in Mylan N.V. fell 18.05% at 4:00 p.m. So what: The generic drugmaker reported that its ex-currency sales grew 28% to $9.45 billion last year and that its full-year diluted earnings per share advanced 21% to $4.30. The company's EPS came in at the high end of previously issued guidance. |
33948.0 | 2016-02-10 00:00:00 UTC | New Strong Sell Stocks for February 10th | ABT | https://www.nasdaq.com/articles/new-strong-sell-stocks-for-february-10th-2016-02-10 | nan | nan | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Abbott Laboratories ( ABT )
Adeptus Health Inc ( ADPT )
Bancorp Inc ( TBBK )
Bank of Commerce Holdings ( BOCH )
Brookdale Senior Living, Inc. ( BKD )
View the entire Zacks Rank #5 List .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ADEPTUS HEALTH (ADPT): Free Stock Analysis Report
BANCORP BNK/THE (TBBK): Free Stock Analysis Report
BANK OF COMMRC (BOCH): Free Stock Analysis Report
BROOKDALE SENR (BKD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Adeptus Health Inc ( ADPT ) Bancorp Inc ( TBBK ) Bank of Commerce Holdings ( BOCH ) Brookdale Senior Living, Inc. ( BKD ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADEPTUS HEALTH (ADPT): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report BROOKDALE SENR (BKD): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Adeptus Health Inc ( ADPT ) Bancorp Inc ( TBBK ) Bank of Commerce Holdings ( BOCH ) Brookdale Senior Living, Inc. ( BKD ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADEPTUS HEALTH (ADPT): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report BROOKDALE SENR (BKD): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Adeptus Health Inc ( ADPT ) Bancorp Inc ( TBBK ) Bank of Commerce Holdings ( BOCH ) Brookdale Senior Living, Inc. ( BKD ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADEPTUS HEALTH (ADPT): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report BROOKDALE SENR (BKD): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Adeptus Health Inc ( ADPT ) Bancorp Inc ( TBBK ) Bank of Commerce Holdings ( BOCH ) Brookdale Senior Living, Inc. ( BKD ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADEPTUS HEALTH (ADPT): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report BROOKDALE SENR (BKD): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? |
33949.0 | 2016-02-08 00:00:00 UTC | Vanguard Dividend Appreciation ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/vanguard-dividend-appreciation-etf-experiences-big-inflow-2016-02-08 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $245.9 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 247,134,771 to 250,435,232). Among the largest underlying components of VIG, in trading today Microsoft Corporation (Symbol: MSFT) is down about 3%, Abbott Laboratories (Symbol: ABT) is down about 1.5%, and Monsanto Co. (Symbol: MON) is lower by about 1.8%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.36. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » . Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Microsoft Corporation (Symbol: MSFT) is down about 3%, Abbott Laboratories (Symbol: ABT) is down about 1.5%, and Monsanto Co. (Symbol: MON) is lower by about 1.8%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.36. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Microsoft Corporation (Symbol: MSFT) is down about 3%, Abbott Laboratories (Symbol: ABT) is down about 1.5%, and Monsanto Co. (Symbol: MON) is lower by about 1.8%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.36. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Microsoft Corporation (Symbol: MSFT) is down about 3%, Abbott Laboratories (Symbol: ABT) is down about 1.5%, and Monsanto Co. (Symbol: MON) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $245.9 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 247,134,771 to 250,435,232). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.36. | Among the largest underlying components of VIG, in trading today Microsoft Corporation (Symbol: MSFT) is down about 3%, Abbott Laboratories (Symbol: ABT) is down about 1.5%, and Monsanto Co. (Symbol: MON) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $245.9 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 247,134,771 to 250,435,232). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.36. |
33950.0 | 2016-02-08 00:00:00 UTC | Extra Space Storage, Abbott Laboratories, First Data, ServiceMaster Global Holdings and ABM Industries highlighted as Zacks Bull and Bear of the Day | ABT | https://www.nasdaq.com/articles/extra-space-storage-abbott-laboratories-first-data-servicemaster-global-holdings-and-abm | nan | nan | For Immediate Release
Chicago, IL - February 08, 2016- Zacks Equity Research highlights Extra Space Storage ( EXR ) as the Bull of the Day and Abbott Laboratories ( ABT ) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on First Data Corporation ( FDC ), ServiceMaster Global Holdings, Inc. ( SERV ) and ABM Industries Inc. ( ABM ).
Here is a synopsis of all five stocks:
Bull of the Day :
It has been a very rocky time for the stock market which is putting extra focus on companies in safer sectors. One area that is gaining renewed traction is the REIT market as this space benefits in a lower interest rate environment and it pays out solid yields too.
While there are many options here, one to put on your radar right now is Extra Space Storage ( EXR ) . The company pays out a nice yield, has a great growth rate, and best of all, EXR has a great track record. Just take a look at the recent performance of EXR compared to the market:
But that isn't the only reason to like EXR these days, as the company still has plenty of potential going forward. In fact, if we look to recent earnings estimate revisions, there is definitely hope that EXR can keep up its outperforming ways in the months ahead.
Recent Estimates
The most recent earnings estimate revisions for EXR stock have been extremely positive, as we haven't seen an analyst ratchet down their expectations for either the current year or current quarter projections in the past sixty days.
The consensus estimate is moving higher too, as the current quarter has gone from $0.81/share 90 days ago to $0.87/share today. We have seen a similar trend for the full year time frame, pushing EXR up to an expected EPS growth rate of just under 20%.
And if that wasn't enough, EXR also has a great history at earnings season, including four straight beats. The company is clearly well-positioned for a beat at its earnings report later this month, and it could be a good candidate for a modest positive EPS surprise. No wonder EXR has earned itself a Zacks Rank #1 (Strong Buy), putting it into the top 5% of all companies that we follow.
Bottom Line
The market has been rough lately so it might be an excellent idea to go with a proven winner in a strong industry. EXR is just that thanks to its history of outperformance, beats in earnings season, and its nice dividend too.
So if you are looking for a stock to get you through this uncertain time in the market, it may be time to give Extra Space Storage a closer inspection for your portfolio.
Bear of the Day :
Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . Shares of this Illinois-based giant have fallen more than 15% this year, more than doubling the loss that the S&P 500 has seen so far in 2016.
While much of these losses are a result of the overall poor trading environment to start the year, a big percentage of the slump can also be blamed on Abbott's most recent earnings report. In this release, Abbott managed to beat estimates by a penny, but struggled on the revenue front and gave weak guidance too. Thanks to this, analysts tracking ABT have been racing to slash their earnings estimates for Abbott stock, suggesting that the pain for ABT investors isn't over by a long shot.
Recent Estimates
There has been total agreement among ABT analysts regarding the company's near term outlook as seven analysts have pushed estimates lower for the current quarter in the last seven days compared to zero higher, while we have seen an 11:0 ratio for the current year in the same time frame too.
These estimate cuts haven't just been one or two cents lower either, as we have seen some big changes in the consensus estimate over the past month. The current quarter is down to a 39 cent consensus profit, down from 50 cents a few weeks ago, while the current year has fallen about 24 cents down to $2.15/share in EPS.
Now, EPS is expected to contract more than 17% this quarter when compared to the year ago period, while the full year growth is expected to come in at 0.0% when compared to the previous year. No wonder ABT is now a Zacks Rank #5 (strong sell) stock that is currently ranked in the bottom 5% of our overall universe of securities.
Additional content:
3 Business Services Stocks to Bet on Amid Q4 Earnings Conundrum
The U.S. economy had an unenterprising end to 2015 as the GDP increased at a paltry 0.7% annualized rate in the fourth quarter, bringing its tally for the year to 2.4% - identical to that recorded in 2014. Although the Fed took off its brakes for the first raise in interest rates in nearly a decade in December, on perceived improvement in the economy, the short-term jitters are likely to prevent it from raising it further anytime soon.
On the surface, it appears that the economy failed to receive any 'slingshot' momentum from strong third-quarter growth, primarily due to the fallout of the growing global malaise on domestic activity. Strong dollar appreciation and the prevailing macroeconomic turmoil, led by the unprecedentedly-weak Chinese growth and a soft European market, continue to adversely affect exports and corporate investment levels.
Solid appreciation of the dollar has dented the export basket, as the U.S. goods and services have been rendered expensive upon foreign soil. The trade deficit widened to $566.5 billion and has reportedly subtracted 0.47 percentage point from the GDP growth in the fourth quarter. Lower oil prices have further added to the woes of the industries that directly or indirectly source businesses from the energy sector.
The Negative Feelers
Non-defense capital goods orders (excluding aircraft), one of the closely watched parameters for business spending plans, contracted 4.3% in December - the largest decline of this kind since November 2009. Business spending on equipment contracted 2.5% in the fourth quarter compared to a 9.9% rise in the third quarter.
With low demand for U.S.-manufactured items, businesses accumulated $68.6 billion worth of inventory in the fourth quarter, shaving 0.45 percentage point from the fourth-quarter GDP growth. Weighed down by higher levels of inventory, overall business investment declined at an annualized rate of 1.8%, the first drop since the third quarter of 2012.
The Markit Composite Purchasing Managers Index (PMI) data declined to 53.2 in January from 54.0 in December. This represents a general slowdown in new business growth and a cautious spending pattern by clients.
The Positive Vibes
When the overall business sentiments are somewhat reeling under the bearish market stance, American households have plenty to rejoice. Buoyed by an average of 284,000 job additions in the fourth quarter, the unemployment rate stood at 5% by the end of 2015 and is expected to fall further.
Enjoying the fruits of a resurgent job market, low inflationary pressures and cheaper oil bills, consumer confidence levels went up. The Conference Board Consumer Confidence Index improved moderately in January to 98.1 from 96.3 in December. Consumer spending, which accounts for over two-thirds of U.S. economy, increased 2.2% during the fourth quarter.
As the companies take stock of the situation and deliberate on their future course of action, let us take a glimpse into how the fourth-quarter earnings season is shaping up so far.
Business Services Sector Performance
About 47.8% of the total S&P 500 companies in the Business Services sector have reported their earnings results till Feb 3, 2016. With a 'beat ratio' of 72.7%, total earnings for these companies are up 4.1% year over year. Revenues increased 2.5% compared with the year-ago period, with a 'beat ratio' of 27.3%. The entire Business Services sector is expected to perform relatively better than the overall equity market with an earnings growth expectation of 3.4% in the fourth quarter versus -5.8% for the S&P 500 index. (Read: Q4 Earnings Season Past the Halfway Mark )
The primary growth drivers in this highly fragmented industry hinge on a healthy economy with decent prospects for job growth, higher disposable income and new business initiatives. An ideal mix of services, effective marketing strategies and ability to retain and attract new customers make the perfect recipe for profitability for most of these companies.
Given the forecast, it might be a good idea to zero-in on a handful of Business Services stocks that are poised to beat earnings estimates this quarter. An earnings surprise should help these stocks outperform in the near term.
How to Pick?
The Business Services sector covers an array of services that include marketing, consulting, staffing, security, telecommunications, Internet services, logistics and waste handling. Amid a diverse range of companies in the Business Services arena, picking the right stock for your portfolio could appear to be a colossal task. An easy way to narrow down the list is to look at stocks that have a solid Zacks Rank and a favorable Earnings ESP .
Earnings ESP is our proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate.
The combination of a Zacks Rank #1 (Strong Buy) or #2 (Buy) or #3 (Hold) and a positive Earnings ESP is usually a harbinger of an earnings beat and serves a perfect success formula on a platter. For investors seeking to benefit by applying this strategy to their portfolios, we have mentioned three Business Services stocks below, which match these criteria, and thus may be potential winners this earnings season.
First Data Corporation ( FDC ): Founded in 1989 and headquartered in Atlanta, GA, First Data offers electronic commerce and payment solutions across the globe. The company serves approximately six million business locations and 4,000 financial institutions in 118 countries around the world.
The company has a long-term earnings growth expectation of 18.6%. First Data currently carries a Zacks Rank #1 along with an Earnings ESP of +5.26%. The company is expected to report its fourth-quarter 2015 results after the closing bell on Feb 9.
ServiceMaster Global Holdings, Inc. ( SERV ): Headquartered in Memphis, TN, ServiceMaster is a premier business services provider of essential residential and commercial services. The company operates through an extensive service network of more than 8,000 company-owned, franchised and licensed locations.
This Zacks Rank #2 stock has a long-term earnings growth expectation of 11.0%, forward PE of 20.0x and an Earnings ESP of +3.23%. The company is scheduled to report its fourth-quarter 2015 results before the opening bell on Feb 25.
ABM Industries Inc. ( ABM ): Headquartered in New York, NY, ABM is one of the largest facility management services providers in the U.S. The company provides engineering, janitorial, parking, and security services to commercial, industrial, institutional, and retail facilities across the country.
The company has a long-term earnings growth expectation of 8.0% and a forward PE of 20.0x. ABM currently carries a Zacks Rank #3 along with an Earnings ESP of +38.46%. The company is expected to report its first-quarter fiscal 2016 results on Mar 1.
Moving Forward
Gus Faucher, senior economist at PNC Financial Services in Pittsburgh, observed: "Together with rising wages, more hiring will allow consumers to continue to spend, and that will be more than enough to power through weakness from trade and the stronger dollar." As the U.S. stocks appear volatile with a topsy-turvy economy, a sneak peek to the space for some possible outperformers backed by a solid Zacks Rank and a positive Zacks Earnings ESP could be a great idea for investors to gain from this earnings season.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EXTRA SPACE STG (EXR): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
FIRST DATA CORP (FDC): Free Stock Analysis Report
SERVICEMASTR GH (SERV): Free Stock Analysis Report
ABM INDUSTRIES (ABM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For Immediate Release Chicago, IL - February 08, 2016- Zacks Equity Research highlights Extra Space Storage ( EXR ) as the Bull of the Day and Abbott Laboratories ( ABT ) as the Bear of the Day. Bear of the Day : Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . Thanks to this, analysts tracking ABT have been racing to slash their earnings estimates for Abbott stock, suggesting that the pain for ABT investors isn't over by a long shot. | For Immediate Release Chicago, IL - February 08, 2016- Zacks Equity Research highlights Extra Space Storage ( EXR ) as the Bull of the Day and Abbott Laboratories ( ABT ) as the Bear of the Day. Click to get this free report EXTRA SPACE STG (EXR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report FIRST DATA CORP (FDC): Free Stock Analysis Report SERVICEMASTR GH (SERV): Free Stock Analysis Report ABM INDUSTRIES (ABM): Free Stock Analysis Report To read this article on Zacks.com click here. Bear of the Day : Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . | Click to get this free report EXTRA SPACE STG (EXR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report FIRST DATA CORP (FDC): Free Stock Analysis Report SERVICEMASTR GH (SERV): Free Stock Analysis Report ABM INDUSTRIES (ABM): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - February 08, 2016- Zacks Equity Research highlights Extra Space Storage ( EXR ) as the Bull of the Day and Abbott Laboratories ( ABT ) as the Bear of the Day. Bear of the Day : Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . | For Immediate Release Chicago, IL - February 08, 2016- Zacks Equity Research highlights Extra Space Storage ( EXR ) as the Bull of the Day and Abbott Laboratories ( ABT ) as the Bear of the Day. Bear of the Day : Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . Thanks to this, analysts tracking ABT have been racing to slash their earnings estimates for Abbott stock, suggesting that the pain for ABT investors isn't over by a long shot. |
33951.0 | 2016-02-08 00:00:00 UTC | Bear of the Day: Abbott Labs (ABT) | ABT | https://www.nasdaq.com/articles/bear-day-abbott-labs-abt-2016-02-08 | nan | nan | Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . Shares of this Illinois-based giant have fallen more than 15% this year, more than doubling the loss that the S&P 500 has seen so far in 2016.
While much of these losses are a result of the overall poor trading environment to start the year, a big percentage of the slump can also be blamed on Abbott's most recent earnings report. In this release, Abbott managed to beat estimates by a penny, but struggled on the revenue front and gave weak guidance too. Thanks to this, analysts tracking ABT have been racing to slash their earnings estimates for Abbott stock, suggesting that the pain for ABT investors isn't over by a long shot.
Recent Estimates
There has been total agreement among ABT analysts regarding the company's near term outlook as seven analysts have pushed estimates lower for the current quarter in the last seven days compared to zero higher, while we have seen an 11:0 ratio for the current year in the same time frame too.
These estimate cuts haven't just been one or two cents lower either, as we have seen some big changes in the consensus estimate over the past month. The current quarter is down to a 39 cent consensus profit, down from 50 cents a few weeks ago, while the current year has fallen about 24 cents down to $2.15/share in EPS.
Now, EPS is expected to contract more than 17% this quarter when compared to the year ago period, while the full year growth is expected to come in at 0.0% when compared to the previous year. No wonder ABT is now a Zacks Rank #5 (strong sell) stock that is currently ranked in the bottom 5% of our overall universe of securities.
Other Picks
Clearly, investors should avoid ABT right now, but where are the better plays in the health care world? Well one area that might be worth looking at these days is the hospital space, and in particular, Acadia Health ( ACHC ).
Not only is this stock in a top 10% industry, but it has a Zacks Rank #1 (Strong Buy) rating and it is looking for EPS growth north of 23%. So, if you are seeking a great pick in the medical world, make sure to take a look at ACHC instead of the struggling Abbott Labs right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA HEALTHCR (ACHC): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . Thanks to this, analysts tracking ABT have been racing to slash their earnings estimates for Abbott stock, suggesting that the pain for ABT investors isn't over by a long shot. Recent Estimates There has been total agreement among ABT analysts regarding the company's near term outlook as seven analysts have pushed estimates lower for the current quarter in the last seven days compared to zero higher, while we have seen an 11:0 ratio for the current year in the same time frame too. | Click to get this free report ACADIA HEALTHCR (ACHC): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . Thanks to this, analysts tracking ABT have been racing to slash their earnings estimates for Abbott stock, suggesting that the pain for ABT investors isn't over by a long shot. | Thanks to this, analysts tracking ABT have been racing to slash their earnings estimates for Abbott stock, suggesting that the pain for ABT investors isn't over by a long shot. Recent Estimates There has been total agreement among ABT analysts regarding the company's near term outlook as seven analysts have pushed estimates lower for the current quarter in the last seven days compared to zero higher, while we have seen an 11:0 ratio for the current year in the same time frame too. Click to get this free report ACADIA HEALTHCR (ACHC): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. | Other Picks Clearly, investors should avoid ABT right now, but where are the better plays in the health care world? Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . Thanks to this, analysts tracking ABT have been racing to slash their earnings estimates for Abbott stock, suggesting that the pain for ABT investors isn't over by a long shot. |
33952.0 | 2016-02-04 00:00:00 UTC | New Strong Sell Stocks for February 4th | ABT | https://www.nasdaq.com/articles/new-strong-sell-stocks-for-february-4th-2016-02-04 | nan | nan | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today:
Abbott Laboratories ( ABT )
AGCO Corporation ( AGCO )
Andersons Inc ( ANDE )
Archer Daniels Midland Company ( ADM )
Bancorp Inc ( TBBK )
View the entire Zacks Rank #5 List .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ADVISORY BOARD (ABCO): Free Stock Analysis Report
ANDERSONS INC (ANDE): Free Stock Analysis Report
ARCHER DANIELS (ADM): Free Stock Analysis Report
BANCORP BNK/THE (TBBK): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott Laboratories ( ABT ) AGCO Corporation ( AGCO ) Andersons Inc ( ANDE ) Archer Daniels Midland Company ( ADM ) Bancorp Inc ( TBBK ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADVISORY BOARD (ABCO): Free Stock Analysis Report ANDERSONS INC (ANDE): Free Stock Analysis Report ARCHER DANIELS (ADM): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott Laboratories ( ABT ) AGCO Corporation ( AGCO ) Andersons Inc ( ANDE ) Archer Daniels Midland Company ( ADM ) Bancorp Inc ( TBBK ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADVISORY BOARD (ABCO): Free Stock Analysis Report ANDERSONS INC (ANDE): Free Stock Analysis Report ARCHER DANIELS (ADM): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott Laboratories ( ABT ) AGCO Corporation ( AGCO ) Andersons Inc ( ANDE ) Archer Daniels Midland Company ( ADM ) Bancorp Inc ( TBBK ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADVISORY BOARD (ABCO): Free Stock Analysis Report ANDERSONS INC (ANDE): Free Stock Analysis Report ARCHER DANIELS (ADM): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott Laboratories ( ABT ) AGCO Corporation ( AGCO ) Andersons Inc ( ANDE ) Archer Daniels Midland Company ( ADM ) Bancorp Inc ( TBBK ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADVISORY BOARD (ABCO): Free Stock Analysis Report ANDERSONS INC (ANDE): Free Stock Analysis Report ARCHER DANIELS (ADM): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? |
33953.0 | 2016-02-02 00:00:00 UTC | Company News for February 02, 2016 | ABT | https://www.nasdaq.com/articles/company-news-for-february-02-2016-2016-02-02 | nan | nan | • Alere Inc.'s ( ALR ) shares surged 45.5% after Abbott Laboratories ( ABT ) agreed to buy the company for around $5.8 billion
• Shares of Questar Corporation ( STR ) skyrocketed 22.6% following news that Dominion Resources, Inc. ( D ) will acquire the company in a all cash deal of nearly $4.4 billion
• Twitter, Inc.'s ( TWTR ) shares jumped 6.6% on news that Silver Lake Partners and investor Marc Andreessen may offer to acquire the company
• Shares of Roper Technologies, Inc. ( ROP ) plunged 6.8% after reporting fourth quarter adjusted earnings of $1.82 per share, missing the Zacks Consensus Estimate of $1.86
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ALERE INC (ALR): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
QUESTAR (STR): Free Stock Analysis Report
DOMINION RES VA (D): Free Stock Analysis Report
TWITTER INC (TWTR): Free Stock Analysis Report
ROPER INDS INC (ROP): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Alere Inc.'s ( ALR ) shares surged 45.5% after Abbott Laboratories ( ABT ) agreed to buy the company for around $5.8 billion • Shares of Questar Corporation ( STR ) skyrocketed 22.6% following news that Dominion Resources, Inc. ( D ) will acquire the company in a all cash deal of nearly $4.4 billion • Twitter, Inc.'s ( TWTR ) shares jumped 6.6% on news that Silver Lake Partners and investor Marc Andreessen may offer to acquire the company • Shares of Roper Technologies, Inc. ( ROP ) plunged 6.8% after reporting fourth quarter adjusted earnings of $1.82 per share, missing the Zacks Consensus Estimate of $1.86 Want the latest recommendations from Zacks Investment Research? Click to get this free report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report QUESTAR (STR): Free Stock Analysis Report DOMINION RES VA (D): Free Stock Analysis Report TWITTER INC (TWTR): Free Stock Analysis Report ROPER INDS INC (ROP): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. | • Alere Inc.'s ( ALR ) shares surged 45.5% after Abbott Laboratories ( ABT ) agreed to buy the company for around $5.8 billion • Shares of Questar Corporation ( STR ) skyrocketed 22.6% following news that Dominion Resources, Inc. ( D ) will acquire the company in a all cash deal of nearly $4.4 billion • Twitter, Inc.'s ( TWTR ) shares jumped 6.6% on news that Silver Lake Partners and investor Marc Andreessen may offer to acquire the company • Shares of Roper Technologies, Inc. ( ROP ) plunged 6.8% after reporting fourth quarter adjusted earnings of $1.82 per share, missing the Zacks Consensus Estimate of $1.86 Want the latest recommendations from Zacks Investment Research? Click to get this free report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report QUESTAR (STR): Free Stock Analysis Report DOMINION RES VA (D): Free Stock Analysis Report TWITTER INC (TWTR): Free Stock Analysis Report ROPER INDS INC (ROP): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report QUESTAR (STR): Free Stock Analysis Report DOMINION RES VA (D): Free Stock Analysis Report TWITTER INC (TWTR): Free Stock Analysis Report ROPER INDS INC (ROP): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. • Alere Inc.'s ( ALR ) shares surged 45.5% after Abbott Laboratories ( ABT ) agreed to buy the company for around $5.8 billion • Shares of Questar Corporation ( STR ) skyrocketed 22.6% following news that Dominion Resources, Inc. ( D ) will acquire the company in a all cash deal of nearly $4.4 billion • Twitter, Inc.'s ( TWTR ) shares jumped 6.6% on news that Silver Lake Partners and investor Marc Andreessen may offer to acquire the company • Shares of Roper Technologies, Inc. ( ROP ) plunged 6.8% after reporting fourth quarter adjusted earnings of $1.82 per share, missing the Zacks Consensus Estimate of $1.86 Want the latest recommendations from Zacks Investment Research? | • Alere Inc.'s ( ALR ) shares surged 45.5% after Abbott Laboratories ( ABT ) agreed to buy the company for around $5.8 billion • Shares of Questar Corporation ( STR ) skyrocketed 22.6% following news that Dominion Resources, Inc. ( D ) will acquire the company in a all cash deal of nearly $4.4 billion • Twitter, Inc.'s ( TWTR ) shares jumped 6.6% on news that Silver Lake Partners and investor Marc Andreessen may offer to acquire the company • Shares of Roper Technologies, Inc. ( ROP ) plunged 6.8% after reporting fourth quarter adjusted earnings of $1.82 per share, missing the Zacks Consensus Estimate of $1.86 Want the latest recommendations from Zacks Investment Research? Click to get this free report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report QUESTAR (STR): Free Stock Analysis Report DOMINION RES VA (D): Free Stock Analysis Report TWITTER INC (TWTR): Free Stock Analysis Report ROPER INDS INC (ROP): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
33954.0 | 2016-02-02 00:00:00 UTC | Abbott Labs to Boost Diagnostics Business with Alere Buyout | ABT | https://www.nasdaq.com/articles/abbott-labs-to-boost-diagnostics-business-with-alere-buyout-2016-02-02 | nan | nan | In a bid to strengthen its presence and leadership in the global diagnostics market, Abbott LaboratoriesABT announced a definitive agreement to acquire Alere ALR .
Financial Terms of the Agreement
Per the terms of the agreement, Alere shareholders will receive $56 per common share in cash upon the completion of the transaction. The total value of the transaction is $5.8 billion. Also, Abbott Labs will assume/refinance Alere's net debt of $2.6 billion.
The acquisition is expected to be immediately accretive to Abbott Labs' bottom line, and add approximately 12-13 cents per share in 2017 and more than 20 cents per share in 2018. The company also expects annual pre-tax synergies of roughly $500 million by 2019, which is projected to increase thereafter.
Our Take
The acquisition should bolster Abbott Labs' diagnostics business, which generated sales of $4.6 billion in 2015, down 1.6% on a reported basis. With the closure of the transaction, Abbott Labs expects total diagnostics sales to exceed $7 billion. The company will also become a lead player in the $5.5 billion point-of-care diagnostic segment.
The acquisition will enable Abbott Labs to gain access to new channels and geographies, including entry into fast growing outlets, such as doctors' offices, clinics, pharmacies and at-home testing. It will also add Alere's complementary portfolio of diagnostic products, which comprises tests for infections such as HIV, tuberculosis, malaria and dengue. We note that Alere develops simple, rapid tests, including Alere i, the molecular test for flu and strep, which can deliver results in less than 15 minutes.
Hence, the combined business will offer the widest array of infectious disease, molecular, cardiometabolic and toxicology testing; and expand Abbott Labs' platforms to include benchtop and rapid strip tests. Although Alere generated more than half of its total sales of $2.5 billion from the U.S. alone, the company has a growing presence in key international markets, which should further strengthen Abbott Labs' business in these territories.
Shares of Alere shot up 45.5% on the news of the acquisition.
Abbott Labs currently has a Zacks Rank #5 (Strong Sell). 2016 is expected to be quite tough for the company due to headwinds in the form of unfavorable movement of foreign exchange rates and challenging market conditions in Venezuela.
Investors interested in the health care sector may consider Celgene Corp. CELG and Gilead Sciences GILD . Both companies sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALERE INC (ALR): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In a bid to strengthen its presence and leadership in the global diagnostics market, Abbott LaboratoriesABT announced a definitive agreement to acquire Alere ALR . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition will enable Abbott Labs to gain access to new channels and geographies, including entry into fast growing outlets, such as doctors' offices, clinics, pharmacies and at-home testing. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. In a bid to strengthen its presence and leadership in the global diagnostics market, Abbott LaboratoriesABT announced a definitive agreement to acquire Alere ALR . With the closure of the transaction, Abbott Labs expects total diagnostics sales to exceed $7 billion. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. In a bid to strengthen its presence and leadership in the global diagnostics market, Abbott LaboratoriesABT announced a definitive agreement to acquire Alere ALR . Our Take The acquisition should bolster Abbott Labs' diagnostics business, which generated sales of $4.6 billion in 2015, down 1.6% on a reported basis. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. In a bid to strengthen its presence and leadership in the global diagnostics market, Abbott LaboratoriesABT announced a definitive agreement to acquire Alere ALR . Our Take The acquisition should bolster Abbott Labs' diagnostics business, which generated sales of $4.6 billion in 2015, down 1.6% on a reported basis. |
33955.0 | 2016-02-01 00:00:00 UTC | Midday Update: Wall Street Pressured By New Decline For Oil, Disappointing Manufacturing Data | ABT | https://www.nasdaq.com/articles/midday-update-wall-street-pressured-new-decline-oil-disappointing-manufacturing-data-2016 | nan | nan | Stocks have pared some of their early losses but were still moderately lower on Monday following downbeat Chinese economic data and a fresh decline for oil prices .
Friday's impressive rally could not insulate Wall Street from a contraction in Chinese manufacturing during December or from a new freefall for oil prices after Persian Gulf producers ruled out the possibility for an emergency OPEC meeting to discuss production cuts. Losses also were magnified by December consumer income and spending data at home showing an as-expected 0.3% gain in income while spending was unchanged as Americans saved more money last month.
The Dow Jones Industrial Average dropped almost 170 points soon after the opening bell, led by losses for energy and financial stocks, but found support at its 16,300 level and has since cut that opening decline in half while the S&P 500 also has seen a modest rebound off its morning lows.
Although the purchasing managers manufacturing index improved from December to 52.4, the more pivotal Institute for Supply Management index stayed below the break-even level of 50.0 for the fourth straight month. Also, construction spending increased just 0.1% in December, following a downward revised 0.6% drop in November, and missing estimates for a 0.6% gain.
European equities declined today but also trimmed earlier losses as dovish comments from European Central Bank president Mario Draghi raised the odds for a March rate cut. Draghi reiterated the bank's plan to revisit monetary policy in March to do whatever it takes to bolster the economy and raise inflation.
Crude oil was down $1.71 to $31.90 per barrel. Natural gas was down 15 cents to $2.14 per 1 million BTU. Gold was up $10 to $1,126.40 per ounce, while silver was up 8 cents to $14.32 an ounce. Copper was down 1 cent to $2.06 per pound.
Among energy ETFs, the United States Oil Fund was down 5.49% to $9.11 with the United States Natural Gas Fund was down 7.54% to $7.85. Among precious-metal funds, the Market Vectors Gold Miners ETF was up 1.47% to 14.45 while SPDR Gold Shares were up 0.74% to $107.74. The iShares Silver Trust was up 0.40% to $13.64.
Here's where the U.S. markets stood at mid-day:
NYSE Composite Index down 71.19 (-0.74%) to 9,561.51
Dow Jones Industrial Average down 93.82 (-0.57%) to 16,372.48
S&P 500 11.06 -0.57% 1929.18
Nasdaq Composite Index down 22.11 (-0.48%) to 4,591.84
GLOBAL SENTIMENT
Nikkei 225 Index up 1.98%
Hang Seng Index down 0.45%
Shanghai China Composite Index down 1.78%
FTSE 100 Index down 0.39%
CAC 40 down 0.56%
DAX down 0.41%
NYSE SECTOR INDICES
NYSE Energy Sector Index down 3.10%
NYSE Financial Sector Index down 1.27%
NYSE Healthcare Sector Index down 0.73%
UPSIDE MOVERS
(+) ASTI (+69.01%) Reported a 90% increase in Q4 revenue
(+) ALR (+45.16%) To be acquired by Abbott Labs ( ABT ) for $56 per share
(+) AYA (+24.08%) CEO David Baazov made CAD $21 per share offer for company
(+) MGI (+23.21%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years.
(+) STR (+22.36%) To be acquired by Dominion Resources ( D ) for $4.4 billion
DOWNSIDE MOVERS
(-) NOK (-12.49%) The International Court of Arbitration of the International Chamber of Commerce issued an undisclosed award to the company regarding a patent license dispute between it and Samsung
(-) ROP (-7.14%) Reported Q4 earnings and revenues below street estimates on flat sales
(-) GPRO (-4.29%) Piper Jaffray reiterated underweight rating and lowered its price target by $1.50
(-) BCS (-1.90%) Agreed with Credit Suisse ( CS ) to settle their dark pool investigations for $154.3 million
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) ASTI (+69.01%) Reported a 90% increase in Q4 revenue (+) ALR (+45.16%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+24.08%) CEO David Baazov made CAD $21 per share offer for company (+) MGI (+23.21%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. Stocks have pared some of their early losses but were still moderately lower on Monday following downbeat Chinese economic data and a fresh decline for oil prices . Friday's impressive rally could not insulate Wall Street from a contraction in Chinese manufacturing during December or from a new freefall for oil prices after Persian Gulf producers ruled out the possibility for an emergency OPEC meeting to discuss production cuts. | (+) ASTI (+69.01%) Reported a 90% increase in Q4 revenue (+) ALR (+45.16%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+24.08%) CEO David Baazov made CAD $21 per share offer for company (+) MGI (+23.21%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. The Dow Jones Industrial Average dropped almost 170 points soon after the opening bell, led by losses for energy and financial stocks, but found support at its 16,300 level and has since cut that opening decline in half while the S&P 500 also has seen a modest rebound off its morning lows. Among energy ETFs, the United States Oil Fund was down 5.49% to $9.11 with the United States Natural Gas Fund was down 7.54% to $7.85. | (+) ASTI (+69.01%) Reported a 90% increase in Q4 revenue (+) ALR (+45.16%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+24.08%) CEO David Baazov made CAD $21 per share offer for company (+) MGI (+23.21%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. Nikkei 225 Index up 1.98% Hang Seng Index down 0.45% Shanghai China Composite Index down 1.78% FTSE 100 Index down 0.39% CAC 40 down 0.56% DAX down 0.41% NYSE Energy Sector Index down 3.10% NYSE Financial Sector Index down 1.27% NYSE Healthcare Sector Index down 0.73% | (+) ASTI (+69.01%) Reported a 90% increase in Q4 revenue (+) ALR (+45.16%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+24.08%) CEO David Baazov made CAD $21 per share offer for company (+) MGI (+23.21%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. Stocks have pared some of their early losses but were still moderately lower on Monday following downbeat Chinese economic data and a fresh decline for oil prices . Gold was up $10 to $1,126.40 per ounce, while silver was up 8 cents to $14.32 an ounce. |
33956.0 | 2016-02-01 00:00:00 UTC | Here's Why Alere's Stock Is Soaring Today | ABT | https://www.nasdaq.com/articles/heres-why-aleres-stock-soaring-today-2016-02-01 | nan | nan | What : Shares of the medical diagnostic company Alere jumped 45% today on a $5.8 billion buyout deal with Abbott Laboratories . Abbott is reportedly paying $56 per share for Alere in an all-cash deal, representing a 50% premium compared to where Alere's shares were trading following Friday's close. Per the terms of the deal, Abbott will also assume $2.6 billion of Alere's outstanding debt.
So what
Now what : According to S&P Capital IQ , Alere's product portfolio is expected to generate around $2.5 billion in sales in 2016. So, Abbott seems to be getting a fairly reasonable price for Alere's diagnostic assets, especially since the deal will grow the company's bottom line right away. That's why investors may want to take a deeper look at Abbott today.
This iSecret stock could make this pop look tiny
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Here's Why Alere's Stock Is Soaring Today originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What : Shares of the medical diagnostic company Alere jumped 45% today on a $5.8 billion buyout deal with Abbott Laboratories . So, Abbott seems to be getting a fairly reasonable price for Alere's diagnostic assets, especially since the deal will grow the company's bottom line right away. This iSecret stock could make this pop look tiny The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What : Shares of the medical diagnostic company Alere jumped 45% today on a $5.8 billion buyout deal with Abbott Laboratories . | What : Shares of the medical diagnostic company Alere jumped 45% today on a $5.8 billion buyout deal with Abbott Laboratories . Abbott is reportedly paying $56 per share for Alere in an all-cash deal, representing a 50% premium compared to where Alere's shares were trading following Friday's close. This iSecret stock could make this pop look tiny The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. | What : Shares of the medical diagnostic company Alere jumped 45% today on a $5.8 billion buyout deal with Abbott Laboratories . Per the terms of the deal, Abbott will also assume $2.6 billion of Alere's outstanding debt. The Motley Fool has no position in any of the stocks mentioned. |
33957.0 | 2016-02-01 00:00:00 UTC | Mid-Morning Market Update: Markets Open Lower; Abbott Laboratories To Buy Alere For $56/Share | ABT | https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-abbott-laboratories-buy-alere-56share-2016-02 | nan | nan | Following the market opening Monday, the Dow traded down 0.88 percent to 16,322.00 while the NASDAQ dipped 0.90 percent to 4,572.47. The S&P also fell, dropping 0.87 percent to 1,923.45.
Leading and Lagging Sectors
On Monday, telecommunications services shares rose by 0.06 percent. Meanwhile, top gainers in the sector included NTT Docomo Inc (ADR) (NYSE: DCM ), up 5 percent, and Nippon Telegraph & Telephone Corp (ADR) (NYSE: NTT ) up 2.5 percent.
In trading on Monday, energy shares fell by 2.72 percent. Meanwhile, top losers in the sector included Vanguard Natural Resources, LLC (NASDAQ: VNR ), down 12 percent, and NGL Energy Partners LP (NYSE: NGL ), down 14 percent.
Top Headline
Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion.
Abbott will pay $56 per share in cash, representing a premium of around 51 percent over Alere's closing price of $37.20 on Friday.
Equities Trading UP
Alere Inc (NYSE: ALR ) shares shot up 45 percent to $53.80 as Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere for $5.8 billion.
Shares of AMAYA INC (NASDAQ: AYA ) got a boost, shooting up 30 percent to $13.72 after the company's CEO David Baazov announced intention to acquire Amaya for C$21 per share.
Ascent Solar Technologies, Inc. (NASDAQ: ASTI ) shares were also up, gaining 69 percent to $0.120 as the company reported a 90 percent rise in Q4 revenue to $2.4 million.
Equities Trading DOWN
Nokia Corporation (ADR) (NYSE: NOK ) shares dropped 12 percent to $6.34 after the company reported a court decision in patent license arbitration versus Samsung Electronics Co. Bank of America downgraded Nokia from Buy to Neutral.
Shares of Roper Technologies Inc (NYSE: ROP ) were down 7 percent to $163.25 after the company reported downbeat Q4 results and issued a weak earnings forecast.
Restoration Hardware Holdings Inc (NYSE: RH ) was down, falling around 5 percent to $58.66. Cowen & Company downgraded Restoration Hardware from Outperform to Market Perform and lowered the price target to $64.00.
Commodities
In commodity news, oil traded down 3.75 percent to $32.36, while gold traded up 0.53 percent to $1,122.30.
Silver traded up 0.29 percent Monday to $14.29, while copper fell 1.11 percent to $2.04.
Eurozone
European shares were lower today. The eurozone's STOXX 600 fell 0.93 percent, the Spanish Ibex Index dipped 0.69 percent, while Italy's FTSE MIB Index dropped 1.21 percent. Meanwhile, the German DAX dropped 1.25 percent, and the French CAC 40 slipped 1.30 percent, while U.K. shares fell 1.32 percent.
Economics
US consumer spending came in flat in December, versus economists' expectations for a 0.1 percent growth.
The ISM manufacturing PMI rose to 48.2 in January, versus a previous reading of 48.00. Economists were expecting a reading of 48.00.
The manufacturing PMI slipped to 52.4 in January, versus a prior reading of 52.70. However, economists were expecting a reading of 52.70.
US construction spending rose 0.1 percent in December, versus economists' expectations for a 0.6 percent growth.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. Equities Trading UP Alere Inc (NYSE: ALR ) shares shot up 45 percent to $53.80 as Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere for $5.8 billion. Abbott will pay $56 per share in cash, representing a premium of around 51 percent over Alere's closing price of $37.20 on Friday. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. Equities Trading UP Alere Inc (NYSE: ALR ) shares shot up 45 percent to $53.80 as Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere for $5.8 billion. US construction spending rose 0.1 percent in December, versus economists' expectations for a 0.6 percent growth. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. Equities Trading UP Alere Inc (NYSE: ALR ) shares shot up 45 percent to $53.80 as Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere for $5.8 billion. The eurozone's STOXX 600 fell 0.93 percent, the Spanish Ibex Index dipped 0.69 percent, while Italy's FTSE MIB Index dropped 1.21 percent. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. Equities Trading UP Alere Inc (NYSE: ALR ) shares shot up 45 percent to $53.80 as Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere for $5.8 billion. In trading on Monday, energy shares fell by 2.72 percent. |
33958.0 | 2016-02-01 00:00:00 UTC | Stock Futures Drop on Chinese Manufacturing Data, Supply-Related Oil Sell-off | ABT | https://www.nasdaq.com/articles/stock-futures-drop-chinese-manufacturing-data-supply-related-oil-sell-2016-02-01 | nan | nan | U.S. stock futures were positioned to open lower on Monday as bearish Chinese manufacturing data coupled with another sell-off in oil was fueling losses across Europe and the U.S. Oil was already more than 3% lower, snapping a five-day winning streak, after two OPEC delegates downplayed the potential for a meeting of OPEC and non-OPEC nations to support oil prices , telling Reuters that, "it's all in the hands of the Russians now."
Investors were also bracing for a deluge of pivotal economic data this week that includes manufacturing and factory orders data and culminates with the January payroll report on Friday. First out of the gate was December personal income and spending data. Income increased an as-expected 0.3% last month, while spending was flat as consumers saved 5.5% in December from 5.3% in November.
Coming up next is the final PMI manufacturing index for January (expected to decline to 52.6), the ISM manufacturing index (expected 48.3), and December construction spending (+0.6%).
-Dow Jones Industrial down 0.58%
-S&P 500 futures down 0.61%
-Nasdaq 100 futures down 0.40%
SENTIMENT
Nikkei up 1.98%
Hang Seng down 0.45%
Shanghai Composite down 1.77%
FTSE-100 down 1.26%
DAX-30 down 1.17%
PRE-MARKET SECTOR WATCH
(-) Large cap tech: Lower
(-) Chip stocks: Lower
(-) Software stocks: Lower
(-) Hardware stocks: Lower
(+/-) Internet stocks: Mixed
(-) Drug stocks: Lower
(-) Financial stocks: Lower
(-) Retail stocks: Lower
(-) Industrial stocks: Lower
(-) Airlines: Lower
(-) Autos: Lower
UPSIDE MOVERS:
(+) ASTI (+76.06%) Reported a 90% increase in Q4 revenue
(+) ALR (+46.32%) To be acquired by Abbott Labs ( ABT ) for $56 per share
(+) AYA (+26.33%) CEO David Baazov made CAD $21 per share offer for company
(+) STR (+20.89%) To be acquired by Dominion Resources ( D ) for $4.4 billion
(+) MSTX (+12.50%) Reported top-line results from a blind Phase 2a study of AIR001
DOWNSIDE MOVERS:
(-) HSBC (-3.05%) Initiated a hiring and salary freeze to lower costs
(-) BCS (-2.60%) Agreed with Credit Suisse ( CS ) to settle their dark pool investigations for $154.3 million
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) ASTI (+76.06%) Reported a 90% increase in Q4 revenue (+) ALR (+46.32%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+26.33%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+20.89%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MSTX (+12.50%) Reported top-line results from a blind Phase 2a study of AIR001 Income increased an as-expected 0.3% last month, while spending was flat as consumers saved 5.5% in December from 5.3% in November. (-) HSBC (-3.05%) Initiated a hiring and salary freeze to lower costs (-) BCS (-2.60%) Agreed with Credit Suisse ( CS ) to settle their dark pool investigations for $154.3 million The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) ASTI (+76.06%) Reported a 90% increase in Q4 revenue (+) ALR (+46.32%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+26.33%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+20.89%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MSTX (+12.50%) Reported top-line results from a blind Phase 2a study of AIR001 (-) Large cap tech: Lower (-) Chip stocks: Lower (-) Software stocks: Lower (-) Hardware stocks: Lower (+/-) Internet stocks: Mixed (-) Drug stocks: Lower (-) Financial stocks: Lower (-) Retail stocks: Lower (-) Industrial stocks: Lower (-) Airlines: Lower (-) Autos: Lower (-) HSBC (-3.05%) Initiated a hiring and salary freeze to lower costs (-) BCS (-2.60%) Agreed with Credit Suisse ( CS ) to settle their dark pool investigations for $154.3 million The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) ASTI (+76.06%) Reported a 90% increase in Q4 revenue (+) ALR (+46.32%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+26.33%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+20.89%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MSTX (+12.50%) Reported top-line results from a blind Phase 2a study of AIR001 U.S. stock futures were positioned to open lower on Monday as bearish Chinese manufacturing data coupled with another sell-off in oil was fueling losses across Europe and the U.S. Oil was already more than 3% lower, snapping a five-day winning streak, after two OPEC delegates downplayed the potential for a meeting of OPEC and non-OPEC nations to support oil prices , telling Reuters that, "it's all in the hands of the Russians now." (-) Large cap tech: Lower (-) Chip stocks: Lower (-) Software stocks: Lower (-) Hardware stocks: Lower (+/-) Internet stocks: Mixed (-) Drug stocks: Lower (-) Financial stocks: Lower (-) Retail stocks: Lower (-) Industrial stocks: Lower (-) Airlines: Lower (-) Autos: Lower | (+) ASTI (+76.06%) Reported a 90% increase in Q4 revenue (+) ALR (+46.32%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+26.33%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+20.89%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MSTX (+12.50%) Reported top-line results from a blind Phase 2a study of AIR001 U.S. stock futures were positioned to open lower on Monday as bearish Chinese manufacturing data coupled with another sell-off in oil was fueling losses across Europe and the U.S. Oil was already more than 3% lower, snapping a five-day winning streak, after two OPEC delegates downplayed the potential for a meeting of OPEC and non-OPEC nations to support oil prices , telling Reuters that, "it's all in the hands of the Russians now." First out of the gate was December personal income and spending data. |
33959.0 | 2016-02-01 00:00:00 UTC | Health Care Sector Update for 02/01/2016: LIVN, ABT | ABT | https://www.nasdaq.com/articles/health-care-sector-update-02012016-livn-abt-2016-02-01 | nan | nan | Top Health-care stocks:
JNJ: flat
PFE: flat
ABT: +0.4%
MRK: -0.1%
AMGN: flat
Health-care shares were mainly unchanged in pre-market trade on Monday.
In health-care stocks news, LivaNova ( LIVN ) said the U.S. Food and Drug Administration has approved its stented aortic bioprosthesis CROWN PRT for the treatment of aortic valve disease and it is expected to be launched in the coming months.
Shares in the company were unchanged at $55.98 pre-bell. This is within the lower band of the stock's 52-week range between $51.28 and $77.00.
And Abbott Laboratories ( ABT ) shares were slightly higher in recent pre-market trade after saying it has agreed to buy Alere ( ALR ) for $56 per share or a total $5.8 billion.
Shares in the company were 0.4% higher at $38 pre-bell. This is within the lower band of the stock's 52-week range between $36 and $51.74.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And Abbott Laboratories ( ABT ) shares were slightly higher in recent pre-market trade after saying it has agreed to buy Alere ( ALR ) for $56 per share or a total $5.8 billion. AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Monday. In health-care stocks news, LivaNova ( LIVN ) said the U.S. Food and Drug Administration has approved its stented aortic bioprosthesis CROWN PRT for the treatment of aortic valve disease and it is expected to be launched in the coming months. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And Abbott Laboratories ( ABT ) shares were slightly higher in recent pre-market trade after saying it has agreed to buy Alere ( ALR ) for $56 per share or a total $5.8 billion. AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Monday. | And Abbott Laboratories ( ABT ) shares were slightly higher in recent pre-market trade after saying it has agreed to buy Alere ( ALR ) for $56 per share or a total $5.8 billion. AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Monday. In health-care stocks news, LivaNova ( LIVN ) said the U.S. Food and Drug Administration has approved its stented aortic bioprosthesis CROWN PRT for the treatment of aortic valve disease and it is expected to be launched in the coming months. | And Abbott Laboratories ( ABT ) shares were slightly higher in recent pre-market trade after saying it has agreed to buy Alere ( ALR ) for $56 per share or a total $5.8 billion. AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Monday. In health-care stocks news, LivaNova ( LIVN ) said the U.S. Food and Drug Administration has approved its stented aortic bioprosthesis CROWN PRT for the treatment of aortic valve disease and it is expected to be launched in the coming months. |
33960.0 | 2016-02-01 00:00:00 UTC | Close Update: Stocks Trim Early Losses Tied to Lower Oil | ABT | https://www.nasdaq.com/articles/close-update-stocks-trim-early-losses-tied-lower-oil-2016-02-01 | nan | nan | Stocks were mixed at Monday's close with the Dow Industrial Average and S&P 500 closing above their worst levels of the day, but modestly lower as another sell-off in oil and downbeat U.S. and Chinese manufacturing data weighed on Wall Street. The Nasdaq squeezed out a slim gain thanks to flows into defensive sectors like utilities and telecommunications.
Stocks opened lower in reaction to weaker oil, another contraction in China's manufacturing sector and sluggish U.S. consumer spending data. By midday, however, equities were making a comeback on technical support in the Dow at 16,300 and the 50% retracement in the S&P 500 at 1,917. Although the rebound started to fizzle out, it regained momentum on dovish comments from Fed Vice Chairman Stanley Fischer that fueled subsequent gains in defensive sectors.
Oil closed in the red for the first time in five days when a delegate for Persian Gulf OPEC members said an emergency meeting to discuss production cuts was "pointless" and could "backfire" in an attempt to raise prices. This caused crude oil to lose all its gains achieved late last week.
Defensive plays bolstered the price of gold to a 3-month high and pushed short-term Treasury yields lower, steepening the yield curve as long-term yields increased disproportionally to yields in shorter-maturing Treasury securities. This typically indicates expectations for inflation to increase.
Theeconomic calendartakes a breather Tuesday with only January vehicle sales released throughout the day. Total sales are expected to increase to 17.5 million, but domestic sales should decrease to 13.6 million.
Here's where the markets stood at the close:
US MARKETS
Dow Jones Industrial Index was down 17.12 points (-0.10%)
S&P 500 was down 0.86 points (-0.04%)
Nasdaq Composite Index was up 6.41 points (+0.14%)
GLOBAL SENTIMENT
FTSE 100 was down 0.39%
Nikkei 225 was up 1.98%
Hang Seng Index was down 0.45%
Shanghai China Composite Index was down 1.78%
UPSIDE MOVERS
(+) EYEG (+110.00%) Initiated by Rodman & Renshaw with a buy rating and a price target of $10 a share
(+) ASTI (+55.77%) Reported a 90% increase in Q4 revenue
(+) ALR (+45.46%) To be acquired by Abbott Labs ( ABT ) for $56 per share
(+) AYA (+20.08%) CEO David Baazov made CAD $21 per share offer for company
(+) STR (+22.56%) To be acquired by Dominion Resources ( D ) for $4.4 billion
(+) MGI (+16.60%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years.
(+) TROV (+15.11%) Tapped to provide FedMed clients with precision cancer monitoring services
DOWNSIDE MOVERS
(-) TTHI (-23.66%) Reported "acceptable" safety and tolerability results from Phase 2 study of diabetes treatment
(-) TEAR (-23.48%) Estimates Q4 and full year revenues below estimates, plans to wind down OcuHub, and prepares to launch $15 million offering
(-) NEOS (-19.88%) Filed shelf registration for $69 million offering
(-) AZUR (-12.70%) Temporarily suspending its distribution and considering various options to strengthen its balance sheet including equity restructuring, a capital raise and strategic alternatives
(-) NOK (-12.01%) The International Court of Arbitration of the International Chamber of Commerce issued an undisclosed award to the company regarding a patent license dispute between it and Samsung
(-) ROP (-6.80%) Reported Q4 earnings and revenues below street estimates on flat sales
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) EYEG (+110.00%) Initiated by Rodman & Renshaw with a buy rating and a price target of $10 a share (+) ASTI (+55.77%) Reported a 90% increase in Q4 revenue (+) ALR (+45.46%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+20.08%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+22.56%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MGI (+16.60%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. Although the rebound started to fizzle out, it regained momentum on dovish comments from Fed Vice Chairman Stanley Fischer that fueled subsequent gains in defensive sectors. Oil closed in the red for the first time in five days when a delegate for Persian Gulf OPEC members said an emergency meeting to discuss production cuts was "pointless" and could "backfire" in an attempt to raise prices. | (+) EYEG (+110.00%) Initiated by Rodman & Renshaw with a buy rating and a price target of $10 a share (+) ASTI (+55.77%) Reported a 90% increase in Q4 revenue (+) ALR (+45.46%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+20.08%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+22.56%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MGI (+16.60%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. Defensive plays bolstered the price of gold to a 3-month high and pushed short-term Treasury yields lower, steepening the yield curve as long-term yields increased disproportionally to yields in shorter-maturing Treasury securities. (-) TTHI (-23.66%) Reported "acceptable" safety and tolerability results from Phase 2 study of diabetes treatment (-) TEAR (-23.48%) Estimates Q4 and full year revenues below estimates, plans to wind down OcuHub, and prepares to launch $15 million offering (-) NEOS (-19.88%) Filed shelf registration for $69 million offering (-) AZUR (-12.70%) Temporarily suspending its distribution and considering various options to strengthen its balance sheet including equity restructuring, a capital raise and strategic alternatives (-) NOK (-12.01%) The International Court of Arbitration of the International Chamber of Commerce issued an undisclosed award to the company regarding a patent license dispute between it and Samsung (-) ROP (-6.80%) Reported Q4 earnings and revenues below street estimates on flat sales The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) EYEG (+110.00%) Initiated by Rodman & Renshaw with a buy rating and a price target of $10 a share (+) ASTI (+55.77%) Reported a 90% increase in Q4 revenue (+) ALR (+45.46%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+20.08%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+22.56%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MGI (+16.60%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. Stocks were mixed at Monday's close with the Dow Industrial Average and S&P 500 closing above their worst levels of the day, but modestly lower as another sell-off in oil and downbeat U.S. and Chinese manufacturing data weighed on Wall Street. Defensive plays bolstered the price of gold to a 3-month high and pushed short-term Treasury yields lower, steepening the yield curve as long-term yields increased disproportionally to yields in shorter-maturing Treasury securities. | (+) EYEG (+110.00%) Initiated by Rodman & Renshaw with a buy rating and a price target of $10 a share (+) ASTI (+55.77%) Reported a 90% increase in Q4 revenue (+) ALR (+45.46%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+20.08%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+22.56%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MGI (+16.60%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. Stocks were mixed at Monday's close with the Dow Industrial Average and S&P 500 closing above their worst levels of the day, but modestly lower as another sell-off in oil and downbeat U.S. and Chinese manufacturing data weighed on Wall Street. Total sales are expected to increase to 17.5 million, but domestic sales should decrease to 13.6 million. |
33961.0 | 2016-02-01 00:00:00 UTC | Mid-Afternoon Market Update: Roper Technologies Falls Following Weak Results; Questar Shares Spike Higher | ABT | https://www.nasdaq.com/articles/mid-afternoon-market-update-roper-technologies-falls-following-weak-results-questar-shares | nan | nan | Toward the end of trading Monday, the Dow traded down 0.53 percent to 16,378.38 while the NASDAQ dipped 0.37 percent to 4,597.08. The S&P also fell, dropping 0.46 percent to 1,931.24.
Leading and Lagging Sectors
On Monday, telecommunications services shares rose by 0.85 percent. Meanwhile, top gainers in the sector included NTT Docomo Inc (ADR) (NYSE: DCM ), up 6 percent, and Internet Gold Golden Lines Ltd (NASDAQ: IGLD ) up 13 percent.
In trading on Monday, energy shares fell by 2.76 percent. Meanwhile, top losers in the sector included Vanguard Natural Resources, LLC (NASDAQ: VNR ), down 13 percent, and Nabors Industries Ltd. (NYSE: NBR ), down 11 percent.
Top Headline
Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion.
Abbott will pay $56 per share in cash, representing a premium of around 51 percent over Alere's closing price of $37.20 on Friday.
Equities Trading UP
Shares of AMAYA INC (NASDAQ: AYA ) got a boost, shooting up 26 percent to $13.26 after the company's CEO David Baazov announced intention to acquire Amaya for C$21 per share.
Alere Inc (NYSE: ALR ) shares shot up 45 percent to $54.06 as Abbott Laboratories announced plans to acquire Alere for $5.8 billion.
Questar Corporation (NYSE: STR ) shares were also up, gaining 23 percent to $24.98 as Dominion Resources, Inc. (NYSE: D ) agreed to buy Questar for around $4.4 billion.
Equities Trading DOWN
Nokia Corporation (ADR) (NYSE: NOK ) shares dropped 12 percent to $6.33 after the company reported a court decision in patent license arbitration versus Samsung Electronics Co. Bank of America downgraded Nokia from Buy to Neutral.
Shares of Roper Technologies Inc (NYSE: ROP ) were down 7 percent to $163.07 after the company reported downbeat Q4 results and issued a weak earnings forecast.
Restoration Hardware Holdings Inc (NYSE: RH ) was down, falling around 5 percent to $58.84. Cowen & Company downgraded Restoration Hardware from Outperform to Market Perform and lowered the price target to $64.00.
Commodities
In commodity news, oil traded down 5.86 percent to $31.65, while gold traded up 0.99 percent to $1,127.50.
Silver traded up 0.68 percent Monday to $14.34, while copper fell 0.36 percent to $2.06.
Eurozone
European shares closed lower today. The eurozone's STOXX 600 fell 0.19 percent, the Spanish Ibex Index dipped 0.31 percent, while Italy's FTSE MIB Index dropped 0.92 percent. Meanwhile, the German DAX dropped 0.41 percent, and the French CAC 40 slipped 0.56 percent, while U.K. shares fell 0.39 percent.
Economics
US consumer spending came in flat in December, versus economists' expectations for a 0.1 percent growth.
The ISM manufacturing PMI rose to 48.2 in January, versus a previous reading of 48.00. Economists were expecting a reading of 48.00.
The manufacturing PMI slipped to 52.4 in January, versus a prior reading of 52.70. However, economists were expecting a reading of 52.70.
US construction spending rose 0.1 percent in December, versus economists' expectations for a 0.6 percent growth.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. Abbott will pay $56 per share in cash, representing a premium of around 51 percent over Alere's closing price of $37.20 on Friday. Shares of Roper Technologies Inc (NYSE: ROP ) were down 7 percent to $163.07 after the company reported downbeat Q4 results and issued a weak earnings forecast. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. Alere Inc (NYSE: ALR ) shares shot up 45 percent to $54.06 as Abbott Laboratories announced plans to acquire Alere for $5.8 billion. Equities Trading DOWN Nokia Corporation (ADR) (NYSE: NOK ) shares dropped 12 percent to $6.33 after the company reported a court decision in patent license arbitration versus Samsung Electronics Co. Bank of America downgraded Nokia from Buy to Neutral. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. Toward the end of trading Monday, the Dow traded down 0.53 percent to 16,378.38 while the NASDAQ dipped 0.37 percent to 4,597.08. The eurozone's STOXX 600 fell 0.19 percent, the Spanish Ibex Index dipped 0.31 percent, while Italy's FTSE MIB Index dropped 0.92 percent. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. In trading on Monday, energy shares fell by 2.76 percent. Eurozone European shares closed lower today. |
33962.0 | 2016-02-01 00:00:00 UTC | Health Care Sector Update for 02/01/2016: ALR,ABT,EYEG,TTHI | ABT | https://www.nasdaq.com/articles/health-care-sector-update-02012016-alrabteyegtthi-2016-02-01 | nan | nan | Top Health Care Stocks
JNJ -0.64%
PZE -1.61%
MRK +0.29%
ABT -0.20%
AMGN -1.56%
Health care stocks were trending lower today, with the NYSE Health Care Index dropping nearly 0.5% while shares of health care companies in the S&P 500 were slipping almost 0.9% as a group.
In company news, Alere Inc. ( ALR ) rallied Tuesday after the diagnostics company agreed to a $5.8 billion buyout proposal from Abbott Laboratories ( ABT ), which would pay $56 in cash for each Alere share, a nearly 48% premium over Friday's closing price for the stock.
Abbott said it expects the transaction would immediately add to its per-share earnings after its close, adding between $0.12 to $0.13 per share to its FY17 net income and more than $0.20 per share during FY18. Abbott also will assume about $2.6 billion of Alere debt as part of the buyout.
ALR shares were up more than 45% at $54.08 apiece this afternoon, just under their session high of $54.11 a share. ABT stock has see-sawed between small gains and losses most of today's session, recently rising about 0.2% to $37.92 a share.
In other sector news,
(+) EYEG, (+80.0%) Rodman & Renshaw begins analyst coverage with a Buy rating and a $10 price target.
(-) TTHI, (-30.8%) Reports top-line data from Phase II testing of TT401 drug candidate, improving HbA1c by up to -1.43% in patients with diabetes in the dose arm compared with patients who received a placebo.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Alere Inc. ( ALR ) rallied Tuesday after the diagnostics company agreed to a $5.8 billion buyout proposal from Abbott Laboratories ( ABT ), which would pay $56 in cash for each Alere share, a nearly 48% premium over Friday's closing price for the stock. ABT stock has see-sawed between small gains and losses most of today's session, recently rising about 0.2% to $37.92 a share. In other sector news, (+) EYEG, (+80.0%) Rodman & Renshaw begins analyst coverage with a Buy rating and a $10 price target. | In company news, Alere Inc. ( ALR ) rallied Tuesday after the diagnostics company agreed to a $5.8 billion buyout proposal from Abbott Laboratories ( ABT ), which would pay $56 in cash for each Alere share, a nearly 48% premium over Friday's closing price for the stock. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT stock has see-sawed between small gains and losses most of today's session, recently rising about 0.2% to $37.92 a share. | In company news, Alere Inc. ( ALR ) rallied Tuesday after the diagnostics company agreed to a $5.8 billion buyout proposal from Abbott Laboratories ( ABT ), which would pay $56 in cash for each Alere share, a nearly 48% premium over Friday's closing price for the stock. ABT stock has see-sawed between small gains and losses most of today's session, recently rising about 0.2% to $37.92 a share. Health care stocks were trending lower today, with the NYSE Health Care Index dropping nearly 0.5% while shares of health care companies in the S&P 500 were slipping almost 0.9% as a group. | In company news, Alere Inc. ( ALR ) rallied Tuesday after the diagnostics company agreed to a $5.8 billion buyout proposal from Abbott Laboratories ( ABT ), which would pay $56 in cash for each Alere share, a nearly 48% premium over Friday's closing price for the stock. ABT stock has see-sawed between small gains and losses most of today's session, recently rising about 0.2% to $37.92 a share. Top Health Care Stocks |
33963.0 | 2016-01-29 00:00:00 UTC | Weakness Seen in Abbott Laboratories (ABT): Stock Tumbles 9.3% | ABT | https://www.nasdaq.com/articles/weakness-seen-in-abbott-laboratories-abt%3A-stock-tumbles-9.3-2016-01-29 | nan | nan | Abbott LaboratoriesABT saw a big move last session, as the company's shares fell by over 9% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for ABT, as the stock is now down nearly 20% in the past one-month time frame.
On Jan 28, 2016, the company released its fourth-quarter 2015 results, wherein sales decreased year over year and fell short of the Zacks Consensus Estimate, mainly impacted by unfavorable foreign exchange movement.
The global healthcare company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks (1 increase, 3 decreases), and the consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
ABT currently has a Zacks Rank #5 (Strong Sell).
Investors interested in the same industry may consider better-ranked stock like AstraZeneca PLC AZN , which carries a Zacks Rank #2 (Buy).
Is ABT going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT saw a big move last session, as the company's shares fell by over 9% on the day. This continues the recent downtrend for ABT, as the stock is now down nearly 20% in the past one-month time frame. ABT currently has a Zacks Rank #5 (Strong Sell). | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT saw a big move last session, as the company's shares fell by over 9% on the day. This continues the recent downtrend for ABT, as the stock is now down nearly 20% in the past one-month time frame. | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT saw a big move last session, as the company's shares fell by over 9% on the day. This continues the recent downtrend for ABT, as the stock is now down nearly 20% in the past one-month time frame. | Abbott LaboratoriesABT saw a big move last session, as the company's shares fell by over 9% on the day. Is ABT going up? This continues the recent downtrend for ABT, as the stock is now down nearly 20% in the past one-month time frame. |
33964.0 | 2016-01-28 00:00:00 UTC | Thursday Sector Laggards: Healthcare, Industrial | ABT | https://www.nasdaq.com/articles/thursday-sector-laggards-healthcare-industrial-2016-01-28 | nan | nan | In afternoon trading on Thursday, Healthcare stocks are the worst performing sector, showing a 2.3% loss. Within that group, Abbott Laboratories (Symbol: ABT) and Endo International plc (Symbol: ENDP) are two large stocks that are lagging, showing a loss of 8.9% and 6.9%, respectively. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 2.0% on the day, and down 8.90% year-to-date. Abbott Laboratories, meanwhile, is down 17.35% year-to-date, and Endo International plc, is down 11.71% year-to-date. Combined, ABT and ENDP make up approximately 2.3% of the underlying holdings of XLV.
The next worst performing sector is the Industrial sector, showing a 0.1% loss. Among large Industrial stocks, United Rentals, Inc. (Symbol: URI) and Alliance Data Systems Corp. (Symbol: ADS) are the most notable, showing a loss of 18.0% and 16.9%, respectively. One ETF closely tracking Industrial stocks is the Industrial Select Sector SPDR ETF ( XLI ), which is up 0.6% in midday trading, and down 8.13% on a year-to-date basis. United Rentals, Inc., meanwhile, is down 36.90% year-to-date, and Alliance Data Systems Corp., is down 25.82% year-to-date. URI makes up approximately 0.3% of the underlying holdings of XLI.
Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:
Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Thursday. As you can see, five sectors are up on the day, while two sectors are down.
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Combined, ABT and ENDP make up approximately 2.3% of the underlying holdings of XLV. Within that group, Abbott Laboratories (Symbol: ABT) and Endo International plc (Symbol: ENDP) are two large stocks that are lagging, showing a loss of 8.9% and 6.9%, respectively. In afternoon trading on Thursday, Healthcare stocks are the worst performing sector, showing a 2.3% loss. | Within that group, Abbott Laboratories (Symbol: ABT) and Endo International plc (Symbol: ENDP) are two large stocks that are lagging, showing a loss of 8.9% and 6.9%, respectively. Combined, ABT and ENDP make up approximately 2.3% of the underlying holdings of XLV. In afternoon trading on Thursday, Healthcare stocks are the worst performing sector, showing a 2.3% loss. | Within that group, Abbott Laboratories (Symbol: ABT) and Endo International plc (Symbol: ENDP) are two large stocks that are lagging, showing a loss of 8.9% and 6.9%, respectively. Combined, ABT and ENDP make up approximately 2.3% of the underlying holdings of XLV. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 2.0% on the day, and down 8.90% year-to-date. | Within that group, Abbott Laboratories (Symbol: ABT) and Endo International plc (Symbol: ENDP) are two large stocks that are lagging, showing a loss of 8.9% and 6.9%, respectively. Combined, ABT and ENDP make up approximately 2.3% of the underlying holdings of XLV. In afternoon trading on Thursday, Healthcare stocks are the worst performing sector, showing a 2.3% loss. |
33965.0 | 2016-01-28 00:00:00 UTC | New Strong Sell Stocks for January 28th | ABT | https://www.nasdaq.com/articles/new-strong-sell-stocks-for-january-28th-2016-01-28 | nan | nan | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Abbott Laboratories ( ABT )
Abraxas Petroleum Corp. ( AXAS )
Altra Industrial Motion Corp ( AIMC )
America Movil SAB de CV ( AMX )
Apogee Enterprises Inc ( APOG )
View the entire Zacks Rank #5 List .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABRAXAS PETE/NV (AXAS): Free Stock Analysis Report
ALTRA INDUS MOT (AIMC): Free Stock Analysis Report
AMER MOVIL-ADR (AMX): Free Stock Analysis Report
APOGEE ENTRPRS (APOG): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Abraxas Petroleum Corp. ( AXAS ) Altra Industrial Motion Corp ( AIMC ) America Movil SAB de CV ( AMX ) Apogee Enterprises Inc ( APOG ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABRAXAS PETE/NV (AXAS): Free Stock Analysis Report ALTRA INDUS MOT (AIMC): Free Stock Analysis Report AMER MOVIL-ADR (AMX): Free Stock Analysis Report APOGEE ENTRPRS (APOG): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Abraxas Petroleum Corp. ( AXAS ) Altra Industrial Motion Corp ( AIMC ) America Movil SAB de CV ( AMX ) Apogee Enterprises Inc ( APOG ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABRAXAS PETE/NV (AXAS): Free Stock Analysis Report ALTRA INDUS MOT (AIMC): Free Stock Analysis Report AMER MOVIL-ADR (AMX): Free Stock Analysis Report APOGEE ENTRPRS (APOG): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Abraxas Petroleum Corp. ( AXAS ) Altra Industrial Motion Corp ( AIMC ) America Movil SAB de CV ( AMX ) Apogee Enterprises Inc ( APOG ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABRAXAS PETE/NV (AXAS): Free Stock Analysis Report ALTRA INDUS MOT (AIMC): Free Stock Analysis Report AMER MOVIL-ADR (AMX): Free Stock Analysis Report APOGEE ENTRPRS (APOG): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Abraxas Petroleum Corp. ( AXAS ) Altra Industrial Motion Corp ( AIMC ) America Movil SAB de CV ( AMX ) Apogee Enterprises Inc ( APOG ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABRAXAS PETE/NV (AXAS): Free Stock Analysis Report ALTRA INDUS MOT (AIMC): Free Stock Analysis Report AMER MOVIL-ADR (AMX): Free Stock Analysis Report APOGEE ENTRPRS (APOG): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? |
33966.0 | 2016-01-28 00:00:00 UTC | Abbott Labs (ABT) Beats on Q4 Earnings, Lags on Revenues | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-q4-earnings-lags-on-revenues-2016-01-28 | nan | nan | Abbott LaboratoriesABT reported fourth-quarter 2015 earnings of 62 cents per share, beating the Zacks Consensus Estimate by a penny but remaining flat year over year.
In the reported quarter, sales came in at $5.2 billion, down 3.1% year over year (on a reported basis) and missing the Zacks Consensus Estimate of $5.3 billion. Sales were impacted by unfavorable foreign exchange movement of 8% during the quarter.
The Quarter in Detail
Abbott Labs operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales were down 4% to $885 million, including the negative impact of 14.9% due to currency fluctuations. Sales in key emerging markets climbed 12.1% on an operational basis driven by growth in India, Russia and China. Abbott Labs successfully integrated the acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia in 2015.
The Medical Devices business generated sales of $1.3 billion, down 5.9% year over year. Sales at Diabetes Care, Vascular and Medical Optics businesses were down 5.2%, 7% and 4.1%, respectively. Sales of MitraClip increased in double digits. Abbott has filed Absorb for regulatory approval in Japan and the U.S. in 2015. Meanwhile, uptake of new cataract products in the premium intraocular lens segment was partially offset by market dynamics in the refractive business.
The Nutrition business increased 0.2% year over year to $1.8 billion. Pediatric Nutrition sales were up 3.7% on an operational basis. Growth was driven by strong demand for Eleva in the premium segment of the Chinese market and uptake of several recently launched non-GMO products in the U.S. Adult Nutrition sales increased 7.9%, led by growth of Ensure in the retail and institutional segments of the market.
Diagnostics business sales decreased 1.1% year over year to $1.2 billion. Core Laboratory and Molecular sales decreased 1.8% and 3.9%, respectively, while Point-of-Care Diagnostics sales grew 7.3%. Molecular Diagnostics sales in the U.S. were affected by the planned scale-down of the genetics business.
2015 Results
Full-year sales of $20.4 billion came in line with the Zacks Consensus Estimate. Sales in the emerging markets increased in double digits driven by growth in EPD, Diagnostics and Nutrition. Earnings per share of $2.15 were also in line with the Zacks Consensus Estimate.
2016 Outlook
Abbott Labs expects earnings per share in the range of $2.10 to $2.20 per share in 2016, including a significant decrease in contribution from Venezuelan operations as a result of challenging market conditions in the country. The current Zacks Consensus Estimate is $2.30.
Earnings per share for the first quarter are projected to be 38-40 cents, below the Zacks Consensus Estimate of 49 cents.
Our Take
Although the company beat on earnings, the revenue miss was disappointing. The Medical devices business continued to lag. Moreover, the guidance for 2016 was quite dismal too.
Abbott Labs currently has a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in the health care sector are Celgene Corp. CELG , Gilead Sciences GILD and Corcept Therapeutics CORT . All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
CORCEPT THERAPT (CORT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported fourth-quarter 2015 earnings of 62 cents per share, beating the Zacks Consensus Estimate by a penny but remaining flat year over year. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. The Quarter in Detail Abbott Labs operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported fourth-quarter 2015 earnings of 62 cents per share, beating the Zacks Consensus Estimate by a penny but remaining flat year over year. In the reported quarter, sales came in at $5.2 billion, down 3.1% year over year (on a reported basis) and missing the Zacks Consensus Estimate of $5.3 billion. | Abbott LaboratoriesABT reported fourth-quarter 2015 earnings of 62 cents per share, beating the Zacks Consensus Estimate by a penny but remaining flat year over year. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. In the reported quarter, sales came in at $5.2 billion, down 3.1% year over year (on a reported basis) and missing the Zacks Consensus Estimate of $5.3 billion. | Abbott LaboratoriesABT reported fourth-quarter 2015 earnings of 62 cents per share, beating the Zacks Consensus Estimate by a penny but remaining flat year over year. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. In the reported quarter, sales came in at $5.2 billion, down 3.1% year over year (on a reported basis) and missing the Zacks Consensus Estimate of $5.3 billion. |
33967.0 | 2016-01-28 00:00:00 UTC | Why Abbott Laboratories Is Getting Crushed Today | ABT | https://www.nasdaq.com/articles/why-abbott-laboratories-getting-crushed-today-2016-01-28 | nan | nan | What: Investors in Abbott Laboratories are having a rough day as shares of the diversified healthcare giant were down by as much as 10% as of 2:45 p.m. EST on much higher-than-normal trading volume after it released its fourth-quarter results.
So what: Sales at Abbott Laboratories came in a $5.2 billion for the quarter, down 3.1% from the year-ago period. Currencies appear to be the source of the decline as they lopped more than 8% off of its top line during the period, causing sales to come up a bit short of the $5.3 billion that many were expecting. The company managed to beat on the bottom line, as earnings per share came in at $0.62, which managed to beat expectations by $0.01.
Performance by business segment during the quarter on a currency-neutral basis looked decent. The company's established pharmaceutical-product division grew by a strong 10.9%, and its nutrition and diagnostics division also grew by mid-single digits. The company's medical-device segment managed to eke out a 0.7% gain. However, all of these gains turned to losses after adjusting for currencies.
The company offered up guidance for 2016 that failed to inspire investors. Management is forecasting that its adjusted 2016 earnings will land between $2.10 to 2.20 per share. That's a bit shy of the $2.26 that the market was looking for; if achieved, it would be flat with the $2.15 that it reported in 2015.
Add it all up, and shares were dumped today.
Now what: While the results were a bit disappointing, shares may be falling so much because Abbott just picked a bad day to report its earnings. The PowerShares Dynamic Pharmaceuticals ETF , an ETF that holds a collection of large pharmaceutical companies, is down by roughly 3% today, as well.
Zooming out and looking at the whole year, it looks like Abbott did just fine. On an operating basis, it grew sales by 9.1%, with an even stronger growth of 17.1% in emerging markets. Those results hint that its long-term strategy to focus on emerging markets is paying off, even if its reported results make it look like the company is standing still.
However, because Abbott's financial statements are so heavily influenced by currency movements, it's tough to know when the company will be able to get back into growth mode. With management predicting that its profitability is going to move sideways in 2016, it's hard for me to see how this stock will keep up with the PJP; so even after today's decline, I'm content to keep away from this stock for now.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Why Abbott Laboratories Is Getting Crushed Today originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What: Investors in Abbott Laboratories are having a rough day as shares of the diversified healthcare giant were down by as much as 10% as of 2:45 p.m. EST on much higher-than-normal trading volume after it released its fourth-quarter results. Currencies appear to be the source of the decline as they lopped more than 8% off of its top line during the period, causing sales to come up a bit short of the $5.3 billion that many were expecting. However, because Abbott's financial statements are so heavily influenced by currency movements, it's tough to know when the company will be able to get back into growth mode. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What: Investors in Abbott Laboratories are having a rough day as shares of the diversified healthcare giant were down by as much as 10% as of 2:45 p.m. EST on much higher-than-normal trading volume after it released its fourth-quarter results. | What: Investors in Abbott Laboratories are having a rough day as shares of the diversified healthcare giant were down by as much as 10% as of 2:45 p.m. EST on much higher-than-normal trading volume after it released its fourth-quarter results. The company managed to beat on the bottom line, as earnings per share came in at $0.62, which managed to beat expectations by $0.01. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. | The company managed to beat on the bottom line, as earnings per share came in at $0.62, which managed to beat expectations by $0.01. On an operating basis, it grew sales by 9.1%, with an even stronger growth of 17.1% in emerging markets. The Motley Fool has no position in any of the stocks mentioned. |
33968.0 | 2016-01-28 00:00:00 UTC | Abbott Labs (ABT) Tops Earnings in Q4 | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-tops-earnings-q4-2016-01-28 | nan | nan | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets.
Abbott Labs is expanding its pediatric nutrition portfolio through new product launches in the U.S. and the ex-U.S. markets. While the company is working on growing the adult nutrition business in the priority international markets, performance of this segment remains a matter of concern, mainly due to competition in the U.S.
Unfavorable movement in foreign currency rates is also affecting the top line adversely.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 5.5%.
Currently, Abbott Labs has a Zacks Rank #5 (Strong Sell). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings : Abbott Labs beat on earnings in fourth-quarter 2015 by a penny. Our consensus called for EPS of 61 cents per share, while the company reported EPS of 62 cents (from continuing operations excluding one-time items).
Revenue: Abbott Labs posted revenues of $5.2 billion was short of our expectations of $5.3 billion.
Key Stats : Foreign currency exchange rate movements negatively impacted sales by 8%. The company expects 2016 earnings per share in the range of $2.10 per share to $2.20 per share (excluding specified items).
Check back later for our full write up on this Abbott Labs earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Key Stats : Foreign currency exchange rate movements negatively impacted sales by 8%. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. We have highlighted some of the key stats from this just-revealed announcement below: Earnings : Abbott Labs beat on earnings in fourth-quarter 2015 by a penny. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. While the company is working on growing the adult nutrition business in the priority international markets, performance of this segment remains a matter of concern, mainly due to competition in the U.S. Unfavorable movement in foreign currency rates is also affecting the top line adversely. |
33969.0 | 2016-01-27 00:00:00 UTC | Will Currency Volatility Keep Hurting Abbott's (ABT) Earnings? | ABT | https://www.nasdaq.com/articles/will-currency-volatility-keep-hurting-abbotts-abt-earnings-2016-01-27 | nan | nan | Abbott LaboratoriesABT is scheduled to report fourth-quarter 2015 and full-year results before the opening bell on Jan 28, 2016.
Abbott Labs has an impressive track record with the company beating estimates in each of the trailing four quarters with an average earnings surprise of 5.55%. Let us see how things are shaping up for this announcement.
Will Currency Continue to Impact?
Although growth has slowed down in emerging markets, these economies still outpace the developing ones on the back of national policies that focus on expanding access to care; and favorable trends like increasing birth rates, aging populations, and adoption of western standards and technologies.
The nutrition business continues to drive revenues as the company expands its pediatric nutrition portfolio through product launches in the U.S. and ex-U.S. markets (including the launch of a non-GMO labeled formula, Similac Advance, in the U.S.; Eleva, in China). However, the adult nutrition business continues to be impacted by competition and market dynamics. On the other hand, the integration of CFR Pharmaceuticals boosted the established pharmaceuticals division (EPD).
For the fourth quarter, sales (on an operational basis) are expected to grow in the mid single digits. However, the top line may be adversely affected by currency fluctuation to the tune of 6.5%, leading to a sales decline in the low single digits. On a segmental basis, the company expects operational sale at the global nutritional business and diagnostic unit to grow in the mid single digits. Vascular sales are estimated to be relatively flat. The global diabetes care business is expected to grow in the low single digits on an operational basis. Growth at the medical optics business is anticipated to be in the mid single digits, while EPD is expected to continue generating low double-digit sales growth.
Concurrent with its third-quarter earnings release, Abbott Labs narrowed its full-year earnings per share outlook to $2.14-$2.16. Unfavorable movement in foreign currency rates will impact sales by about 8% in 2015.
What Our Model Indicates
Our proven model does not conclusively show that Abbott Labs is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. However, that is not the case here as you will see below.
Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -1.64%. This is because the Most Accurate estimate stands at 60 cents, while the Zacks Consensus Estimate is pegged higher at 61 cents.
Zacks Rank: Abbott Labs currently carries a Zacks Rank #4 (Sell). As it is, we caution against stocks with Sell-rated stocks (Zacks Rank #4 and #5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
AstraZeneca PLC AZN has an Earnings ESP of +24.32% and a Zacks Rank #2. The company is scheduled to report 2015 results on Feb 4.
Gilead Sciences Inc. GILD has an Earnings ESP of +2.75% and a Zacks Rank #1. The company will report fourth-quarter 2015 results on Feb 2.
AbbVie Inc. ABBV has an Earnings ESP of 0.88% and a Zacks Rank #3. The company is scheduled to report fourth-quarter 2015 results on Jan 29.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is scheduled to report fourth-quarter 2015 and full-year results before the opening bell on Jan 28, 2016. Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs has an impressive track record with the company beating estimates in each of the trailing four quarters with an average earnings surprise of 5.55%. | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report fourth-quarter 2015 and full-year results before the opening bell on Jan 28, 2016. On a segmental basis, the company expects operational sale at the global nutritional business and diagnostic unit to grow in the mid single digits. | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report fourth-quarter 2015 and full-year results before the opening bell on Jan 28, 2016. Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -1.64%. | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report fourth-quarter 2015 and full-year results before the opening bell on Jan 28, 2016. Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -1.64%. |
33970.0 | 2016-01-27 00:00:00 UTC | Pre-Market Earnings Report for January 28, 2016 : MO, BMY, LLY, CELG, BABA, ABT, TMO, TWC, NEE, F, EPD, RTN | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-january-28-2016-mo-bmy-lly-celg-baba-abt-tmo-twc-nee-f-epd-rtn | nan | nan | The following companies are expected to report earnings prior to market open on 01/28/2016. Visit our Earnings Calendar for a full list of expected earnings releases.
Altria Group ( MO ) is reporting for the quarter ending December 31, 2015. The tobacco company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.68. This value represents a 3.03% increase compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for MO is 20.98 vs. an industry ratio of 21.40.
Bristol-Myers Squibb Company ( BMY ) is reporting for the quarter ending December 31, 2015. The large cap pharmaceutical company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.27. This value represents a 41.30% decrease compared to the same quarter last year. In the past year BMY has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 11.43%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BMY is 32.99 vs. an industry ratio of 61.80.
Eli Lilly and Company ( LLY ) is reporting for the quarter ending December 31, 2015. The large cap pharmaceutical company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.77. This value represents a 2.67% increase compared to the same quarter last year. In the past year LLY has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 17.11%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for LLY is 23.96 vs. an industry ratio of 61.80.
Celgene Corporation ( CELG ) is reporting for the quarter ending December 31, 2015. The biomedical (gene) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $1.02. This value represents a 12.09% increase compared to the same quarter last year. In the past year CELG has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for CELG is 25.73 vs. an industry ratio of -19.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Alibaba Group Holding Limited ( BABA ) is reporting for the quarter ending December 31, 2015. The internet company's consensus earnings per share forecast from the 17 analysts that follow the stock is $0.70. This value represents a 27.27% increase compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BABA is 39.42 vs. an industry ratio of 20.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2015. The large cap pharmaceutical company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.61. This value represents a 14.08% decrease compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 1.89%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 18.68 vs. an industry ratio of 61.80.
Thermo Fisher Scientific Inc ( TMO ) is reporting for the quarter ending December 31, 2015. The medical instruments company's consensus earnings per share forecast from the 13 analysts that follow the stock is $2.11. This value represents a 6.03% increase compared to the same quarter last year. In the past year TMO has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 0.56%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for TMO is 18.17 vs. an industry ratio of -5.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Time Warner Cable Inc ( TWC ) is reporting for the quarter ending December 31, 2015. The cable tv company's consensus earnings per share forecast from the 13 analysts that follow the stock is $1.78. This value represents a 12.32% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for TWC is 27.48 vs. an industry ratio of -94.50, implying that they will have a higher earnings growth than their competitors in the same industry.
NextEra Energy, Inc. ( NEE ) is reporting for the quarter ending December 31, 2015. The electric power utilities company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.11. This value represents a 7.77% increase compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for NEE is 18.83 vs. an industry ratio of 19.70.
Ford Motor Company ( F ) is reporting for the quarter ending December 31, 2015. The auto (domestic) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.49. This value represents a 88.46% increase compared to the same quarter last year. F missed the consensus earnings per share in the 1st calendar quarter of 2015 by -8%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for F is 7.09 vs. an industry ratio of -2.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Enterprise Products Partners L.P. ( EPD ) is reporting for the quarter ending December 31, 2015. The oil/gas company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.35. This value represents a 2.78% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for EPD is 17.35 vs. an industry ratio of 14.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Raytheon Company ( RTN ) is reporting for the quarter ending December 31, 2015. The aerospace and defense company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.79. This value represents a 3.76% decrease compared to the same quarter last year. In the past year RTN has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 5%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for RTN is 17.81 vs. an industry ratio of 6.90, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2015. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 18.68 vs. an industry ratio of 61.80. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2015. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 18.68 vs. an industry ratio of 61.80. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2015. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 18.68 vs. an industry ratio of 61.80. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2015. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 18.68 vs. an industry ratio of 61.80. |
33971.0 | 2016-01-27 00:00:00 UTC | Which Of The Latest 13F Filers Holds Abbott Laboratories? | ABT | https://www.nasdaq.com/articles/which-latest-13f-filers-holds-abbott-laboratories-2016-01-27 | nan | nan | At Holdings Channel , we have reviewed the latest batch of the 20 most recent 13F filings for the 12/31/2015 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 12 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen .
Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers:
In terms of shares owned, we count all 8 of the above funds having decreased their positions from 09/30/2015 to 12/31/2015.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 12/31/2015 reporting period (out of the 623 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 09/30/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. We found that between these two periods, funds reduced their holdings by 2,433,919 shares in the aggregate, from 40,666,048 down to 38,232,129 for a share count decline of approximately -5.99%. The overall top three funds holding ABT on 12/31/2015 were:
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT).
10 S&P 500 Components Hedge Funds Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At Holdings Channel , we have reviewed the latest batch of the 20 most recent 13F filings for the 12/31/2015 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 12 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT). Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count all 8 of the above funds having decreased their positions from 09/30/2015 to 12/31/2015. | At Holdings Channel , we have reviewed the latest batch of the 20 most recent 13F filings for the 12/31/2015 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 12 of these funds. We then compared that number to the sum total of ABT shares those same funds held back at the 09/30/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count all 8 of the above funds having decreased their positions from 09/30/2015 to 12/31/2015. | Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 12/31/2015 reporting period (out of the 623 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 09/30/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 12/31/2015 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. | We then compared that number to the sum total of ABT shares those same funds held back at the 09/30/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 12/31/2015 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel , we have reviewed the latest batch of the 20 most recent 13F filings for the 12/31/2015 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 12 of these funds. |
33972.0 | 2016-01-26 00:00:00 UTC | IUSV, C, CSCO, ABT: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iusv-c-csco-abt-large-outflows-detected-etf-2016-01-26 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core U.S. Value ETF (Symbol: IUSV) where we have detected an approximate $69.2 million dollar outflow -- that's a 9.3% decrease week over week (from 6,450,000 to 5,850,000). Among the largest underlying components of IUSV, in trading today Citigroup Inc (Symbol: C) is up about 1.7%, Cisco Systems, Inc. (Symbol: CSCO) is up about 1.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.9%. For a complete list of holdings, visit the IUSV Holdings page » The chart below shows the one year price performance of IUSV, versus its 200 day moving average:
Looking at the chart above, IUSV's low point in its 52 week range is $84.01 per share, with $139.04 as the 52 week high point - that compares with a last trade of $116.94. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSV, in trading today Citigroup Inc (Symbol: C) is up about 1.7%, Cisco Systems, Inc. (Symbol: CSCO) is up about 1.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.9%. For a complete list of holdings, visit the IUSV Holdings page » The chart below shows the one year price performance of IUSV, versus its 200 day moving average: Looking at the chart above, IUSV's low point in its 52 week range is $84.01 per share, with $139.04 as the 52 week high point - that compares with a last trade of $116.94. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IUSV, in trading today Citigroup Inc (Symbol: C) is up about 1.7%, Cisco Systems, Inc. (Symbol: CSCO) is up about 1.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.9%. For a complete list of holdings, visit the IUSV Holdings page » The chart below shows the one year price performance of IUSV, versus its 200 day moving average: Looking at the chart above, IUSV's low point in its 52 week range is $84.01 per share, with $139.04 as the 52 week high point - that compares with a last trade of $116.94. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IUSV, in trading today Citigroup Inc (Symbol: C) is up about 1.7%, Cisco Systems, Inc. (Symbol: CSCO) is up about 1.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core U.S. Value ETF (Symbol: IUSV) where we have detected an approximate $69.2 million dollar outflow -- that's a 9.3% decrease week over week (from 6,450,000 to 5,850,000). For a complete list of holdings, visit the IUSV Holdings page » The chart below shows the one year price performance of IUSV, versus its 200 day moving average: Looking at the chart above, IUSV's low point in its 52 week range is $84.01 per share, with $139.04 as the 52 week high point - that compares with a last trade of $116.94. | Among the largest underlying components of IUSV, in trading today Citigroup Inc (Symbol: C) is up about 1.7%, Cisco Systems, Inc. (Symbol: CSCO) is up about 1.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.9%. For a complete list of holdings, visit the IUSV Holdings page » The chart below shows the one year price performance of IUSV, versus its 200 day moving average: Looking at the chart above, IUSV's low point in its 52 week range is $84.01 per share, with $139.04 as the 52 week high point - that compares with a last trade of $116.94. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33973.0 | 2016-01-24 00:00:00 UTC | Experienced Insider Continues to Buy Absolute Software | ABT | https://www.nasdaq.com/articles/experienced-insider-continues-buy-absolute-software-2016-01-24 | nan | nan | Ian J. Giffen is a director at Absolute Software Corp. ( ABT ), which he joined in 2008. He previously served as vice president at Alias Research Inc. as well as an advisor for several private venture investment funds. Giffen holds a degree in business administration from the University of Strathclyde in Glasgow.
In two purchases during December 2015, Giffen purchased 10,000 shares in Absolute Software Corp.
Absolute Software provides security and data risk management solutions for computers, tablets, and smartphones. The company operates with the understanding that data is a company's most valuable asset.
Warning! GuruFocus has detected 2 Warning Signs with AMZN. Click here to check it out.
AMZN 15-Year Financial Data
The intrinsic value of AMZN
Peter Lynch Chart of AMZN
Warning! GuruFocus has detected 5 Warning Signs with NCMI. Click here to check it out.
NCMI 15-Year Financial Data
The intrinsic value of NCMI
Peter Lynch Chart of NCMI
Warning! GuruFocus has detected 5 Warning Signs with NCMI. Click here to check it out.
AXP 15-Year Financial Data
The intrinsic value of AXP
Peter Lynch Chart of AXP
Warning! GuruFocus has detected 1 Warning Sign with BNED. Click here to check it out.
BNED 15-Year Financial Data
The intrinsic value of BNED
Peter Lynch Chart of BNED
Warning! GuruFocus has detected 1 Warning Sign with BNED. Click here to check it out.
TSX:ABT 15-Year Financial Data
The intrinsic value of TSX:ABT
Peter Lynch Chart of TSX:ABT
Absolute Software has a market cap of $296.85 million, a P/E ratio of 47.80, an enterprise value of $217.52 million and a dividend yield of 3.28.
Below is a Peter Lynch chart for Absolute Software Corp.
According to GuruFocus, Absolute Software has a financial strength rating of 8/10 and no debt, which is a great sign for investors. The company also has a dividend yield that is close to a 10-year high and a Piotroski F-Score rating of 7, which indicates a healthy financial situation.
I believe that Griffin is making a good investment with his fourth quarter purchases in Absolute Software.
Disclaimer: Author does not currently hold any shares in this stock.
Cheers to your investment success.
Read More:
Weitz Funds Comments on Allergan
Wallace Weitz Comments on Avon Products
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ian J. Giffen is a director at Absolute Software Corp. ( ABT ), which he joined in 2008. TSX:ABT 15-Year Financial Data The intrinsic value of TSX:ABT Peter Lynch Chart of TSX:ABT Absolute Software has a market cap of $296.85 million, a P/E ratio of 47.80, an enterprise value of $217.52 million and a dividend yield of 3.28. He previously served as vice president at Alias Research Inc. as well as an advisor for several private venture investment funds. | TSX:ABT 15-Year Financial Data The intrinsic value of TSX:ABT Peter Lynch Chart of TSX:ABT Absolute Software has a market cap of $296.85 million, a P/E ratio of 47.80, an enterprise value of $217.52 million and a dividend yield of 3.28. Ian J. Giffen is a director at Absolute Software Corp. ( ABT ), which he joined in 2008. AMZN 15-Year Financial Data The intrinsic value of AMZN Peter Lynch Chart of AMZN Warning! | TSX:ABT 15-Year Financial Data The intrinsic value of TSX:ABT Peter Lynch Chart of TSX:ABT Absolute Software has a market cap of $296.85 million, a P/E ratio of 47.80, an enterprise value of $217.52 million and a dividend yield of 3.28. Ian J. Giffen is a director at Absolute Software Corp. ( ABT ), which he joined in 2008. NCMI 15-Year Financial Data The intrinsic value of NCMI Peter Lynch Chart of NCMI Warning! | Ian J. Giffen is a director at Absolute Software Corp. ( ABT ), which he joined in 2008. TSX:ABT 15-Year Financial Data The intrinsic value of TSX:ABT Peter Lynch Chart of TSX:ABT Absolute Software has a market cap of $296.85 million, a P/E ratio of 47.80, an enterprise value of $217.52 million and a dividend yield of 3.28. Below is a Peter Lynch chart for Absolute Software Corp. |
33974.0 | 2016-01-05 00:00:00 UTC | VIG, MDT, MMM, ABT: ETF Outflow Alert | ABT | https://www.nasdaq.com/articles/vig-mdt-mmm-abt-etf-outflow-alert-2016-01-05 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $122.6 million dollar outflow -- that's a 0.6% decrease week over week (from 248,780,110 to 247,181,138). Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is trading flat, 3M Co (Symbol: MMM) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $76.65. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is trading flat, 3M Co (Symbol: MMM) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $76.65. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is trading flat, 3M Co (Symbol: MMM) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $76.65. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is trading flat, 3M Co (Symbol: MMM) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $122.6 million dollar outflow -- that's a 0.6% decrease week over week (from 248,780,110 to 247,181,138). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $76.65. | Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is trading flat, 3M Co (Symbol: MMM) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $76.65. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33975.0 | 2015-12-19 00:00:00 UTC | These Stocks Just Raised Their Dividends | ABT | https://www.nasdaq.com/articles/these-stocks-just-raised-their-dividends-2015-12-19 | nan | nan | Income investors will find it hard to bid goodbye to 2015. The year was stuffed full of dividend raises, with a great number of stocks hiking their payouts, in many cases substantially.
Luckily for us dividend lovers, we still have a bit of time before 2015 comes to a close. Last week, entirely in character, the market graced us with a healthy set of increases; as usual, I've selected three notables for this installment. Here's to hoping we get a last batch of raisers before popping open the New Year's Eve Champagne.
MasterCard
Ring up another dividend hike for purchase card processing giant MasterCard , which last week increased its quarterly payout by 19%, to $0.19 per share.
That sounds major, but it's actually a fairly modest raise by the company's usual standards. It tends to hike its dividend every year around this time, and previous increases have been higher. Last year's was 45%, while the company doubled the payout in 2013.
High and sustained profitability helps fuel these growing dividends. In its Q3, MasterCard maintained its top and bottom lines despite a strong U.S. dollar that has sapped growth for some American multinationals. The company kept net profit more or less steady at $977 million (from Q3 2014's $1 billion), while incrementally upping its revenue to $2.5 billion.
The company's free cash flow is very robust, over $3.2 billion in fiscal 2014, but it dispensed a comparatively light $515 million in total dividends that year. This equated to a very low cash dividend payout ratio (the percentage of free cash flow used for distributions) in the mid-teens.
MA Cash Dividend Payout Ratio (Annual) data by YCharts .
All in all, even at the new, raised amount, MasterCard's distribution yields a wafer-thin 0.8%. That's well below the current 2.1% average yield of stocks on the S&P 500 index. So investors shouldn't worry at all about the sustainability of that payout. After all, it's rather miserly when taking into account the company's considerable financial resources.
MasterCard's new dividend is to be paid next Feb. 9 to stockholders of record as of the preceding Jan. 8.
Abbott Laboratories
This sturdy pharmaceutical giant is a Dividend Aristocrat, one of the very few stocks that have raised their payout at least once annually for a minimum of 25 years consecutively. Abbott Laboratories ' latest quarterly dividend hike is its 44th in a row (when taking its 2013 spin-off of AbbVie into account), and shakes out in an 8% raise, to $0.26 per share.
ABT Dividend data by YCharts .
Like MasterCard, Abbott Laboratories has proven to be very resilient in foreign markets. In fact, it was revenue from abroad that pushed the top line incrementally higher on a year-over-year basis (to $5.2 billion) in the most recently reported quarter. Key foreign locales such as Russia, India, Brazil, and China turned in growth for the company.
Meanwhile, the bottom line saw a bigger advance, by nearly 8% to $580 million. Both line items beat average analyst estimates.
Over the years, the company has traditionally been fairly conservative in its cash management, disbursing 50% or less of its annual free cash flow as dividends. I see no reason to believe it will quit the habit; this tendency, combined with those improving results, should allow Abbot Laboratories to keep up those annual dividend hikes well into the foreseeable future.
The company's next distribution will be handed out next Feb. 16 to stockholders of record as of Jan. 15, 2016.
Elsewhere in the pharmaceutical sector, Eli Lilly declared a comparatively modest raise in its quarterly dividend, by 2% to $0.51 per share.
That caution makes sense because, on the back of key patent expirations (among other blows), the company has had its struggles. In fiscal 2014, for example, the company's revenue slid by 15% to land at just under $20 billion. Net income suffered a queasier decline, by nearly 50% to $2.4 billion.
Meanwhile, Eli Lilly's annual cash dividend payout ratio has climbed to a relatively high 73%, after several years of hovering in the 45% to 55% range. Peer pharmas such as Abbott Laboratories have more successfully managed to stay within or below that latter band.
LLY Cash Dividend Payout Ratio (Annual) data by YCharts .
That's not to say the future is necessarily gloomy. Eli Lilly has several promising treatments in the pipeline, such a potential blockbuster it's developing to fight Alzheimer's that's shown some encouraging results (albeit with a setback or several) in recent clinical trials.
So, better times probably lie ahead for the company. I think its results will improve, and hence that cash dividend payout ratio will come down to levels more typical of the broader pharma sector. Hopefully, this will fuel more substantial raises to the dividend in the future, keeping the company on pace with some of its fellow big pharma players.
Eli Lilly's new dividend is to be paid next March 10 to shareholders of record as of Feb. 12.
The $15,978 Social Security bonus most retirees completely overlook
If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. In fact, one MarketWatch reporter argues that if more Americans knew about this, the government would have to shell out an extra $10 billion annually. For example: one easy, 17-minute trick could pay you as much as $15,978 more... each year! Once you learn how to take advantage of all these loopholes, we think you could retire confidently with the peace of mind we're all after. Simply click here to discover how you can take advantage of these strategies.
The article These Stocks Just Raised Their Dividends originally appeared on Fool.com.
Eric Volkman has no position in any stocks mentioned. The Motley Fool owns shares of and recommends MasterCard. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT Dividend data by YCharts . In fact, it was revenue from abroad that pushed the top line incrementally higher on a year-over-year basis (to $5.2 billion) in the most recently reported quarter. I see no reason to believe it will quit the habit; this tendency, combined with those improving results, should allow Abbot Laboratories to keep up those annual dividend hikes well into the foreseeable future. | ABT Dividend data by YCharts . MA Cash Dividend Payout Ratio (Annual) data by YCharts . Meanwhile, Eli Lilly's annual cash dividend payout ratio has climbed to a relatively high 73%, after several years of hovering in the 45% to 55% range. | ABT Dividend data by YCharts . The company's free cash flow is very robust, over $3.2 billion in fiscal 2014, but it dispensed a comparatively light $515 million in total dividends that year. Abbott Laboratories This sturdy pharmaceutical giant is a Dividend Aristocrat, one of the very few stocks that have raised their payout at least once annually for a minimum of 25 years consecutively. | ABT Dividend data by YCharts . Abbott Laboratories ' latest quarterly dividend hike is its 44th in a row (when taking its 2013 spin-off of AbbVie into account), and shakes out in an 8% raise, to $0.26 per share. Meanwhile, Eli Lilly's annual cash dividend payout ratio has climbed to a relatively high 73%, after several years of hovering in the 45% to 55% range. |
33976.0 | 2015-12-17 00:00:00 UTC | Zoetis (ZTS) Declares 14.5% Hike in Quarterly Dividend | ABT | https://www.nasdaq.com/articles/zoetis-zts-declares-14.5-hike-in-quarterly-dividend-2015-12-17 | nan | nan | Zoetis Inc.ZTS declared an increase of 14.5% in its quarterly dividend. The company announced a dividend of $0.095 per share for the first quarter of 2016, payable on Mar 1, 2016, to shareholders of record as on Jan 21, 2016. This represents an increase from $0.083 per share paid in each of the previous four quarters.
The new quarterly dividend comes to about 38 cents per share on a yearly basis, reflecting a forward yield of nearly 0.8% based on the raised dividend and the stock's last closing price of $47.09 (Dec 16, 2015).
The increase in dividend is in line with the company's strategy of returning excess capital to shareholders. In Dec 2014, the board of directors at Zoetis approved a 15% increase in the quarterly dividend to $0.083 per share. We are encouraged by the company's policy to reward shareholders through regular dividends.
Meanwhile, the company continues to pursue lucrative internal and external growth opportunities. Zoetis acquired Abbott Laboratories' ABT animal health assets for $255 million. This business is focused on the veterinary surgical market. It will strengthen Zoetis' pain portfolio and sedation product portfolio and complement its diagnostic business. The company also acquired PHARMAQ in a bid to strengthen its core livestock business. We expect to see more of such acquisitions/deals at Zoetis in the near future, as the company continues to focus on its strategy of acquiring complementary businesses and products.
Zoetis currently carries a Zacks Rank #3 (Hold). A couple of other well-ranked stocks in the health care sector are Achillion Pharmaceuticals, Inc. ACHN and Corcept Therapeutics Incorporated CORT , both sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
CORCEPT THERAPT (CORT): Free Stock Analysis Report
ACHILLION PHARM (ACHN): Free Stock Analysis Report
ZOETIS INC (ZTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Zoetis acquired Abbott Laboratories' ABT animal health assets for $255 million. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The company announced a dividend of $0.095 per share for the first quarter of 2016, payable on Mar 1, 2016, to shareholders of record as on Jan 21, 2016. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis acquired Abbott Laboratories' ABT animal health assets for $255 million. Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis acquired Abbott Laboratories' ABT animal health assets for $255 million. The new quarterly dividend comes to about 38 cents per share on a yearly basis, reflecting a forward yield of nearly 0.8% based on the raised dividend and the stock's last closing price of $47.09 (Dec 16, 2015). | Zoetis acquired Abbott Laboratories' ABT animal health assets for $255 million. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The company announced a dividend of $0.095 per share for the first quarter of 2016, payable on Mar 1, 2016, to shareholders of record as on Jan 21, 2016. |
33977.0 | 2015-12-11 00:00:00 UTC | Daily Dividend Report: ABT, EIX, WPC, GE, LII, FMC, PNY | ABT | https://www.nasdaq.com/articles/daily-dividend-report-abt-eix-wpc-ge-lii-fmc-pny-2015-12-11 | nan | nan | Abbott ( ABT ) increased the company's quarterly dividend to 26 cents per share from 24 cents per share. The cash dividend is payable Feb. 16, 2016, to shareholders of record at the close of business on Jan. 15, 2016.
Edison International ( EIX ) declared a quarterly common stock dividend of $0.48 per share, payable on January 31, 2016, to shareholders of record on December 31, 2015. This action increases the annual dividend rate by 15 percent, from $1.67 per share to $1.92 per share.
W. P. Carey ( WPC ) increased its quarterly cash dividend to $0.9646 per share, equivalent to an annualized dividend rate of $3.86 per share. The dividend is payable on January 15, 2016, to stockholders of record as of December 31, 2015.
GE declared a $0.23 per share dividend on the outstanding common stock of the Company payable January 25, 2016 to shareowners of record at the close of business on December 21, 2015. The ex-dividend date is December 17, 2015.
Lennox International ( LII ) voted to declare a quarterly cash dividend of $0.36 per share of common stock. The dividend is payable on January 15, 2016, to stockholders of record as of December 31, 2015.
FMC Corporation ( FMC ) declared a regular quarterly dividend of 16.5 cents per share, payable on January 21, 2016, to shareholders of record at the close of business on December 31, 2015.
Piedmont Natural Gas (PNY) announced the declaration of a quarterly dividend on Common Stock of 33 cents per share, payable January 15, 2016, to holders of record at the close of business on December 2 | Abbott ( ABT ) increased the company's quarterly dividend to 26 cents per share from 24 cents per share. Edison International ( EIX ) declared a quarterly common stock dividend of $0.48 per share, payable on January 31, 2016, to shareholders of record on December 31, 2015. GE declared a $0.23 per share dividend on the outstanding common stock of the Company payable January 25, 2016 to shareowners of record at the close of business on December 21, 2015. | Abbott ( ABT ) increased the company's quarterly dividend to 26 cents per share from 24 cents per share. Edison International ( EIX ) declared a quarterly common stock dividend of $0.48 per share, payable on January 31, 2016, to shareholders of record on December 31, 2015. FMC Corporation ( FMC ) declared a regular quarterly dividend of 16.5 cents per share, payable on January 21, 2016, to shareholders of record at the close of business on December 31, 2015. | Abbott ( ABT ) increased the company's quarterly dividend to 26 cents per share from 24 cents per share. Edison International ( EIX ) declared a quarterly common stock dividend of $0.48 per share, payable on January 31, 2016, to shareholders of record on December 31, 2015. FMC Corporation ( FMC ) declared a regular quarterly dividend of 16.5 cents per share, payable on January 21, 2016, to shareholders of record at the close of business on December 31, 2015. | Abbott ( ABT ) increased the company's quarterly dividend to 26 cents per share from 24 cents per share. Edison International ( EIX ) declared a quarterly common stock dividend of $0.48 per share, payable on January 31, 2016, to shareholders of record on December 31, 2015. GE declared a $0.23 per share dividend on the outstanding common stock of the Company payable January 25, 2016 to shareowners of record at the close of business on December 21, 2015. |
33978.0 | 2015-12-07 00:00:00 UTC | Health Care Select Sector SPDR Fund Experiences Big Outflow | ABT | https://www.nasdaq.com/articles/health-care-select-sector-spdr-fund-experiences-big-outflow-2015-12-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $175.9 million dollar outflow -- that's a 1.3% decrease week over week (from 194,115,324 to 191,665,324). Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Express Scripts Holding Co (Symbol: ESRX) is off about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $71.31. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Express Scripts Holding Co (Symbol: ESRX) is off about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $175.9 million dollar outflow -- that's a 1.3% decrease week over week (from 194,115,324 to 191,665,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Express Scripts Holding Co (Symbol: ESRX) is off about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.6%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $71.31. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Express Scripts Holding Co (Symbol: ESRX) is off about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $175.9 million dollar outflow -- that's a 1.3% decrease week over week (from 194,115,324 to 191,665,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $71.31. | Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Express Scripts Holding Co (Symbol: ESRX) is off about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $175.9 million dollar outflow -- that's a 1.3% decrease week over week (from 194,115,324 to 191,665,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $71.31. |
33979.0 | 2015-12-04 00:00:00 UTC | Zacks Industry Outlook Highlights: Bayer, Abbott Laboratories, Roche Holding, Medtronic and Johnson & Johnson | ABT | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-bayer-abbott-laboratories-roche-holding-medtronic-and-0 | nan | nan | Chicago, IL - December 04, 2015 - Today, Zacks Equity Research discusses the MedTech (Part 1), including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Roche Holding AG ( RHHBY ), Medtronic plc ( MDT ) and Johnson & Johnson ( JNJ ).
Industry: MedTech (Part 1)
Link: http://www.zacks.com/ commentary/63962/medtech- industry-stock-outlook---dec- 2015
Despite the socio-economic and political instability prevailing in most geographic markets at present, the MedTech industry overall has so far witnessed a positive run in 2015. While the global economy has been through a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend. Its powerful long-term tailwinds, including mergers & acquisitions, emerging market expansion, positive demographic trends and new product innovation, have been the vital force behind the rise.
Impressive Prospects Ahead
According to a survey by EvaluateMedTech World Preview, the MedTech space is positioned for impressive growth in the near term. This should compel investors to keep an eye out on the sector that is generally not in the limelight from the investment perspective.
At a glance, Medtech sales worldwide are expected to grow at a CAGR of 4.1% to $478 billion by 2020. Steering ahead of Cardiology and Diagnostics, In Vitro Diagnostics (IVD) is expected to emerge as the sector leader. Neurology, meanwhile, holds promise as the fastest growing division among the top 15 segments by 2020. On the other hand, Orthopedics, which is already going downhill, may prove to be one of the slowest growing segments in 2020 with a CAGR of 3.2% per year.
Changing Trends in MedTech
Investors interested in the Medical Devices industry generally keep analyzing existing trends - like longer life expectancies, mergers and acquisitions, emerging market opportunities, increased regulatory scrutiny and health care reforms. However, here are some of the emerging trends that one should also take into account, as these might eventually transform the prospects of the industry.
Evolving Home Medical Devices Market: With growing awareness, self-health care has become one of the driving forces within the home medical devices market. A recent report published in mddionline.com states that the global home healthcare market will reach $303.6 billion by 2020, up over 70% from $176.1 billion in 2013. Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health, among others.
3D Printing Redefining Personalized Care: The global medical 3D printing market (dental, medical prosthetic, orthopedic and surgical instruments) is estimated to reach $983.2 million by 2020 with an impressive CAGR of 20.3%, per Meticulous Research. Companies likely to rule this market include Stratasys Ltd and 3D Systems, Inc.
Mobile Applications Gaining Popularity: Currently, more than 500 million smartphone users worldwide sport health-related apps on their mobile devices and the number is projected to climb to more than 1.7 billion by 2018. This indicates enormous opportunity in this segment.
In Vitro Diagnostics to Dominate: According to a survey by EvaluateMedTech World Preview, IVD is expected to emerge as the sector leader by 2020 (14% of the total medical device market) with sales of $71.6 billion reflecting annual growth of 6.1%. Roche Holding AG ( RHHBY ) is expected to lead this space with a 17% market share and sales of $12.20 billion by 2020.
Evolving trends, however, do not have to mean that earlier trends like the reliance on emerging markets are no longer valid. While economists are not naturally enthusiastic about the near-term prospects of currently troubled nations like Brazil, Russia and China, the appointment of promising political groups in India and Indonesia ensures that reform tops the economic agenda of both these countries.
Per a 'Fortune' report by Ian Bremmer, along with Malaysia, these two nations are blessed with less socio-political conflict now. Besides, investors are looking forward to the set of fresh stimulus, offered by the People's Bank of China (PBoC) with the hope that market prospects in China will improve in 2016.
Healthy Stocks in the MedTech Family
With the $43 billion acquisition of its Irish rival Covidien, Medtronic plc ( MDT ) has changed the medical device landscape. The combination of these two medical giants, apart from creating yet another leader of small and medium-sized device makers, has stirred up competition for Johnson & Johnson ( JNJ ), which is still the industry monarch in terms of revenues.
While Medtronic enjoys a competitive edge with its huge and growing Cardiac and Vascular portfolio, J&J's forte lies in the orthopedic space, which is unfortunately not gaining much traction among investors (CAGR of 2.4% between 2014 and 2020, lower than the expected market growth rate).
However, unlike Medtronic, J&J is not solely dependent on MedTech, thanks to its pharmaceutical division whose scale of growth Medtronic can barely replicate in the near future (according to an article in The Motley Fool by Dan Carroll). Nevertheless, both the stocks are great picks based on their solid dividend history, strong cash flow and core business expertise.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Chicago, IL - December 04, 2015 - Today, Zacks Equity Research discusses the MedTech (Part 1), including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Roche Holding AG ( RHHBY ), Medtronic plc ( MDT ) and Johnson & Johnson ( JNJ ). Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health, among others. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. | Chicago, IL - December 04, 2015 - Today, Zacks Equity Research discusses the MedTech (Part 1), including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Roche Holding AG ( RHHBY ), Medtronic plc ( MDT ) and Johnson & Johnson ( JNJ ). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health, among others. | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Chicago, IL - December 04, 2015 - Today, Zacks Equity Research discusses the MedTech (Part 1), including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Roche Holding AG ( RHHBY ), Medtronic plc ( MDT ) and Johnson & Johnson ( JNJ ). Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health, among others. | Chicago, IL - December 04, 2015 - Today, Zacks Equity Research discusses the MedTech (Part 1), including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Roche Holding AG ( RHHBY ), Medtronic plc ( MDT ) and Johnson & Johnson ( JNJ ). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health, among others. |
33980.0 | 2015-12-01 00:00:00 UTC | Short Iradimed: Don't Underestimate Lingering FDA Risk To The Company's Single-Product Growth Story | ABT | https://www.nasdaq.com/articles/short-iradimed-dont-underestimate-lingering-fda-risk-companys-single-product-growth-story | nan | nan | By True Intrinsic Value :
Please also see the below article from the New York Times:
FDA Steps Up Oversight of Infusion Pumps
Business
Iradimed ( IRMD ) is a single product medical device company focused on non-magnetic intravenous (IV) infusion pump systems which allow for the administration of medication to patients during the course of an MRI procedure. Today, the company generates all of its revenue from a single product.
FDA Issues and Developments
In September 2014, shortly after going public in July 2014, Iradimed received a warning letter from the FDA regarding its failure to file an updated 510(k) when the company updated the code in its software for the IV pump. According to a press release put out by the company:
The FDA also requested the company stop shipping its pump in the United States at the time of the letter. The company eventually filed a submission for pre-market notification under section 510(k) in an effort to gain approval to resume domestic pump shipments.
On December 22, 2014, the company began to resume pumps sales in the United States as the FDA reviewed its 510(k) submission.
Current Situation
Today, the company has yet to fully clear the warning letter it received well over a year ago from the FDA. Management has underestimated the amount of time that it would take to clear the letter on a number of different occasions.
On the company's most recent Q3 earnings call, management stated that it believes it should receive final clearance in the first quarter of 2016. Given its repeated misjudgments on the timing of this clearance, we do not believe that management has much credibility in being able to judge when the letter will actually be cleared.
If the letter is not cleared in the first half of 2016, it could materially delay the launch of any new products from the company, specifically a monitoring device it has been developing, which unlike its current product faces direct competition from InVivo ( NVIV ). Investors are carelessly ignoring that this product cannot be sold until the warning letter is cleared. If the company cannot launch a new device, then it could materially reduce the amount of revenue the company is capable of generating in future periods, thus making it significantly less attractive on a price-to-sales basis, particularly if management were to eventually sell the company to a strategic acquirer.
Additionally and more importantly, if the FDA is ultimately not satisfied with the due diligence the company conducts on Iradimed's MRI infusion pump and its compliance procedures, the FDA ultimately reserves the right to block future shipments or even request a recall of Iradimed's products in the field. As we have witnessed previously, the FDA has begun aggressively sanctioning infusion pumps given the inherent safety issues with products in this market.
In November of 2014, the FDA issued a third product recall of the Hospira (HSP) GemStar infusion pumps. As a result of product recalls and poor safety issues, the FDA required Hospira to retire its GemStar and Symbiq pumps at a cost of more than $300 million to the company. In addition Medrad, an Iradimed competitor, also ran into multiple issues with the FDA including at least two product recalls. Ultimately, given the difficulties with the FDA, Medrad chose to withdraw from the infusion pump market.
Additionally, Baxter ( BAX ) was forced to recall the Sigma Spectrum Infusion Pump in February 2014 after receiving 3,500 reports of a system error malfunction. The recalled infusion pumps were distributed between February 20, 2013, and January 15, 2014. Baxter initiated the recall in February. The FDA has designated the action a Class I recall, the most serious type. Additionally, the FDA made a further infusion pump recall on October 31, 2013, when it made Abbott ( ABT ) recall its Acclaim Infusion Pumps and Hospira recall its Acclaim Encore Infusion Pumps.
In Q4 of 2013, Medrad issued a major recall based on software errors within the pump in addition to tubing failures. The software errors have resulted in the pump inadvertently shutting down, inaccurate flow rates and broken tubing, all of which are potential risks to the patient.
On March 21, 2014, the FDA released a report of medical device recalls from 2003 and 2012. The FDA found the total overall count of medical device events increased 97%.
(click to enlarge)
The agency says it has received reports of 710 patient deaths linked to problems with the devices, though FDA officials say they think the number may be significantly higher. Some of those deaths involved patients who suffered drug overdoses accidentally, either because a hospital worker entered incorrect dosage data into a pump or because the device's software malfunctioned. There are an estimated two million infusion pumps used in hospital and clinical settings and hundreds of thousands more used by patients in their homes. The pumps use a variety of designs to intravenously deliver food, fluids and drugs like pain medications , insulin and cancer treatments.
The pump-related initiative comes as the Obama administration tries to reinvigorate the FDA after years of criticism by lawmakers and others that it was a rubber stamp for industry. The FDA Center for Devices and Radiological Health, which oversees scores of critical products like heart implants, imaging equipment and infusion pumps, has come under particular scrutiny.
A few years ago, for example, several top scientists at the center contended in letters to lawmakers that their superiors had ignored both their recommendations and policy guidelines in approving the sale of devices. Along with reports of 710 deaths, the center also received more than 10,000 complaints annually about infusion pumps from 2005 to 2009. In that same time frame, manufacturers of infusion pumps issued 79 recalls, among the highest for any medical device.
Infusion pumps normally use software to automatically control both the rate and volume of a medication's flow. To set a pump for an individual patient's needs, a doctor, a nurse or other healthcare worker enters information by using the buttons on a pump's keypad, which resembles that of a phone.
Jeffrey E. Shuren became the director of the Center for Devices and Radiological Health at the FDA in January 2010.
(click to enlarge)
Jeffrey Shuren, the director of the Center for Devices and Radiological Health at the Food and Drug Administration. From 2005 to 2009, more than 10,000 complaints were received annually by the FDA about the pumps. Credit: Daniel Rosenbaum for The New York Times
Conclusion
In addition to the lingering FDA issues discussed above, the temporary halt in shipments in late 2014 also created a significant backlog in orders from customers. Although the company has been able to work this level down over 2015, the magnitude of backlog remains significant and has created customer frustration and the risk of canceling orders. Customers can simply revert back to running long lines, which is far less costly that ordering a $25k machine from IRMD.
Furthermore, the working down of this US-focused backlog has resulted in abnormally high margins for the company as a whole given the higher margins in the US from selling direct vs. selling through distributors internationally. We expect that once the backlog it worked down to a normal level margins will compress as the US to international revenue mix is normalized. We believe that this could impact margins by 100 bps in 2016 along with another 100 bps burden from increased regulatory, compliance, and legal costs.
For a company trading at 22x 2016 EV/EBITDA and over 8x 2016 EV/Sales, we believe the market is not pricing in this lingering regulatory risk.
Additionally, after the share price's significant run over 300% in the last 12-month period, the CEO has now filed to sell 1 million shares, roughly 15% of his total holdings. This clearly reinforces the unattractiveness of the stock's valuation at these levels. In addition, it also further illustrates management's desire to take substantial profits off the table prior to any word back from the FDA in early 2016.
We would advise investors to consider shorting the stock at these levels given the hefty valuation and the potential for further intervention in the company's operations by the FDA, which could result in material downside at the current stock price above $31. Given the significant potential downside risk to Iradimed given the outstanding issues with the FDA that have yet to be resolved, we consider the company to be un-investable today and would put fair value at little more than the cash on the company's balance sheet.
See also Wide Moat Business Type Series: Airports on seekingalpha.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Additionally, the FDA made a further infusion pump recall on October 31, 2013, when it made Abbott ( ABT ) recall its Acclaim Infusion Pumps and Hospira recall its Acclaim Encore Infusion Pumps. As a result of product recalls and poor safety issues, the FDA required Hospira to retire its GemStar and Symbiq pumps at a cost of more than $300 million to the company. Some of those deaths involved patients who suffered drug overdoses accidentally, either because a hospital worker entered incorrect dosage data into a pump or because the device's software malfunctioned. | Additionally, the FDA made a further infusion pump recall on October 31, 2013, when it made Abbott ( ABT ) recall its Acclaim Infusion Pumps and Hospira recall its Acclaim Encore Infusion Pumps. By True Intrinsic Value : Please also see the below article from the New York Times: FDA Steps Up Oversight of Infusion Pumps Business Iradimed ( IRMD ) is a single product medical device company focused on non-magnetic intravenous (IV) infusion pump systems which allow for the administration of medication to patients during the course of an MRI procedure. (click to enlarge) Jeffrey Shuren, the director of the Center for Devices and Radiological Health at the Food and Drug Administration. | Additionally, the FDA made a further infusion pump recall on October 31, 2013, when it made Abbott ( ABT ) recall its Acclaim Infusion Pumps and Hospira recall its Acclaim Encore Infusion Pumps. By True Intrinsic Value : Please also see the below article from the New York Times: FDA Steps Up Oversight of Infusion Pumps Business Iradimed ( IRMD ) is a single product medical device company focused on non-magnetic intravenous (IV) infusion pump systems which allow for the administration of medication to patients during the course of an MRI procedure. Additionally and more importantly, if the FDA is ultimately not satisfied with the due diligence the company conducts on Iradimed's MRI infusion pump and its compliance procedures, the FDA ultimately reserves the right to block future shipments or even request a recall of Iradimed's products in the field. | Additionally, the FDA made a further infusion pump recall on October 31, 2013, when it made Abbott ( ABT ) recall its Acclaim Infusion Pumps and Hospira recall its Acclaim Encore Infusion Pumps. Current Situation Today, the company has yet to fully clear the warning letter it received well over a year ago from the FDA. Along with reports of 710 deaths, the center also received more than 10,000 complaints annually about infusion pumps from 2005 to 2009. |
33981.0 | 2015-11-02 00:00:00 UTC | What's in the Cards for Zoetis (ZTS) this Earnings Season? | ABT | https://www.nasdaq.com/articles/whats-in-the-cards-for-zoetis-zts-this-earnings-season-2015-11-02 | nan | nan | Zoetis Inc.ZTS is scheduled to report third-quarter 2015 results before the opening bell on Nov 3. Last quarter, the company had posted a positive earnings surprise of 13.16%. The company has recorded positive earnings surprises in all of the four trailing quarters with an average beat of 11.47%. Let's see how things are shaping up for this announcement.
Factors at Play this Quarter
Zoetis' robust and diversified product portfolio should help support revenues. The company's companion animal and livestock segment should continue to do well. The addition of Abbott Laboratories' ABT Animal Health business, Apoquel and other new products should have driven the top line. Zoetis acquired Abbott animal health assets in Feb 2015, in a bid to strengthen its pain and sedation product portfolio, and the diagnostic business. The company announced comprehensive operational efficiency initiatives, which are expected to generate cost savings of approximately $300 million by 2017.
However, foreign currency movements can prove to be a threat this quarter. For 2015, excluding one-time items, earnings are expected to be in the range of $1.63 to $1.68 per share (previous guidance: $1.61 to $1.68 per share). The company expects revenues to be between $4.7 billion and $4.775 billion. We may see an update on the same along with the third-quarter results.
What Our Model Indicates
Our proven model does not conclusively show that Zoetis is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -2.50%. This is because the Most Accurate estimate is 39 cents while the Zacks Consensus Estimate stands at 40 cents per share.
Zacks Rank: Zoetis currently carries a Zacks Rank #4 (Sell). The company's Zacks Rank #4 along with a negative ESP makes a beat unlikely this season.
Stocks That Warrant a Look
Here are a few health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
The Earnings ESP for Alnylam Pharmaceuticals, Inc. ALNY is +2.31% and it carries a Zacks Rank #3. The company is expected to release results on Nov 4.
Merrimack Pharmaceuticals, Inc. MACK has an Earnings ESP of +2.44% and a Zacks Rank #3. It is expected to release results on Nov 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALNYLAM PHARMA (ALNY): Free Stock Analysis Report
MERRIMACK PHAR (MACK): Free Stock Analysis Report
ZOETIS INC (ZTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The addition of Abbott Laboratories' ABT Animal Health business, Apoquel and other new products should have driven the top line. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis acquired Abbott animal health assets in Feb 2015, in a bid to strengthen its pain and sedation product portfolio, and the diagnostic business. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The addition of Abbott Laboratories' ABT Animal Health business, Apoquel and other new products should have driven the top line. The Earnings ESP for Alnylam Pharmaceuticals, Inc. ALNY is +2.31% and it carries a Zacks Rank #3. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The addition of Abbott Laboratories' ABT Animal Health business, Apoquel and other new products should have driven the top line. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. | The addition of Abbott Laboratories' ABT Animal Health business, Apoquel and other new products should have driven the top line. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. |
33982.0 | 2015-11-01 00:00:00 UTC | 5 Healthcare Trends to Invest in for the Next 20 Years | ABT | https://www.nasdaq.com/articles/5-healthcare-trends-invest-next-20-years-2015-11-01 | nan | nan | Image by stevepb via pixabay
The worldwide population growth over the past few decades has been nothing short of explosive: there were more than three times as many humans alive in 2010 as there were in 1950. While population growth in general is expected to slow over the coming decades, the global population is poised to get older and wealthier, which should combine to increase the demand for healthcare services for decades into the future. With a megatrend like that in place there are also bound to be dozens of smaller trends at play in the healthcare sector, so investors in the space should be aware of them and looking for ways to position their portfolios to take advantage.
We asked our team of Motley Fool contributors to share a trend in healthcare that is here to stay and could make for a great investing idea for at least 20 years into the future.
Dan Caplinger : One of the most important parts of Medicare reform over the past several years has been the shift away from service-based payments toward more of a quality-based payment model. In effect, Medicare is looking to reward those hospitals and healthcare facilities that offer high-quality care in a way that reduces the need for subsequent readmissions. By doing so, Medicare gives an incentive for healthcare providers to get things right the first time rather than plan for a return trip to a hospital.
The system is still new enough that investors shouldn't draw any firm conclusions from the ratings. However, it's clear that hospitals and other healthcare facilities -- both nonprofit and for-profit -- will need to watch closely to make sure that their quality levels allow them to get the maximum reimbursements possible from Medicare. Going forward, it seems likely that this trend will gain momentum, and hospital organizations will have to work increasingly hard in order to sustain and build on their reputations for quality service.
Investors should also watch closely to see what kinds of innovations hospital companies come up with, as the moves they make now could result in competitive advantages down the road that could generate stronger returns.
: While the rising costs of drugs have grabbed headlines recently, it's likely that the government will look for ways to help rein in the cost increases. One way they may do just that is making it easier for biosimilar drugs, which are generic version of biologics, to find their way to market.
Most drugs fall into one of two categories: chemical and biologic. Chemical drugs have faced generic competition for years once they lose patent protection, as manufacturers can easily flood the market with generic alternatives that dramatically reduce prices.
That hasn't happened with biologic drugs: since they are produced from living organisms, they are susceptible to heat and microbial contamination, which makes manufacturing copycats far more difficult. Up until recently the regulatory pathway for biologic drugs was unclear, but that all changed earlier this year when the FDA approved its first biosimilar.
Now that the door has been busted open, it's likely that we will see a flood of biosimilars hit the market over the coming decades, which could go a long way toward reining in drug prices. While this is a win for consumers, it could spell trouble for big pharma companies like Eli Lilly and even blue-chip biotechs like Amgen , which depend on revenue from biologic drugs that have already lost or will soon lose patent protection.
Of course, one company's loss is another's gain, so investors can put the trend on their side in a number of ways. Pharma giant Pfizerpurchased Hospira to help build up its biosimilar presence, and Novartis ' Sandoz could also be a big player in the biologic market. For those interested in a smaller biosimilar pure-play, Coherus Biosciences already has three biosimilars in advanced trials.
No matter how this story plays out, biosimilars represent both a huge threat and a huge opportunity, making this an important trend to watch over the coming 20 years.
: One trend in healthcare that's likely to be a boon to doctors, patients, and some investors is the growth in electronic health records, or EHRs. An increasingly busy corner of the software world is devoted to healthcare-oriented information technology, and many are focused on EHRs.
Imagine going to your primary care physician, a specialist, or an emergency room, with whoever examines you having access to your records electronically. They'll be able to see your prescriptions, health issues, treatments, immunizations, lab results, and more. That's a prescription for better care, as doctors can make more informed decisions.
It's a relatively new concept, and many in the healthcare community are not embracing it, as it's costly and not a simple thing to implement. But there's an important catalyst giving growth traction now: the U.S. government, which enacted the Health Information Technology for Economic and Clinical Health (HITECH) Act as part of the American Recovery and Reinvestment Act of 2009, promoting the adoption of health information technology. It offered both financial carrots and sticks to spur adoption (such as offering billions of dollars in incentive money for providers to use EHRs in "meaningful" ways), which has helped companies in the EHR business grow.
One such company to consider for your portfolio is Cerner , which offers integrated systems that can help medical practices not only with EHRs but with scheduling, payments, and more. The company received a $4.3 billion contract this summer from the U.S. military, which will provide more wind in its sails. It pays no dividend at the moment, but is free-cash-flow positive and has double-digit net margins, which suggests that this could be a great company to play on the trend of EHRs.
: Every day almost 10,000 baby boomers turn 65 in the U.S. -- that's one every nine seconds. Boomers, who made political and social protests the norm in their youth, will demand control over their healthcare -- something we haven't seen in previous generations. In addition, thanks to medical advances over their lifetime, boomers will live longer.
So what stocks or healthcare industries are boomers likely to put on the fast lane to continued success?
Let's start with wearables, in the form of monitoring devices for people with chronic medical illnesses. I'm talking about innovations from companies like Abbott Laboratories , with its pain-free wearable for monitoring glucose, or , whose wristbands are being used by cardiac-surgeons to track activity in their patients. Medical wearables could provide colossal opportunities in the coming decades.
What about Big Pharma? The average 70-year-old takes three times more prescription drugs than the typical 40-year-old does, so this sub-sector looks set for multi-decade gains. Oncology titan Roche Holding could be a particularly good bet. Roche has one of the most robust drug pipelines in Big Pharma, and its strong diagnostics business provides a unique edge. Combining diagnostics tools with treatment means more integrated, personalized healthcare solutions -- exactly what this demanding generation will expect.
Sean Williams : The next big thing in healthcare is actually here already, but you're probably going to witness it evolve slowly over the next 10 to 20 years.
Personalized medicine, or the idea of throwing out the one-size-fits-all cures for certain diseases, such as cancer, is one way I believe you could find substantial profits and improved quality of life for many years to come. Personalized medicine focuses on the idea of targeting specific genes or proteins within a person's body to effect positive biologic change.
Two ways to consider taking advantage of personalized medicine is through diagnostics and drug developers themselves.
Within diagnostics, a company like Myriad Genetics with its BRACAnalysis test has spearheaded the campaign to identify women who have a much higher risk factor for breast and ovarian cancer. The test analyzes whether or not the patient is a BRCA1 or BRCA2 gene mutation carrier. Some patients, like Angelina Jolie, took the pre-emptive measure of getting a mastectomy to substantially lower their risks. Others can use the test as a cue to be screened for breast and ovarian cancer early and often.
Another approach is to consider cancer drug developers focused on specific genes, or on enhancing the way your body fights disease. Cancer immunotherapy vaccines are a great example of a medicine designed to teach your immune system how to more effectively and efficiently locate and destroy cancer cells. For instance, Bristol-Myers Squibb 's Opdivo demonstrated a response rate of around 60% in patients expressing high levels of PD-L1 in advanced non-small cell lung cancer patients. It also boosted survival times by a whopping eight months, which is impressive for NSCLC patients who've progressed on prior therapies.
The future is now when it comes to personalized medicine, and you should consider examining ways to incorporate this huge growth potential into your portfolio.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article 5 Healthcare Trends to Invest in for the Next 20 Years originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. Cheryl Swanson owns shares of Amgen and Pfizer. Dan Caplinger has no position in any stocks mentioned. Sean Williams has no position in any stocks mentioned. Selena Maranjian owns shares of Amgen, Cerner, and Novartis. The Motley Fool recommends Cerner. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With a megatrend like that in place there are also bound to be dozens of smaller trends at play in the healthcare sector, so investors in the space should be aware of them and looking for ways to position their portfolios to take advantage. While this is a win for consumers, it could spell trouble for big pharma companies like Eli Lilly and even blue-chip biotechs like Amgen , which depend on revenue from biologic drugs that have already lost or will soon lose patent protection. Personalized medicine, or the idea of throwing out the one-size-fits-all cures for certain diseases, such as cancer, is one way I believe you could find substantial profits and improved quality of life for many years to come. | Chemical drugs have faced generic competition for years once they lose patent protection, as manufacturers can easily flood the market with generic alternatives that dramatically reduce prices. No matter how this story plays out, biosimilars represent both a huge threat and a huge opportunity, making this an important trend to watch over the coming 20 years. Personalized medicine focuses on the idea of targeting specific genes or proteins within a person's body to effect positive biologic change. | While population growth in general is expected to slow over the coming decades, the global population is poised to get older and wealthier, which should combine to increase the demand for healthcare services for decades into the future. We asked our team of Motley Fool contributors to share a trend in healthcare that is here to stay and could make for a great investing idea for at least 20 years into the future. : One trend in healthcare that's likely to be a boon to doctors, patients, and some investors is the growth in electronic health records, or EHRs. | One way they may do just that is making it easier for biosimilar drugs, which are generic version of biologics, to find their way to market. : One trend in healthcare that's likely to be a boon to doctors, patients, and some investors is the growth in electronic health records, or EHRs. Two ways to consider taking advantage of personalized medicine is through diagnostics and drug developers themselves. |
33983.0 | 2015-10-30 00:00:00 UTC | Mylan Tops Q3 Earnings, Misses Revenues, Updates View | ABT | https://www.nasdaq.com/articles/mylan-tops-q3-earnings-misses-revenues-updates-view-2015-10-30 | nan | nan | Mylan 's MYL third-quarter 2015 earnings (excluding special items) of $1.43 cents per share beat the Zacks Consensus Estimate of $1.38. Earnings increased 23% from the year-ago quarter driven by higher revenues.
Mylan Inc. (MYL) - Earnings Surprise | FindTheCompany
Revenues climbed 30% (36% on a constant currency basis) to $2.7 billion, missing the Zacks Consensus Estimate of $2.8 billion. Total revenue recorded year-over-year growth on the back of solid revenue growth at the Generics segment. However, performance of specialty segment was disappointing. Foreign currency exchange rates negatively impacted revenues by $122 million in the third quarter of 2015.
Third Quarter in Details
Generics third-party net sales, derived from sales in North America, Europe and rest of the world, climbed 40% to $2.3 billion. Segmental third-party net sales grew 28% to $1.1 billion in North America. New product launches, acquisitions and higher volumes aided revenues.
Third-party net sales from the European market increased 79% to $629 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Third-party net sales from rest of the world rose 32% to $546.9 million. Segmental performance improved on the back of acquisitions, new product launches in Australia and Japan, and increased sales of antiretroviral products.
Third-party net sales at the Specialty segment fell 5% to $437.8 million. Specialty segment sales were hurt by lower average net selling prices due to competitive market conditions for its flagship product, EpiPen Auto-Injector, for severe allergic reactions.
Adjusted gross margin during the third quarter of 2015 expanded to 58% from 54% in the year-ago quarter on the back of new product introductions, net sales from acquisitions and increased margins on existing products in North America.
2015 Outlook Update
Mylan updated its 2015 guidance. The company expects adjusted earnings per share at the high end of the previously guided range of $4.15 to $4.35. The Zacks Consensus Estimate for 2015 earnings is at $4.20.
Our Take
Mylan's third-quarter earnings were better than expected. We are encouraged by strong sales at the Generics segment. However, we remain concerned about the performance of the company's Specialty segment. The company is facing competitive market conditions for EpiPen Auto-Injector and has lowered the average net selling price. Meanwhile, Mylan remains committed to the acquisition of Perrigo Company PRGO . Investor focus is expected to remain on Mylan-Perrigo updates in the near term.
Mylan holds a Zacks Rank #1 (Strong Buy). Anika Therapeutics Inc. ANIK is a better-ranked stock in the health care sector. The stock sports the same Zacks Rank as Mylan.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
MYLAN NV (MYL): Free Stock Analysis Report
PERRIGO CO PLC (PRGO): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Third-party net sales from the European market increased 79% to $629 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan 's MYL third-quarter 2015 earnings (excluding special items) of $1.43 cents per share beat the Zacks Consensus Estimate of $1.38. | Third-party net sales from the European market increased 79% to $629 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Specialty segment sales were hurt by lower average net selling prices due to competitive market conditions for its flagship product, EpiPen Auto-Injector, for severe allergic reactions. | Third-party net sales from the European market increased 79% to $629 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Adjusted gross margin during the third quarter of 2015 expanded to 58% from 54% in the year-ago quarter on the back of new product introductions, net sales from acquisitions and increased margins on existing products in North America. | Third-party net sales from the European market increased 79% to $629 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings increased 23% from the year-ago quarter driven by higher revenues. |
33984.0 | 2015-10-27 00:00:00 UTC | See Which Of The Latest 13F Filers Holds Abbott Laboratories | ABT | https://www.nasdaq.com/articles/see-which-latest-13f-filers-holds-abbott-laboratories-2015-10-27 | nan | nan | At Holdings Channel , we have reviewed the latest batch of the 25 most recent 13F filings for the 09/30/2015 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 17 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen .
Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers:
In terms of shares owned, we count 9 of the above funds having increased existing ABT positions from 06/30/2015 to 09/30/2015, with 3 having decreased their positions and 3 new positions. Worth noting is that Torch Wealth Management LLC , included in this recent batch of 13F filers, exited ABT common stock as of 09/30/2015.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 09/30/2015 reporting period (out of the 738 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 06/30/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. We found that between these two periods, funds increased their holdings by 2,607,462 shares in the aggregate, from 51,445,938 up to 54,053,400 for a share count increase of approximately 5.07%. The overall top three funds holding ABT on 09/30/2015 were:
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT).
10 S&P 500 Components Hedge Funds Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At Holdings Channel , we have reviewed the latest batch of the 25 most recent 13F filings for the 09/30/2015 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 17 of these funds. Worth noting is that Torch Wealth Management LLC , included in this recent batch of 13F filers, exited ABT common stock as of 09/30/2015. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT). | At Holdings Channel , we have reviewed the latest batch of the 25 most recent 13F filings for the 09/30/2015 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 17 of these funds. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count 9 of the above funds having increased existing ABT positions from 06/30/2015 to 09/30/2015, with 3 having decreased their positions and 3 new positions. Worth noting is that Torch Wealth Management LLC , included in this recent batch of 13F filers, exited ABT common stock as of 09/30/2015. | Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 09/30/2015 reporting period (out of the 738 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 06/30/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 09/30/2015 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. | Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 09/30/2015 reporting period (out of the 738 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 06/30/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 09/30/2015 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. |
33985.0 | 2015-10-22 00:00:00 UTC | Noteworthy ETF Outflows: VIG, ABT, MON, CAT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-vig-abt-mon-cat-2015-10-22 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $40.5 million dollar outflow -- that's a 0.2% decrease week over week (from 247,127,192 to 246,602,192). Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Monsanto Co. (Symbol: MON) is up about 0.3%, and Caterpillar Inc. (Symbol: CAT) is higher by about 3.3%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $78.14. Comparing the most recent share price to the 200 day moving average can also be a useful | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Monsanto Co. (Symbol: MON) is up about 0.3%, and Caterpillar Inc. (Symbol: CAT) is higher by about 3.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $40.5 million dollar outflow -- that's a 0.2% decrease week over week (from 247,127,192 to 246,602,192). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $78.14. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Monsanto Co. (Symbol: MON) is up about 0.3%, and Caterpillar Inc. (Symbol: CAT) is higher by about 3.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $40.5 million dollar outflow -- that's a 0.2% decrease week over week (from 247,127,192 to 246,602,192). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $78.14. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Monsanto Co. (Symbol: MON) is up about 0.3%, and Caterpillar Inc. (Symbol: CAT) is higher by about 3.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $40.5 million dollar outflow -- that's a 0.2% decrease week over week (from 247,127,192 to 246,602,192). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $78.14. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Monsanto Co. (Symbol: MON) is up about 0.3%, and Caterpillar Inc. (Symbol: CAT) is higher by about 3.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $40.5 million dollar outflow -- that's a 0.2% decrease week over week (from 247,127,192 to 246,602,192). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $78.14. |
33986.0 | 2015-10-22 00:00:00 UTC | Company News for October 22, 2015 | ABT | https://www.nasdaq.com/articles/company-news-for-october-22-2015-2015-10-22 | nan | nan | • Shares of Abbott Laboratories ( ABT ) gained 1.1% after the company posted third quarter earnings per share of $0.54, beating the Zacks Consensus Estimate by a cent
• Shares of Baker Hughes Incorporated ( BHI ) advanced 2.3% after the company reported third quarter loss per share of $0.05, narrower than the Zacks Consensus Estimate of a loss of $0.15
• Shares of Northern Trust Corporation ( NTRS ) declined 4.3% after the company posted third quarter earnings per share of $0.96, missing the Zacks Consensus Estimate by a cent
• Packaging Corporation of America's ( PKG ) shares dropped 5.8% after the company reported third quarter earnings per share of $1.26 that fell short of the Zacks Consensus Estimate of $1.29
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
BAKER-HUGHES (BHI): Free Stock Analysis Report
NORTHERN TRUST (NTRS): Free Stock Analysis Report
PACKAGING CORP (PKG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ( ABT ) gained 1.1% after the company posted third quarter earnings per share of $0.54, beating the Zacks Consensus Estimate by a cent • Shares of Baker Hughes Incorporated ( BHI ) advanced 2.3% after the company reported third quarter loss per share of $0.05, narrower than the Zacks Consensus Estimate of a loss of $0.15 • Shares of Northern Trust Corporation ( NTRS ) declined 4.3% after the company posted third quarter earnings per share of $0.96, missing the Zacks Consensus Estimate by a cent • Packaging Corporation of America's ( PKG ) shares dropped 5.8% after the company reported third quarter earnings per share of $1.26 that fell short of the Zacks Consensus Estimate of $1.29 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAKER-HUGHES (BHI): Free Stock Analysis Report NORTHERN TRUST (NTRS): Free Stock Analysis Report PACKAGING CORP (PKG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ( ABT ) gained 1.1% after the company posted third quarter earnings per share of $0.54, beating the Zacks Consensus Estimate by a cent • Shares of Baker Hughes Incorporated ( BHI ) advanced 2.3% after the company reported third quarter loss per share of $0.05, narrower than the Zacks Consensus Estimate of a loss of $0.15 • Shares of Northern Trust Corporation ( NTRS ) declined 4.3% after the company posted third quarter earnings per share of $0.96, missing the Zacks Consensus Estimate by a cent • Packaging Corporation of America's ( PKG ) shares dropped 5.8% after the company reported third quarter earnings per share of $1.26 that fell short of the Zacks Consensus Estimate of $1.29 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAKER-HUGHES (BHI): Free Stock Analysis Report NORTHERN TRUST (NTRS): Free Stock Analysis Report PACKAGING CORP (PKG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ( ABT ) gained 1.1% after the company posted third quarter earnings per share of $0.54, beating the Zacks Consensus Estimate by a cent • Shares of Baker Hughes Incorporated ( BHI ) advanced 2.3% after the company reported third quarter loss per share of $0.05, narrower than the Zacks Consensus Estimate of a loss of $0.15 • Shares of Northern Trust Corporation ( NTRS ) declined 4.3% after the company posted third quarter earnings per share of $0.96, missing the Zacks Consensus Estimate by a cent • Packaging Corporation of America's ( PKG ) shares dropped 5.8% after the company reported third quarter earnings per share of $1.26 that fell short of the Zacks Consensus Estimate of $1.29 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAKER-HUGHES (BHI): Free Stock Analysis Report NORTHERN TRUST (NTRS): Free Stock Analysis Report PACKAGING CORP (PKG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ( ABT ) gained 1.1% after the company posted third quarter earnings per share of $0.54, beating the Zacks Consensus Estimate by a cent • Shares of Baker Hughes Incorporated ( BHI ) advanced 2.3% after the company reported third quarter loss per share of $0.05, narrower than the Zacks Consensus Estimate of a loss of $0.15 • Shares of Northern Trust Corporation ( NTRS ) declined 4.3% after the company posted third quarter earnings per share of $0.96, missing the Zacks Consensus Estimate by a cent • Packaging Corporation of America's ( PKG ) shares dropped 5.8% after the company reported third quarter earnings per share of $1.26 that fell short of the Zacks Consensus Estimate of $1.29 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAKER-HUGHES (BHI): Free Stock Analysis Report NORTHERN TRUST (NTRS): Free Stock Analysis Report PACKAGING CORP (PKG): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
33987.0 | 2015-10-21 00:00:00 UTC | Abbott (ABT) Posts Higher-Than-Expected Q3 Earnings | ABT | https://www.nasdaq.com/articles/abbott-abt-posts-higher-than-expected-q3-earnings-2015-10-21 | nan | nan | Abbott LaboratoriesABT reported third-quarter 2015 earnings of 54 cents per share, beating the Zacks Consensus Estimate by a penny, but remaining flat year over year.
In the reported quarter, sales came in at $5.2 billion, up 1.4% year over year (on a reported basis), surpassing the Zacks Consensus Estimate of $5.1 billion. Sales were impacted by unfavorable foreign exchange movement of 9.5% during the quarter.
The Quarter in Detail
Abbott operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
EPD sales were up 24.6% to $961 million, including the negative impact of 18% due to currency fluctuations. Sales in key emerging markets climbed 37.1% on an operational basis driven by growth in India, Russia, Brazil, China, and certain markets in Latin America.
The Medical Devices business generated sales of $1.2 billion, down 7.4% year over year. Sales at Diabetes Care, Vascular and Medical Optics businesses were down 8.4%, 7.8% and 5.3%, respectively. Sales of cataract products increased in the high single digits driven by continuous demand for recently launched products in the premium intraocular lens segment. Abbott launched XIENCE Alpine and Absorb GT1 in several markets of Europe and Asia. The company expects to file for its approval in China in the next few months.
The Nutrition business increased 0.2% year over year to $1.8 billion. Pediatric Nutrition sales were up 4.1%. Growth was driven by strong demand for Eleva in the premium segment of the Chinese market and Similac Advance non-GMO in the U.S. However, Adult Nutrition sales decreased 4.5%, mainly due to competition in the U.S. and overall market dynamics.
Diagnostics business sales decreased 2.1% year over year to $1.2 billion. Core Laboratory and Molecular sales decreased 3.1% and 4.8%, respectively, while Point-of-Care Diagnostics sales grew 10%. Molecular Diagnostics sales in the U.S. were affected by market dynamics in the oncology business and the planned scale-down of the genetics business.
2015 Outlook Narrowed
Abbott narrowed its earnings guidance for 2015 to the range of $2.14 per share - $2.16 per share from $2.10 per share - $2.20 per share guided earlier. The Zacks Consensus Estimate is currently $2.16.
Our Take
Abbott's third-quarter results were impressive. Moreover, the company's efforts to expand its pediatric nutrition portfolio through new product launches in the U.S. and ex-U.S. markets are encouraging. However, the unfavorable impact of currency fluctuations will continue to dampen revenues, going ahead.
Abbott currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector are Bayer BAYRY , Bristol-Myers Squibb Company BMY and Novo Nordisk A/S NVO . All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported third-quarter 2015 earnings of 54 cents per share, beating the Zacks Consensus Estimate by a penny, but remaining flat year over year. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. The Quarter in Detail Abbott operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics. | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported third-quarter 2015 earnings of 54 cents per share, beating the Zacks Consensus Estimate by a penny, but remaining flat year over year. In the reported quarter, sales came in at $5.2 billion, up 1.4% year over year (on a reported basis), surpassing the Zacks Consensus Estimate of $5.1 billion. | Abbott LaboratoriesABT reported third-quarter 2015 earnings of 54 cents per share, beating the Zacks Consensus Estimate by a penny, but remaining flat year over year. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In the reported quarter, sales came in at $5.2 billion, up 1.4% year over year (on a reported basis), surpassing the Zacks Consensus Estimate of $5.1 billion. | Abbott LaboratoriesABT reported third-quarter 2015 earnings of 54 cents per share, beating the Zacks Consensus Estimate by a penny, but remaining flat year over year. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Diagnostics business sales decreased 2.1% year over year to $1.2 billion. |
33988.0 | 2015-10-21 00:00:00 UTC | Abbott Labs (ABT) Tops Earnings in Q3 | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-tops-earnings-in-q3-2015-10-21 | nan | nan | Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets.
Abbott is expanding its pediatric nutrition portfolio through new product launches in the U.S. and the ex-U.S. markets (including the launch of a non-GMO labeled formula, Similac Advance, in the U.S. and the organic version of an infant formulation, Eleva, in China). While the company is working on growing the adult nutrition business in the priority international markets, performance of this segment remains a matter of concern, mainly due to competition in the U.S. and low demand at the institutional level.
Unfavorable movement in foreign currency rates is also affecting the top line adversely.
Abbott has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 5.91%.
Currently, Abbott has a Zacks Rank #4 (Sell). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Abbott beat on earnings in third-quarter 2015 by a penny. Our consensus called for EPS of 53 cents per share, while the company reported EPS of 54 cents (from continuing operations excluding one-time items).
Revenue: Abbott posted revenues of $5.2 billion, surpassing our expectations of $5.1 billion.
Key Stats: Strong performance by international nutrition and established pharmaceutical businesses positively impacted results. Excluding the impact of 2014 acquisitions and currency fluctuation, sales in emerging market grew in double-digits on an organic basis. The company narrowed its full-year 2015 earnings guidance to $2.14 per share - $2.16 per share (excluding specified items) from $2.10 per share - $2.20 per share. The mid-point of this range remains altered.
Check back later for our full write up on this Abbott earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Key Stats: Strong performance by international nutrition and established pharmaceutical businesses positively impacted results. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: Abbott beat on earnings in third-quarter 2015 by a penny. |
33989.0 | 2015-10-20 00:00:00 UTC | Pre-Market Earnings Report for October 21, 2015 : KO, BA, BIIB, ABT, EMC, GM, TMO, KMB, ITW, BHI, STJ, NLSN | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-october-21-2015-ko-ba-biib-abt-emc-gm-tmo-kmb-itw-bhi-stj-nlsn | nan | nan | The following companies are expected to report earnings prior to market open on 10/21/2015. Visit our Earnings Calendar for a full list of expected earnings releases.
Coca-Cola Company ( KO ) is reporting for the quarter ending September 30, 2015. The beverages company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.50. This value represents a 5.66% decrease compared to the same quarter last year. In the past year KO has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 5%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for KO is 20.89 vs. an industry ratio of 1.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Boeing Company ( BA ) is reporting for the quarter ending September 30, 2015. The aerospace and defense company's consensus earnings per share forecast from the 9 analysts that follow the stock is $2.22. This value represents a 3.74% increase compared to the same quarter last year. In the past year BA has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 15.71%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BA is 17.20 vs. an industry ratio of 20.30.
Biogen Inc. ( BIIB ) is reporting for the quarter ending September 30, 2015. The biomedical (gene) company's consensus earnings per share forecast from the 23 analysts that follow the stock is $3.83. This value represents a 1.06% increase compared to the same quarter last year. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2015 by -2.3%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BIIB is 17.18 vs. an industry ratio of 1.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2015. The large cap pharmaceutical company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.53. This value represents a 14.52% decrease compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 4%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 19.51 vs. an industry ratio of 4.50, implying that they will have a higher earnings growth than their competitors in the same industry.
EMC Corporation ( EMC ) is reporting for the quarter ending September 30, 2015. The computer storage company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.33. This value represents a 8.33% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for EMC is 19.25 vs. an industry ratio of 3.60, implying that they will have a higher earnings growth than their competitors in the same industry.
General Motors Company ( GM ) is reporting for the quarter ending September 30, 2015. The auto (domestic) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.15. This value represents a 18.56% increase compared to the same quarter last year. GM missed the consensus earnings per share in the 1st calendar quarter of 2015 by -11.34%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for GM is 7.39 vs. an industry ratio of -5.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Thermo Fisher Scientific Inc ( TMO ) is reporting for the quarter ending September 30, 2015. The medical instruments company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.78. This value represents a 4.09% increase compared to the same quarter last year. In the past year TMO has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 3.37%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for TMO is 17.51 vs. an industry ratio of -6.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Kimberly-Clark Corporation ( KMB ) is reporting for the quarter ending September 30, 2015. The consumer company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.49. This value represents a 7.45% decrease compared to the same quarter last year. KMB missed the consensus earnings per share in the 4th calendar quarter of 2014 by -1.46%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for KMB is 20.39 vs. an industry ratio of 19.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Illinois Tool Works Inc. ( ITW ) is reporting for the quarter ending September 30, 2015. The machinery company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.36. This value represents a 6.25% increase compared to the same quarter last year. In the past year ITW has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 1.56%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ITW is 16.38 vs. an industry ratio of 17.30.
Baker Hughes Incorporated ( BHI ) is reporting for the quarter ending September 30, 2015. The oil (field services) company's consensus earnings per share forecast from the 15 analysts that follow the stock is $-0.15. This value represents a 114.71% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BHI is -111.10 vs. an industry ratio of 8.50.
St. Jude Medical, Inc. ( STJ ) is reporting for the quarter ending September 30, 2015. The medical products company's consensus earnings per share forecast from the 21 analysts that follow the stock is $0.97. This value represents a no change for the same quarter last year. In the past year STJ has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for STJ is 17.10 vs. an industry ratio of 19.00.
Nielsen N.V. ( NLSN ) is reporting for the quarter ending September 30, 2015. The business info service company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.66. This value represents a 3.13% increase compared to the same quarter last year. In the past year NLSN has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for NLSN is 19.12 vs. an industry ratio of 19.20.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2015. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 19.51 vs. an industry ratio of 4.50, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 19.51 vs. an industry ratio of 4.50, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2015. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 19.51 vs. an industry ratio of 4.50, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2015. In the past year ABT has beat the expectations every quarter. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2015. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 19.51 vs. an industry ratio of 4.50, implying that they will have a higher earnings growth than their competitors in the same industry. |
33990.0 | 2015-10-19 00:00:00 UTC | Will Currency Hit Abbott Laboratories (ABT) in Q3 Earnings? | ABT | https://www.nasdaq.com/articles/will-currency-hit-abbott-laboratories-abt-in-q3-earnings-2015-10-19 | nan | nan | Abbott LaboratoriesABT is scheduled to report third-quarter 2015 results before the opening bell on Oct 21, 2015.
Abbott Labs has an impressive track record with the company beating estimates in each of the trailing four quarters with an average earnings surprise of 5.91%. Let us see how things are shaping up for this announcement.
Will Currency Impact Continue?
Although the nutrition business continues to drive revenues, with the company expanding its pediatric nutrition portfolio through new product launches in the U.S. and the ex-U.S. markets (including the launch of a non-GMO labeled formula, Similac Advance, in the U.S. and the organic version of an infant formulation, Eleva, in China), performance of the adult nutrition business remains a matter of concern. While the company is working on growing the adult nutrition business in the priority international markets, the segment is facing competition in the U.S. and low demand at the institutional level.
For the third quarter, the company expects the global nutritional business to grow in the mid single digits on an operational basis, mainly driven by performance in the international markets. Both the global diabetes care and medical optics businesses are expected to grow in the low single digit this quarter. The established pharmaceuticals division is expected to continue to generate double-digit sales growth.
The company expects third-quarter earnings in the range of 52 cents−54 cents per share, reflecting double-digit growth. However, the top line may be adversely affected by currency fluctuation of above 9% during the third quarter, leading to sales growth in the low single digits. Operational sales growth is expected in the low double digits.
What Our Model Indicates
Our proven model does not conclusively shows that Abbott Labs is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, stands at -1.83%. This is because the Most Accurate estimate stands at 52 cents, while the Zacks Consensus Estimate is 53 cents.
Zacks Rank: Abbott Labs currently carries a Zacks Rank #4 (Sell). The company's Zacks Rank #4 when combined with an earnings ESP of -1.83% makes a surprise prediction difficult.
Moreover, we caution against stocks with Zacks Rank #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Amgen Inc. AMGN has an Earnings ESP of +1.27% and carries a Zacks Rank #1 (Strong Buy). The company is scheduled to release third-quarter 2015 results on Oct 28.
The Earnings ESP for Bristol-Myers Squibb Company BMY is +2.86% and it carries a Zacks Rank #3. The company is scheduled to release third-quarter results on Oct 27.
Eli Lilly and Company LLY has an Earnings ESP of +2.67% and carries a Zacks Rank #3. The company is scheduled to release third-quarter 2015 results on Oct 22.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is scheduled to report third-quarter 2015 results before the opening bell on Oct 21, 2015. Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs has an impressive track record with the company beating estimates in each of the trailing four quarters with an average earnings surprise of 5.91%. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report third-quarter 2015 results before the opening bell on Oct 21, 2015. Amgen Inc. AMGN has an Earnings ESP of +1.27% and carries a Zacks Rank #1 (Strong Buy). | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report third-quarter 2015 results before the opening bell on Oct 21, 2015. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. | Abbott LaboratoriesABT is scheduled to report third-quarter 2015 results before the opening bell on Oct 21, 2015. Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. The company expects third-quarter earnings in the range of 52 cents−54 cents per share, reflecting double-digit growth. |
33991.0 | 2015-10-14 00:00:00 UTC | Abbott Labs Releases Data on Dissolving Heart Stent Absorb | ABT | https://www.nasdaq.com/articles/abbott-labs-releases-data-on-dissolving-heart-stent-absorb-2015-10-14 | nan | nan | Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight on the commercial potential of the candidate once it is successfully developed and commercialized.
Abbott LaboratoriesABT has announced results from the phase III trial, ABSORB, on drug-eluting coronary bioresorbable vascular scaffold, Absorb, at the end of one year.
The trial compared the safety and effectiveness of Absorb to metallic drug eluting stent, Xience, in about 2,000 patients suffering from coronary artery disease. Absorb is a fully dissolving heart stent.
The trial met its primary endpoint. Results from the trial showed that target lesion failure (TLF) was 7.8% for Absorb versus 6.1% for Xience. However, pre-specified secondary endpoint results were not statistically different and there was no statistically significant difference in the rate of definite and/or probable stent thrombosis.
Results from the trial will be used to support the regulatory approval of Absorb in the U.S.
These data were presented during a late-breaking session at the 27th Transcatheter Cardiovascular Therapeutics (TCT).
Abbott Labs also presented results from another randomized, single-blinded, controlled trial that compared Absorb to Xience at TCT. This trial, ABSORB China, was conducted to support Absorb's approval in China. The trial was conducted in China.
The trial met its primary endpoint of in-segment late loss at one year as Absorb proved its non-inferiority to Xience.
We note that Abbott Labs has completed regulatory submissions for the approval of Absorb in both the U.S. and Japan. These markets along with China represent more than 50% of the world's coronary stent market and hence hold immense scope for growth upon approval.
Meanwhile, Abbott Labs has also received approval for Absorb GT1 in Europe, an improved version of the Absorb stent system that improves the ease of use.
A potential approval of Absorb in the U.S. and China will boost the vascular segment significantly.
However, Abbott Labs expects currency to have a greater-than-expected negative impact on 2015 total sales, which remains a concern.
Abbott Labs currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the healthcare sector include AbbVie Inc. ABBV , Sanofi SNY and Novo Nordisk NVO . All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT has announced results from the phase III trial, ABSORB, on drug-eluting coronary bioresorbable vascular scaffold, Absorb, at the end of one year. Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has announced results from the phase III trial, ABSORB, on drug-eluting coronary bioresorbable vascular scaffold, Absorb, at the end of one year. This trial, ABSORB China, was conducted to support Absorb's approval in China. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has announced results from the phase III trial, ABSORB, on drug-eluting coronary bioresorbable vascular scaffold, Absorb, at the end of one year. This trial, ABSORB China, was conducted to support Absorb's approval in China. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has announced results from the phase III trial, ABSORB, on drug-eluting coronary bioresorbable vascular scaffold, Absorb, at the end of one year. Results from the trial will be used to support the regulatory approval of Absorb in the U.S. |
33992.0 | 2015-10-12 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 13, 2015 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-october-13-2015-2015-10-12 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 13, 2015. A cash dividend payment of $0.24 per share is scheduled to be paid on November 15, 2015. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ABT has paid the same dividend. At the current stock price of $41.89, the dividend yield is 2.29%.
The previous trading day's last sale of ABT was $41.89, representing a -19.04% decrease from the 52 week high of $51.74 and a 7.41% increase over the 52 week low of $39.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). ABT's current earnings per share, an indicator of a company's profitability, is $2.98. Zacks Investment Research reports ABT's forecasted earnings growth in 2015 as -5.18%, compared to an industry average of 4.4%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Medical Devices ETF ( IHI )
SPDR S&P Health Care Equipment ( XHE )
Direxion S&P 500 Volatility Response Shares ( VSPY ).
The top-performing ETF of this group is IHI with an decrease of -4.68% over the last 100 days. It also has the highest percent weighting of ABT at 10.66%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2015 as -5.18%, compared to an industry average of 4.4%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | ABT's current earnings per share, an indicator of a company's profitability, is $2.98. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 13, 2015. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) Direxion S&P 500 Volatility Response Shares ( VSPY ). | ABT's current earnings per share, an indicator of a company's profitability, is $2.98. Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 13, 2015. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. |
33993.0 | 2015-10-09 00:00:00 UTC | Boston Scientific Funds MValve to Boost TMVR Expansion | ABT | https://www.nasdaq.com/articles/boston-scientific-funds-mvalve-to-boost-tmvr-expansion-2015-10-09 | nan | nan | Boston Scientific CorporationBSX recently declared that it has closed an additional round of financing with MValve Technologies Ltd., in keeping with its plans to invest toward the development of a unique mitral regurgitation (MR) treatment solution that will work with the Boston Scientific Lotus Valve. Notably, Boston Scientific has funded MValve since 2012 and has an exclusive option to acquire this percutaneous mitral valve replacement system developer.
With this additional round of finance, MValve plans to fund a first-in-human clinical trial for its docking system for transcatheter mitral valve replacement (TMVR) in patients with mitral regurgitation. Notably, mitral regurgitation is a common heart valve disorder that occurs when the mitral valve does not close properly, causing an abnormal reversal of blood flow from the left ventricle into the left atrium.
This approach by MValve, which has Boston Scientific's Lotus Valve deployed inside the docking system, targets the treatment of mitral regurgitation in a broad range of patients as well as improve long-term clinical outcomes in them. Boston Scientific's Lotus Aortic Valve System is a differentiated second-generation valve replacement technology, consisting of a pre-loaded, stent-mounted tissue valve prosthesis and catheter delivery system for percutaneous placement of the valve.
Boston Scientific's strong initiative to finance the development of MValve Technologies is based on the company's optimism about robust growth opportunities in the TMVR segment under the company's Structural Heart portfolio. Both the companies are looking forward to continued development of this unique mitral system, which is expected to provide physicians with a transformative and suitable treatment option.
At the moment, the MValve docking system is not available for sale and the Lotus Valve System is still an investigational device in the U.S. However, it has won CE mark in the European Union.
In this regard, we note that, to expedite growth in the billion dollar TMVR market, an array of medical device majors have come forward in recent times. Last week, Medtronic plc MDT acquired California-based medical device start-up firm - Twelve, Inc. Twelve's TMVR technology has been designed to treat inoperable patients suffering from mitral valve regurgitation. The technology, therefore, is expected to strongly support Medtronic's expansion in the TMVR space. This, in turn, will imply strong competition for Boston Scientific.
With a similar aim in view, in July 2015, Edwards Lifesciences agreed to buy CardiAQ Valve Technologies - a privately held medical device developer of percutaneous mitral heart valve replacement system - for $400 million.
Following suit, in September, Abbott Laboratories ABT acquired the remaining equities of Minnesota-based Tendyne (those that it already did not own). Tendyne, which is focused on developing minimally invasive mitral valve replacement therapies, was taken over for a total price of $250 million.
Currently, both Boston Scientific and Medtronic carry a Zacks Rank #3 (Hold). Abbott on the other hand, retains a Zacks Rank #2 (Buy). A better-ranked medical product stock is Baxter International Inc. BAX , with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
BAXTER INTL (BAX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Following suit, in September, Abbott Laboratories ABT acquired the remaining equities of Minnesota-based Tendyne (those that it already did not own). Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Boston Scientific has funded MValve since 2012 and has an exclusive option to acquire this percutaneous mitral valve replacement system developer. | Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Following suit, in September, Abbott Laboratories ABT acquired the remaining equities of Minnesota-based Tendyne (those that it already did not own). With this additional round of finance, MValve plans to fund a first-in-human clinical trial for its docking system for transcatheter mitral valve replacement (TMVR) in patients with mitral regurgitation. | Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Following suit, in September, Abbott Laboratories ABT acquired the remaining equities of Minnesota-based Tendyne (those that it already did not own). Boston Scientific CorporationBSX recently declared that it has closed an additional round of financing with MValve Technologies Ltd., in keeping with its plans to invest toward the development of a unique mitral regurgitation (MR) treatment solution that will work with the Boston Scientific Lotus Valve. | Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Following suit, in September, Abbott Laboratories ABT acquired the remaining equities of Minnesota-based Tendyne (those that it already did not own). Notably, Boston Scientific has funded MValve since 2012 and has an exclusive option to acquire this percutaneous mitral valve replacement system developer. |
33994.0 | 2015-10-08 00:00:00 UTC | Roche (RHHBY) Reports Positive Data on Skin Cancer Drugs | ABT | https://www.nasdaq.com/articles/roche-rhhby-reports-positive-data-on-skin-cancer-drugs-2015-10-08 | nan | nan | RocheRHHBY announced positive data from a phase III study, coBRIM, on Zelboraf in combination with Cotellic (cobimetinib).
Data from the study showed that Cotellic in combination with Zelboraf, enabled patients with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer than Zelboraf alone.
Long-term data on the safety ground is expected later in 2015.
Zelboraf is already approved for treating patients with unresectable or metastatic melanoma with a BRAF V600 mutation detected by a validated test, such as Roche's cobas 4800 BRAF Mutation Test. We note that Cotellic is being developed by Roche, a leader in the oncology space, in collaboration with Exelixis, Inc. EXEL . It is being evaluated in combination with several investigational medicines, including immunotherapy, in several tumor types such as non-small cell lung and colorectal cancers.
As per the collaboration agreement, Exelixis is entitled to low double-digit royalties on sales of the drug in ex-U.S. markets. Upon FDA approval, the company will be initially entitled to an equal share of profits and losses in the U.S., which will decline as product sales increase. Exelixis will also share marketing and commercialization costs in the U.S.
Cotellic has already been approved for use in combination with Zelboraf for patients with advanced melanoma in Switzerland. The EU Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for the Cotellic/Zelboraf combination in Sep 2015. A decision is expected by the end of 2015.
Meanwhile, Roche is expecting a decision from the FDA on its new drug application for Cotellic by Nov 11, 2015. A potential approval will broaden Roche's skin cancer franchise.
Roche has a strong presence in the oncology market. In particular, the company dominates the breast cancer space on strong demand for its HER2 franchise drugs. The HER2 franchise includes drugs like Herceptin, Perjeta and Kadcyla.
Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks include Abbott Laboratories ABT and Novo Nordisk A/S NVO . Both carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
EXELIXIS INC (EXEL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked health care stocks include Abbott Laboratories ABT and Novo Nordisk A/S NVO . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. It is being evaluated in combination with several investigational medicines, including immunotherapy, in several tumor types such as non-small cell lung and colorectal cancers. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks include Abbott Laboratories ABT and Novo Nordisk A/S NVO . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks include Abbott Laboratories ABT and Novo Nordisk A/S NVO . Data from the study showed that Cotellic in combination with Zelboraf, enabled patients with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer than Zelboraf alone. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks include Abbott Laboratories ABT and Novo Nordisk A/S NVO . Exelixis will also share marketing and commercialization costs in the U.S. Cotellic has already been approved for use in combination with Zelboraf for patients with advanced melanoma in Switzerland. |
33995.0 | 2015-10-07 00:00:00 UTC | Express Scripts Includes Praluent and Repatha in Formulary | ABT | https://www.nasdaq.com/articles/express-scripts-includes-praluent-and-repatha-in-formulary-2015-10-07 | nan | nan | Pharmacy benefit manager Express Scripts ESRX announced that it will include two new cholesterol-lowering drugs - Regeneron/Sanofi's REGN / SNY Praluent and Amgen's AMGN Repatha - on its National Preferred Formulary.
Both the drugs are first PCSK9 inhibitors that were approved earlier in 2015 in the U.S. The drugs are approved for use in patients with clinical atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia who need additional lowering of LDL cholesterol.
Repatha has also been approved for the rarer homozygous familial hypercholesterolemia. Patients suffering from high cholesterol had been dependent on statins. However, the long-term effect of lowering LDL with the usage of these drugs has yet to be proven.
Inclusion of the drugs in the formulary will give approximately 25 million Americans access to the drugs at the best possible price. Express Scripts stated that it has implemented its Cholesterol Care Value (CCV) program using clinical documentation, whereby needy patients can have access to drugs with minimal risk and at an appropriate cost.
While Praluent is priced at an annual cost of $14,600, Repatha comes at a cost of $14,100. The company will have access to the drugs at a discounted rate. Consequently, National Preferred Formulary clients will spend approximately $750 million on PCSK9 inhibitors in 2016 on a collective basis, much lower than industry estimates. Meanwhile, Express Scripts plans to cap the entire plan cost in 2016 for PCSK9 inhibitors for clients enrolled in the CCV program, thereby providing additional long-term protection to its payers and patients.
The news will be a big boost for both the drugs as Express Scripts decided to include both in the plan. Consequently, a large number of patients can access both the drugs at better prices. We remind investors Express Scripts chose hepatitis C treatment Viekira Pak over Sovaldi in Dec 2014 leading to a pricing war between the two.
Express Scripts believes that there is urgent need to tightly manage pharmacy benefit, implement smarter formularies, control compounded medication use and offer appropriate clinical support to ensure best possible treatments for patients at lower prices.
Express Scripts currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
REGENERON PHARM (REGN): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Pharmacy benefit manager Express Scripts ESRX announced that it will include two new cholesterol-lowering drugs - Regeneron/Sanofi's REGN / SNY Praluent and Amgen's AMGN Repatha - on its National Preferred Formulary. | Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Pharmacy benefit manager Express Scripts ESRX announced that it will include two new cholesterol-lowering drugs - Regeneron/Sanofi's REGN / SNY Praluent and Amgen's AMGN Repatha - on its National Preferred Formulary. | Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Pharmacy benefit manager Express Scripts ESRX announced that it will include two new cholesterol-lowering drugs - Regeneron/Sanofi's REGN / SNY Praluent and Amgen's AMGN Repatha - on its National Preferred Formulary. | A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Pharmacy benefit manager Express Scripts ESRX announced that it will include two new cholesterol-lowering drugs - Regeneron/Sanofi's REGN / SNY Praluent and Amgen's AMGN Repatha - on its National Preferred Formulary. |
33996.0 | 2015-10-07 00:00:00 UTC | AmerisourceBergen (ABC) Acquires PharMEDium for $2.6B | ABT | https://www.nasdaq.com/articles/amerisourcebergen-abc-acquires-pharmedium-for-%242.6b-2015-10-07 | nan | nan | AmerisourceBergenABC announced that it has signed a definitive agreement to acquire privately held PharMEDium Healthcare Holdings, Inc. from Clayton, Dubilier & Rice for $2.6 billion in cash.
Details of the Transaction
The acquisition, expected to close in the first quarter of fiscal 2016 (ending Dec 31, 2015), will add approximately 22-26 cents to the company's bottom line in fiscal 2016. Synergies from the transaction are targeted at an approximate $30 million by fiscal 2018.
Upon acquisition, PharMEDium will become part of AmerisourceBergen Drug Corporation. PharMEDium provides customized outsourced compounded sterile preparations that address specific hospital and physician clinical needs and quality standards in formulations. These formulations are not available commercially. The CSPs are in a ready-to-use form with improved safety, labeling, sterility assurance and extended expiration dating supported by appropriate studies, which is generally not possible for hospital pharmacies to do by themselves. The company maintains four compounding facilities that serve over 3,000 hospital customers.
Our Take
The acquisition will strengthen AmerisourceBergen's core business and broaden its service offerings to health systems.
We note that AmerisourceBergen has been actively pursuing acquisitions to strengthen its core areas. The company had earlier acquired animal health distribution company MWI Veterinary Supply, Inc., for approximately $2.5 billion. The acquisition diversified the company's existing pharmaceutical distribution & services businesses into the attractive animal health market, which currently holds huge potential. MWI Veterinary Supply sells pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, supplies, pet food and nutritional products.
These acquisitions should strengthen AmerisourceBergen's position in the highly competitive pharmaceutical distribution and related health care services market, which includes players like Cardinal Health CAH and McKesson MCK . The accretion from these acquisitions should also offset the impact of declining contribution from generic inflation.
AmerisourceBergen carries a Zacks Rank #2 (Buy). Abbott Laboratories ABT also looks attractive in the health care space with the same Zacks Rank as AmerisourceBergen.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CARDINAL HEALTH (CAH): Free Stock Analysis Report
AMERISOURCEBRGN (ABC): Free Stock Analysis Report
MCKESSON CORP (MCK): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT also looks attractive in the health care space with the same Zacks Rank as AmerisourceBergen. Click to get this free report CARDINAL HEALTH (CAH): Free Stock Analysis Report AMERISOURCEBRGN (ABC): Free Stock Analysis Report MCKESSON CORP (MCK): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. AmerisourceBergenABC announced that it has signed a definitive agreement to acquire privately held PharMEDium Healthcare Holdings, Inc. from Clayton, Dubilier & Rice for $2.6 billion in cash. | Click to get this free report CARDINAL HEALTH (CAH): Free Stock Analysis Report AMERISOURCEBRGN (ABC): Free Stock Analysis Report MCKESSON CORP (MCK): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT also looks attractive in the health care space with the same Zacks Rank as AmerisourceBergen. The company had earlier acquired animal health distribution company MWI Veterinary Supply, Inc., for approximately $2.5 billion. | Click to get this free report CARDINAL HEALTH (CAH): Free Stock Analysis Report AMERISOURCEBRGN (ABC): Free Stock Analysis Report MCKESSON CORP (MCK): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT also looks attractive in the health care space with the same Zacks Rank as AmerisourceBergen. The acquisition diversified the company's existing pharmaceutical distribution & services businesses into the attractive animal health market, which currently holds huge potential. | Click to get this free report CARDINAL HEALTH (CAH): Free Stock Analysis Report AMERISOURCEBRGN (ABC): Free Stock Analysis Report MCKESSON CORP (MCK): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT also looks attractive in the health care space with the same Zacks Rank as AmerisourceBergen. The company had earlier acquired animal health distribution company MWI Veterinary Supply, Inc., for approximately $2.5 billion. |
33997.0 | 2015-10-06 00:00:00 UTC | Boston Scientific's Bioabsorbable Stent Wins FDA Approval | ABT | https://www.nasdaq.com/articles/boston-scientifics-bioabsorbable-stent-wins-fda-approval-2015-10-06 | nan | nan | Boston Scientific Corporation 's BSX SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) recently won the U.S. Food and Drug Administration (FDA) approval for treating coronary artery disease (CAD) patients. Post approval, this medical device major will immediately initiate the commercial launch of the first and only FDA-approved BP-DES device in the U.S. market.
According to the company, this launch will be a significant milestone in the history of stent technology evolution. This first-of-its-kind polymer absorbable stent will not only deliver improved patient outcome but also reduce the overall healthcare cost related to CAD therapy.
Currently, CAD is the leading cause of death in the U.S., claiming over 370,000 lives each year. To avoid cardiac restenosis, heart patients are traditionally implanted with drug-eluting stents (DES) with permanent polymers. However, long-term polymer exposure is prone to increased life-risking complications for these patients.
Unlike standard DES, Boston Scientific's SYNERGY BP-DES facilitates the absorption of the drug coating as well as the polymer, shortly after drug elution is complete at three months. Thereby, the SYNERGY stent system promotes more rapid and complete arterial healing, at much reduced risk of complications associated with other DES.
Results from the Evolve II trial also supported the clinical safety and efficacy of this device in treating CAD patients which revealed no incidence of stent thrombosis and a very low target lesion revascularization rate of 1.1%, following four years of the SYNERGY stent implantation.
In order to further highlight the effectiveness of the SYNERGY stent in a high-risk patient group, Boston Scientific is planning to start the EVOLVE Short Dual Anti-Platelet Therapy (DAPT) Study in the first quarter of 2016. The study will evaluate the safety of a three-month use of DAPT in patients at high risk of bleeding undergoing percutaneous coronary intervention with the SYNERGY stent. Boston Scientific has already received an Investigational Device Exemption (IDE) for this prospective study.
Currently, the global coronary stent market is estimated to grow at a CAGR of 6.6% during the 2013-2019 period to reach $8.3 million in 2019. We expect Boston Scientific to capture a larger share of this huge market potential, once its SYNERGY stent hits the market.
With the era of bare-metal stents and standard DES now almost over, other healthcare providers will also try to tap into the booming bioabsorbable stent market. In fact, they are engaged in the innovation of such stents on their own.
In this respect, the Bioresorbable Vascular Scaffold (BVS) of the renowned healthcare provider Abott Laboratories ABT is worth mentioning. BVS is expected to make a mark in the U.S. stent market, with an FDA approval slated for 2016. The device has already received CE Mark approval in Europe.
Since Abott's bioabsorbable stent is yet to be approved in the U.S., it will give a competitive leverage to Boston Scientific's SYNERGY stent.
Currently, Boston Scientific has a Zacks Rank #2 (Buy). Some other top-ranked medical product stocks are Enzymotec Ltd. ENZY , ICU Medical, Inc. ICUI and NuVasive, Inc. NUVA . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis Report
ENZYMOTEC LTD (ENZY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In this respect, the Bioresorbable Vascular Scaffold (BVS) of the renowned healthcare provider Abott Laboratories ABT is worth mentioning. Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report ENZYMOTEC LTD (ENZY): Free Stock Analysis Report To read this article on Zacks.com click here. Boston Scientific Corporation 's BSX SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) recently won the U.S. Food and Drug Administration (FDA) approval for treating coronary artery disease (CAD) patients. | Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report ENZYMOTEC LTD (ENZY): Free Stock Analysis Report To read this article on Zacks.com click here. In this respect, the Bioresorbable Vascular Scaffold (BVS) of the renowned healthcare provider Abott Laboratories ABT is worth mentioning. Boston Scientific Corporation 's BSX SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) recently won the U.S. Food and Drug Administration (FDA) approval for treating coronary artery disease (CAD) patients. | Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report ENZYMOTEC LTD (ENZY): Free Stock Analysis Report To read this article on Zacks.com click here. In this respect, the Bioresorbable Vascular Scaffold (BVS) of the renowned healthcare provider Abott Laboratories ABT is worth mentioning. Boston Scientific Corporation 's BSX SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) recently won the U.S. Food and Drug Administration (FDA) approval for treating coronary artery disease (CAD) patients. | In this respect, the Bioresorbable Vascular Scaffold (BVS) of the renowned healthcare provider Abott Laboratories ABT is worth mentioning. Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report ENZYMOTEC LTD (ENZY): Free Stock Analysis Report To read this article on Zacks.com click here. Boston Scientific Corporation 's BSX SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) recently won the U.S. Food and Drug Administration (FDA) approval for treating coronary artery disease (CAD) patients. |
33998.0 | 2015-10-06 00:00:00 UTC | Valeant Shares Down 37% since August; More Pain Ahead? | ABT | https://www.nasdaq.com/articles/valeant-shares-down-37-since-august-more-pain-ahead-2015-10-06 | nan | nan | Shares of Valeant PharmaceuticalsVRX have plummeted around 37% in the last two months. The downtrend was particularly steep in September after Democratic presidential candidate Hillary Clinton commented on the rising prices of specialty drugs that led to a massive selloff in the biotech sector.
Last week, all 18 Democratic members of the House of Committee on Oversight and Government Reform requested Chairman Jason Chaffetz to issue a subpoena to compel Valeant to provide documents relating to the massive price hike of two of its drugs.
The drugs in question are Isuprel and Nitropres. These drugs were acquired by the company earlier in 2015 and are used by hospitals and other providers to treat serious heart conditions. Since the acquisition, the company has increased their prices by 212% and 525%, respectively. We note that Valeant has been quite aggressive on the acquisition front over the last few years and has now come into the spotlight for hiking prices of the drugs it purchased.
The Democrats believe drug companies should be accountable when they deploy the strategy of buying old, neglected drugs and convert them into high-priced 'specialty' drugs. Valeant was accused of following the same business model as Martin Shkreli, whose company had spiked the price of Daraprim from $13.50 to $750.
The Road Ahead
In response, the chairman of the company has written a letter to its shareholders stating that the company is well-positioned for strong organic growth, even with negligible or no price increases. However, we believe Valeant will not be able to get away with this easily. Hence, investors will continue to bear the brunt of the decline in its stock price.
Pricing dynamics in the health care sector have been in the spotlight since 2014. We remind investors that pharmacy benefit manager Express Scripts Holding Co. ESRX released data in Mar 2015, wherein it was mentioned how new expensive hepatitis C (HCV) therapies, along with the exploitation of loopholes for compounded medications, fueled a phenomenal 13.1% surge in drug spending in the U.S. in 2014.
The Democrats are expected to focus on this issue strongly. It remains to be seen what strategy Valeant will adopt to counter the negative investor sentiment. We expect the company to throw some light on the same on its third-quarterearnings callscheduled for Oct 19.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> - See more at: http://www.zacks.com/stock/news/192573/apollo-bids-higher-for-xchanging-takeover-shares-up-21#sthash.etqxrSbo.dpuf
Valeant currently holds a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Both carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> - See more at: http://www.zacks.com/stock/news/192573/apollo-bids-higher-for-xchanging-takeover-shares-up-21#sthash.etqxrSbo.dpuf
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> - See more at: http://www.zacks.com/stock/news/192573/apollo-bids-higher-for-xchanging-takeover-shares-up-21#sthash.etqxrSbo.dpuf
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The downtrend was particularly steep in September after Democratic presidential candidate Hillary Clinton commented on the rising prices of specialty drugs that led to a massive selloff in the biotech sector. | Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Last week, all 18 Democratic members of the House of Committee on Oversight and Government Reform requested Chairman Jason Chaffetz to issue a subpoena to compel Valeant to provide documents relating to the massive price hike of two of its drugs. | Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Since the acquisition, the company has increased their prices by 212% and 525%, respectively. |
33999.0 | 2015-10-05 00:00:00 UTC | Amicus Therapeutics Plunges on Delay in NDA Submission | ABT | https://www.nasdaq.com/articles/amicus-therapeutics-plunges-on-delay-in-nda-submission-2015-10-05 | nan | nan | Shares of Amicus TherapeuticsFOLD plunged significantly after the FDA asked for additional data on its lead candidate, galafold (migalastat).
The candidate is being evaluated for the treatment of Fabry disease. Amicus announced that it has received minutes from its pre New Drug Application (NDA) meeting with the FDA held in Sep 2015. Thereafter, the company has been conducting additional follow-up interactions with the FDA.
Amicus has been asked by the FDA to produce additional data on galafold's effect on gastrointestinal symptoms in Fabry disease to support its NDA submission requesting full approval as well as a Subpart H strategy.
The FDA has also asked for further integration of existing clinical data across studies. This will require more time to complete, causing a delay in NDA submission, Amicus is not likely to submit the NDA for galafold in the U.S. by the end of 2015.
Our Take
The delay in submission of the NDA was quite disappointing as galafold is Amicus' lead candidate. The NDA submission and a potential approval thereafter would have boosted the company's growth prospects. We note that the candidate is in review in the EU.
Amicus does not have any approved product in its kitty at the moment.
Meanwhile, the company is also developing next-generation enzyme replacement therapy products for Fabry disease, Pompe disease and mucopolysaccharidosis type 1.
We note that the prescribed treatments for Fabry disease include Sanofi's SNY Fabrazyme and Shire's SHPG Replagal among others.
Amicus currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMICUS THERAPT (FOLD): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Click to get this free report AMICUS THERAPT (FOLD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Amicus TherapeuticsFOLD plunged significantly after the FDA asked for additional data on its lead candidate, galafold (migalastat). | Click to get this free report AMICUS THERAPT (FOLD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Shares of Amicus TherapeuticsFOLD plunged significantly after the FDA asked for additional data on its lead candidate, galafold (migalastat). | Click to get this free report AMICUS THERAPT (FOLD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Shares of Amicus TherapeuticsFOLD plunged significantly after the FDA asked for additional data on its lead candidate, galafold (migalastat). | A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Click to get this free report AMICUS THERAPT (FOLD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Amicus has been asked by the FDA to produce additional data on galafold's effect on gastrointestinal symptoms in Fabry disease to support its NDA submission requesting full approval as well as a Subpart H strategy. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.